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Abstract
Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the central 
nervous system (CNS) causing neurological disability in young adults, characterised by 
discrete acute and chronic lesions that are predominantly located in the CNS white 
matter. The role the extracellular matrix (ECM) has been widely studied as it is thought 
to be implicated in the pathogenesis of MS. Components such as chondroitin sulphate 
proteoglycans (CSPGs) are up-regulated in response to injury and inflammation and 
participate in the formation of sclerotic lesions. Research into the role of a disintegrin 
and metalloproteinase with thrombospondin motifs (ADAMTS) in CNS injury and 
inflammation has demonstrated that this protease may aid the recovery process by 
cleaving CSPGs, which are inhibitory to neurite outgrowth and axonal regeneration.
In vivo studies were carried out investigating the distribution and expression of 
aggrecan and versican by dual label immunohistochemistry (IHC) and western blotting 
(WB) using antibodies which specially recognise cleavage-derived aggrecan and 
versican neoepitopes and intact protein. ADAMTS-9 expression was assessed by real 
time PCR (qRT-PCR), IHC and western blotting. In active lesions, both IHC and WB 
indicated that intact versican and aggrecan as well as their neoepitopes and ADAMTS-9 
expression were all increased in areas of myelin thinning with ongoing demyelination 
and macrophage activation, compared to control and normal appearing white matter 
(NAWM) brain tissue. Immunostaining for CSPG neoepitope was particularly strong at 
the plaque border in chronic active lesions (CAL) compared to chronic inactive lesions 
(CL), NAWM and control brain tissue, suggesting active enzymatic cleavage of intact 
protein. IHC studies demonstrated that ADAMTS-9 was expressed predominantly by 
astrocytes, endothelium, macrophages and neurons with increased expression within 
MS active lesions. qRT-PCR studies confirmed ADAMTS-9 expression in MS tissue. In 
summary this study provides evidence that ADAMTS-9 plays an important role in 
cleavage of the ECM CSPGs, aggrecan and versican, in active lesions in MS.
The role of CSPGs in neurite outgrowth from human neurons has been largely untested 
but is critical for understanding of regeneration following CNS injury. This thesis aimed 
to assess the effect of the ECM components, aggrecan, on neurite outgrowth of 
neuroblastoma cell line (SHSY-5Y) and expression of ADAMTS-9. This was achieved by 
several methods including qRT-PCR, ICC and WB. These data provided evidence that 
neurite outgrowth from SHSY-5Y cells is inhibited by aggrecan, this inhibition was 
associated with high level expression of ADAMTS-9.
This thesis also aimed to investigate the expression of ADAMTS-9 by cells of the CNS 
to gain a better understanding of how these enzymes might be regulated and their 
possible role in the pathogenesis of MS. Cells were treated with pro-inflammatory 
cytokines in vitro, to mimic in vivo inflammatory conditions, and following this, ICC and 
WB data demonstrated that ADAMTS-9 was constitutively expressed by primary 
human astrocytes, microglia (CHME3) and neuronal (SHSY-5Y) cell lines in vitro, under 
basal condition. In primary astrocytes, ADAMTS-9 expression was increased following 
treatment with lOng/mL interferon-y compared to control untreated cells. In contrast, 
dual treatment with interleukin-1 and tumour necrosis factor resulted in down 
regulation of ADAMTS-9. Thus illustrating the external inflammatory mileu influences 
the expression of ADAMTS-9 in lesions in MS, which in turn influences the degradation 
of the ECM components aggrecan and versican, which are also upregulated in lesions. 
Further work to understand how these changes in the ECM influence CNS repair is 
needed.
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1 Multiple sclerosis
Multiple sclerosis (MS) is a complex disease displaying several pathological features 
including demyelination, inflammation, axonal/neuronal damage, changes in the 
immune system and blood brain barrier (BBB) dysfunction, affecting mainly the white 
matter of the central nervous system (CNS) (Lucchinetti et al., 2011; Polman et al.,
2011). Demyelination of axons and the formation of inflammatory lesions (plaques) 
leads to the disruption of nerve conduction within the CNS typically associated with 
specific symptoms displayed by the patient (lessmann et al., 2012). MS can result in a 
range of severe neurological deficits generally leading to disability for the individual. 
The development of MS is influenced by environmental factors, genetic factors and 
predisposition to autoimmunity in general (Altmann et al., 2004; Milo& Kahana, 2010). 
The MS Trust has estimated that approximately 2.5 million people in the world have 
MS; 100,000 of these cases are in the UK (Gourraud et al., 2012). MS has a personal, 
social and economic load on society, which was estimated to be ~£1 million per MS
patient (Orton et al., 2006).
1.1 Clinical symptoms and disease course in MS
Typically the first symptoms experienced by people with MS occurs between the ages 
of 20-40 years, but they may commence as early 3 years and as late as the seventh 
decade. Women are affected twice as often as men (Lublin and Reingold et al., 1996; 
Huijbregts et al., 2006). Symptoms occurs in specific parts of the body dependent on 
which areas of CNS are damaged, which includes memory problems, depression, 
emotional changes, tremor and visual disturbance (Shivane & Charabarty, 2007). MS 
patients usually present with relapse-remitting symptoms with repeated neurologic 
episodes, each of which is usually followed by either partial or complete recovery with 
a period free of new symptoms known as relapse remitting MS (RRMS). Around 50- 
60% patients with RRMS ultimately develop to secondary progressive MS (SPMS). 
Approximately 10% of patients follow a primary progressive (PPMS) course, with a 
progressive neurologic deterioration from the onset (Pender et al., 2007; Antel et al.,
2012). The classification of MS and the time course of neurological disability in the 
different forms of MS are illustrated in Figure (1-1).
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Figure 1-1: Summary of the clinical classification of MS subtypes
Progressive relapsing (PRMS) (a); Disease progression from the beginning, 
characterized by steady progression of the clinical neurological damage w ith relapse 
and remissions, is a very rare condition. Around 80-90% of MS patients show relapse- 
remitting symptoms that begin w ith period of varying neurological impairment 
interspersed with periods of remission (RRMS) (b). Around half of MS patients w ith 
RRMS will go onto development secondary-progressive MS (SPMS) which is 
characterized by fewer attacks and incomplete recovery as the disease becomes more 
progressive (c). Around 10-20% of patients present as primary-progressive MS (PPMS) 
which is characterised by an increase in disability from onset over time in the absence 
of improvement and remissions (d). Figure adapted from Zuvich et al., (2009).
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1.2 Diagnosis of MS
MS can be misdiagnosed as other conditions can imitate it, e.g. neuromyelitis optica. 
There are also no specific tests that can determine entirely if a patient has MS or is 
likely to have it in the future (Charil et al., 2006; Kuhmann, 2013). Current diagnosis of 
definite MS is supported by both clinical investigations and by laboratory testing 
including the sampling of cerebrospinal fluid (CSF) for presence of oligoclonal bands 
(OCB) recognising an immune reaction within the brain and the use of magnetic 
resonance imaging (MRI) for lesion identification (Barazini et al., 2009; Reynolds et al., 
2011).
MRI shows white matter lesions in more than 95% of MS patients. The most recent 
McDonald criteria formally integrate data from MRI and focusing on early diagnosis of 
patients presenting with a clinically isolated syndrome (CIS) suggestive of MS (Miller et 
al., 2008). Patients suspected of having MS may have neurological symptoms upon 
initial examination that are clinically monofocal (no dissemination in space, for which a 
single CNS lesion can explain signs and symptoms) or multifocal (dissemination in 
space, for which symptoms and signs can only be explained by at least two lesions in 
separate parts of the CNS) (Polman e ta l., 2011).
1.3 Aetiology of MS
1.3.1 Environmental factors
The aetiology of MS remains unclear, but is thought to involve exposure to 
environmental factors in those with genetic susceptibility (Olson et al., 2001; Handel et 
al., 2010; Sadovnick, 2013). This includes smoking (Pittas et al., 2009; Hedstrom et al.,
2013), obesity (Hedstrom et al., 2012; Munger, 2013) and lack of ultraviolet radiation 
(UVR), indicating that environmental factors play a crucial role in the development of 
MS (Lucas et al., 2011). As the geographical distribution of MS prevalence is linked to 
exposure to sunlight, which relates to vitamin D synthesis, this is also associated 
consistently with an increased risk of developing MS (Goldberg et al., 1986; Ascherio et 
al., 2010; Burton et al., 2010).
Viral infections have been implicated with either the aetiology or progression of MS
such as Epstein-Barr virus (EBV), and human herpes virus (Libbey et al., 2007; Tselis,
2012). Bacterial infections in addition to Borrelia burgodorferi have been proposed to
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play a role in MS aetiology. The common respiratory pathogen Chlamydia pneumonia 
is known to infect endothelial cells, which is believed to assist in the migration of 
leukocytes into brain parenchyma (Stratton et al., 2006; Contini et al., 2010).
1.3.2 Genetics in MS
Susceptibility to MS is determined by a complex interaction of susceptibility genes in 
an individual; the incidence of MS in relatives of people with MS is twenty times higher 
than in the general population, indicative of a genetic link. Similarly studies of dizygotic 
twins have demonstrated a concordance rate of less than 5% and monozygotic twins 
show a concordance rate of approximately 30% (Taylor, 2011), again indicative of a 
genetic association. The major histocompatibility complex (MHC) located on 
chromosomes 6; 1 7 p ll,  3q21-24 and 1 8 p ll  were the first genes described as potential 
regions linked to MS (Sotgiu et al., 2004). The previously completed GWAS and follow- 
up projects have identified 110 independent SNPs outside the HLA locus showing 
genome wide significant association with MS risk (Lill et al., 2015), in particular 
inheritance of the HLA-DRB*1501, DRB5*0101, DQB1*0602 and DQA1*0102 
haplotypes (Kaushansky et al., 2015; Lima et al., 2015) is linked to increased likelihood 
of developing MS.
A genome-wide association study (GWAS) identified more than 10,000 additional risk 
loci as part of the Wellcome Trust case control consortium 2 (WTCCC2) project (Sawcer 
et al., 2014; Dankowski et al., 2015). Cases were recruited through the International 
MS Genetic Consortium (IMSGC) and compared with the WTCCC2 common control set 
(IMSG, 2011). The study implicated a multitude of genes coding for cytokine and 
chemokine pathways [CXCR5, IL2RA, IL-7R, IL-7, IL12RB1, IL22RA2, IL12A, IL12B, IRF8 
(interferon regulatory factors 8), TNFRSF1A (tumour necrosis factor receptor 
superfamily member 1A)] co-stimulatory molecules (CD37, CD40, CD58, CD80, CD86) 
and signal transduction proteins [MALT1 (mucosa-associated lymphoid translocation 
proteinl), RGS1 (regulator of G-protein signallingl), STAT3 (signal tranducer and 
activator of transcription 3), TAGAP (T-cell activation RhoGTPase activating), TYK2 
(tyrosine kinase 2)] (IMSG, 2011; Bashinskaya et al., 2015), All these genes coded for 
molecules with immunological relevance, in keeping witht the autoimmune proposed 
aetiology of MS.
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Genes were also identified which were linked to previously reported environmental 
factors which influence the incidence of MS, such as vitamin D deficiency [CYP27B1, 
(cytochrome P450 family 27 subfamily B l) (Bahlo et al., 2009; Pierrot-Deseilligny & 
Souberbielle, 2010). The gene encoding vascular cell adhesion molecule (VCAM1) was 
also identified as a susceptibility gene, which correlated with effective treatment of MS 
patients with natalizumab, a therapeutic antibody, which blocks VCAM1 preventing 
migration of inflammatory cells into the CNS, reducing relapse rates considerably 
(Steinman, 2009).
Other genes have also been reported as being MS susceptibility loci associated with 
single nucleotide polymorphisms such as interleukin-7 receptor, interleukin-2 receptor, 
ecotropic viral integration site 5 (EVI5) and kinesin family member 1(3 (KIFip) 
(Aulchenko et al., 2008; Hoppenbrouwers et al., 2008; Maier et al., 2009; Haas et al.,
2011). The IL-7R and IL-2R cytokine receptors were also identified as susceptibility loci 
in the GWAS study, reinforcing the importance of this family of cytokines and 
receptors in MS pathogenesis (IMSGC, 2011; Bashinskaya eta l., 2015).
1.4 Pathology of MS
In 1868, Charcot first described the pathological hallmark of MS including, 
inflammation and infiltration of immune cells within the CNS, mainly in the white 
matter, but grey matter is also involved (Lucchinetti et al., 2005). The affected areas of 
brain tissue in MS are known as lesions or plaques which are usually localised around 
post capillary vessels (Shivane & Chakrabarty, 2007). The distribution of lesions is more 
common in specific areas including optic nerve, spinal cord, periventricular regions, 
and brainstem (Akenami et al., 2000). Pathological features include; oligodendrocyte 
damage, demyelination, axonal damage, BBB leakage, glial scar formation and the 
presence of inflammatory infiltrates that mainly consist of lymphocytes and 
macrophages (Sospedra & Martin, 2005). The classification of MS lesions is quite 
difficult to fully define due to the nature of MS as a disease. Numerous attempts to 
identify lesion types based on aggressiveness, ranging from gradually to quickly 
developing severe chronic lesions have been reported (Bruck et al., 1995; Lucchinetti 
et al., 2000). MS lesions can be typically staged into four different categories 
active/acute lesion, chronic active, chronic inactive and normal appearing white matter 
(NAWM) (Brosnan & John, 2009).
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Active lesions (AL) contain activated macrophages, containing myelin debris as a result 
of the demyelination process, assembled oligodendrocyte precursor cells (OPCs) at the 
edge of some initial acute plaques in an attempt to repair damaged oligodendrocytes 
(Chang et al., 2002; Patani et al., 2007). The typical active lesion can be sub divided 
into two different types;
Acute MS plaques are referred to as the early active lesions that contain an even 
distribution of macrophages/ activated microglia throughout the whole lesion, with 
disrupted myelin (Lassmann, 2011).
Chronic active plaques (CAL) also referred to as the late active lesion, contain foamy 
macrophages digesting myelin in the advanced edge; axonal damage can be seen, 
reactive astrocytes, demyelination is found in the lesion core. The chronic inactive 
plaque is also known as a silent plaque, is hypo-cellular (few macrophages and 
lymphocytes are seen), reduction in OPCs, reactive astrocytes with extensive gliosis, 
and myelin loss is clearly marked (Trapp et al., 1998; Hickey et al., 1999).
1.5 Cellular constituents of the CNS and their role in MS
The CNS consists of the cerebral endothelium, astrocytes, oligodendrocytes, microglia 
and neurons. The cells within the CNS communicate through various transporter 
mechanisms, ion channels and signalling pathways to maintain homeostasis within the 
CNS (Bear et al., 2007; Higgins et al., 2013). Glial stem cells/ progenitor cells, described 
as self-renewing, are also present in the CNS which are multipotent cells that generate 
all cells types including astrocytes and oligodendrocytes (Purves et al., 2008).
1.5.1 Glial cells in MS
Virchow in 1846 first described the term neuroglia; this term has been used since the 
1850s as a generic name of CNS cells (Kettenman& Verkhratsky, 2008). Glial cells form 
the protective and supportive network of the CNS in a number of ways and including 
oligodendrocytes (OLGs) providing insulation of neurons with myelin, and macroglia 
(astrocytes) providing maintenance and participation in signal transmission. Microglia 
act as macrophages and form the basis of the immune system in the CNS (Love et al., 
2008). They also produce many molecules with inflammatory and immune function, 
such as cytokines, chemokines and proteases (Minager eta l., 2002).
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1.5.2 Microglia in MS
Microglia are the resident macrophages of the CNS and are small cells derived from 
progenitor cells in the embryonic yolk sac, which are spaced evenly throughout white 
and grey matter (Ginhoux et al., 2013). There are significantly more microglia in white 
matter versus grey matter (Mittelbronn et al., 2001). Microglia represent 
approximately 20% of the total cells in the CNS (Brodel, 2010; de Pablos et al., 2013). 
In healthy nervous tissue, microglia are able to participate in both innate and adaptive 
immunity. Following immune stimulation, microglia become activated, migrate to the 
injured area, and regulate expression of levels of MHC II antigens which have the 
ability to activate lymphocytes in an immune response. Microglia can be found in three 
states resting, reactive (activated non-phagocytic) and activated phagocytic (Jack eta l., 
2005: Boche et al., 2013). Microglia can be distinguished by their activation state, 
resting cells have typical ramified morphology. In comparison, microglia under insult 
are enlarged and spherical in shape known as amoeboid cells (Loughlin et al., 1993; 
Nimmerjahn et al., 2005).
Microglia are also important in embryogenesis through secretion of neurotrophic 
factors such as nerve growth factors (NGF), brain-derived neurotrophic factor (BDNF), 
insulin-like growth factor (IGF) and neurotrophin-3 in response to both physiological 
and pathological stimulation (Ransohoff, 2011; Wake et al., 2011). Microglia can 
express a-amino-3-hydroxy-5-methy-4 isoxazolepropionic acid (AMPA) receptors to 
glutamate (Noda et al., 2000), P2 purinoceptors in response to ATP (Koizumi et al., 
2007, and a range of cytokines and growth factors that can affect neural circuits and 
brain homeostasis or disease (Wake et al., 2011). These signals facilitate the 
recruitment of microglia, including the release of nucleotide adenosine triphosphate 
(ATP) and uridine triphosphate (UTP) from damaged neurons, which have been shown 
to be key mediators in the recruitment of microglia through activation of P2 
purinoceptors following injury, leading to the removal of dying cells or their debris 
(Davalos et al., 2005; Flaynes et al., 2006). Activated microglia can also eliminate 
neurotoxins and reactive oxygen species (ROS) through their expression of catalases 
such as superoxide dismutase, along with the removal of cellular debris (Wang et al., 
2004; Stables eta l., 2010).
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Microglial cells express Toll-like receptors (TLRs) which are the first line of defence 
mediated by the recognition of pathogen associated molecules patterns (PAMPs) 
expressed by microbes (Jack et al., 2007; Aravalli et al., 2007). Upon PAMP binding to 
specific TLRs, activation of signalling pathways occurs, mediated by transcription 
factors and protein kinases, leading to activation of cytotoxic and inflammatory 
mediators e.g. cytokines such as IL-lp and IL-6, chemokines such as CCL2 and CCL5 and 
complement proteins and cell killing by release of nitric oxide (NO) and superoxide 
radicals (Von Bernhandi & Ramirez, 2001; Takeda & Akira, 2005; Glezer et al., 2007). In 
addition to TLRs, microglia express nuclear oligomerisation domain-like receptors 
(NLRs) that are able to detect pathogens including viruses and bacterial products 
within the cytoplasm. NLRs also activate signalling pathways leading to activation of 
caspase-1 via inflammation which in turn leads to increased expression of cytokines 
such as IL-1 and IL-18 (Fukata eta l., 2009; Zhongeta l., 2013).
Microglia are highly motile under normal physiological conditions and interactions 
between synapses and microglia occur in the brain with implications for synapse 
homeostasis, development and disease. Both presynaptic (SNAP-25) and postsynaptic 
(PSD95) reactivity could be detected inside microglia during normal cortical 
development that is associated with changes in the morphology of the postsynaptic 
spine (Poalicelli et al., 2011). Activation of microglia results in ATP release that 
subsequently activates astrocytes' purinoceptors (P2Y12) to release glutamate and 
activate presynaptic mGluRs to enhance glutamate activation of AMPA receptors 
(Wake eta l., 2011).
Microglia undergo a process called reactive microgliosis in response to inflammation 
whereby microglia proliferate extensively and up-regulate the expression of ECM 
protein involved in glial scar formation including CSPGs. There are many members of 
the CSPGs and individual CSPGs are synthesised by different cell types and at different 
time points following injury. Reactive astrocytes synthesise brevican, neurocan and 
phosphocan, while reactive microglia account for increased expression of aggrecan 
and versican (Siebert et al., 2014).
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1.5.3 Astrocytes
Astrocytes are the major cellular constituent of the CNS outnumbering neurons 10:1 
(Okada et al., 2005). There are two different subtypes of astrocytes: protoplasmic 
astrocytes which are located in grey matter and fibrous astrocytes which are found in 
white matter (Purves et ol., 2008). In the healthy CNS, astrocytes play a vital role in 
many functions including homeostasis of extracellular matrix fluid, removal of excess 
ions (in particular potassium) from the external environmental of neurons, regulate 
intracellular Ca++, recycling of neurotransmitters and are involved in the uptake of 
glucose and glutamate (Pellerin & Magistretti, 2005; Sofroniew & Vinters, 2010; Moore 
et al., 2011). Astrocytes also play a crucial role in the formation and maintenance of 
the BBB through the glia limitans (Hamm et al., 2004). Astrocytes can be detected in 
vivo by using antibodies against intermediate filaments proteins including glial fibrillary 
acidic protein (GFAP) and S-100J3 (Zheng eta l., 2000: Roelofs e ta l ., 2005).
Astrocytes do not have the potential to release free radicals, but they are known to 
attract T cells through the production of cytokines (Constantinescu et al., 2005), MMPs 
(Larsen et al., 2003; Crocker et al., 2006) and chemokines (Choi et al., 2014) that 
contribute to MS pathogenesis. Supporting a role for astrocytes in the immune 
response, they produce IL-12 and IL-23, which helps to initiate both T h l and T h l7  T 
cells which play a crucial role in MS pathogenesis (Constantinescu et al., 2005). Others 
indicate that cytokines produced by astrocytes, including IL-1, IL-6, TNF and IL-10, can 
drive and determine the immune response in demyelinating disease (Benveniste et al., 
1995). In vitro studies have shown that astrocytes produce pro-inflammatory cytokines 
including IL-9, IL-10, IL-11 by activation ofTLRson astrocytes (Nair eta l., 2008; Bsibsi et 
al., 2006). In contrast, astrocytes express IL-4 receptors and upon exposure to IL-4 they 
express neutrophins, nerve growth factor which support axonal growth (Minager et al., 
2002; Pellerin & Magistretti, 2005).
1.5.4 Oligodendrocytes
Oligodendrocytes (OLGs) are a type of glial cell that are responsible for synthesis of 
myelin, each OLG is able to myelinate more than 40 axons (Funfschilling et al., 2012; 
Nave et al., 2010). OLGs are the end products of many stages of proliferation and 
differentiation of OLG precursor cells (OPCs). Throughout the CNS, OLGs have been
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distinguished at different stages of maturation expressing individual phenotypes 
including expression of chondroitin sulphate proteoglycan (neural/glia antigen-2; NG2), 
surface gangliosides (A2B5), proteolipid protein (PLP), myelin basic protein (MBP), 
galactocerebroside (Gale) and 2, 3-cyclic nucleotide-3-phosphohydrolase (CNPase) 
(Armstrong et al., 1992; Norton et al., 1996; Levine et al., 2001). The proliferation and 
differentiation of OLGs are controlled by many factors including cytokines and growth 
factors. An additional role of OLGs is that they are essential for long term integrity and 
survival of axons (Kassmann & Nava, 2008; Edgar et al., 2004; Lappe-Siefke eta l., 2003).
1.5.5 Cerebral endothelia and the BBB
The blood brain barrier (BBB) is a term used for the separation of the brain 
parenchyma from the blood circulation which acts as a filter, allowing the transport of 
substances which are less than 0.5 kDa (e.g. glucose) into the CNS and blocking large 
molecules including cells from entering (Petty et al., 2002; Abbott et al., 2010). The 
BBB is comprised of capillary endothelial cells adjacent to a thin but multilayered 
basement membrane which separates them from closely adherent pericytes, 
perivascular macrophages and the astrocyte foot-processes termed the glia limitans 
(Francis eta l., 2003).
Basement membrane and astrocyte end-feet which are opposed to the outer 
endothelial cell (EC) surface act as a structural support for the tight junctions and acts 
as a two way signalling pathway between the endothelium and the surrounding 
neuroenviroment (Luissint et al., 2012). The tight junctions consist of three main 
proteins (claudin, occludin and junction adhesion molecules). Astrocyte end-feet play 
a vital role in proteoglycan synthesis resulting in an increase in human brain 
microvascular endothelial cell charge selectivity (Carvey et al., 2009: Persidsky et al., 
2006).
Pericytes (PCs) are also cells that wrap around ECs providing structural support and 
vasodynamic capacity to the microvascular tube. PCs play a key role in angiogenesis, 
maintaining structural integrity and differentiation of the vessel, and formation of 
endothelial TJs (Daneman et al., 2010). Figure (1-2) shows a schematic diagram of the 
BBB.
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Figure 1-2: Schematic diagram of the major cellular components of the 
BBB
The CNS presents three main barriers to penetration by cells or substances, the first is 
mainly created by brain endothelial cells which adhere to each other through the 
formation of tight junctions (TJ) consist of three main proteins (claudin, occludin and 
junction adhesion molecules) (outlined within in the box), the basement membrane 
(BM) that consists of proteins (collagen, elastin, fibronectin and laminin), pericytes 
w ithin the BM and astrocytic end feet also contribute to the composition o f the BBB. 
This protects the CNS from infiltration of immune cells, pathogens and antibody 
mediated immune responses. Figure adapted from Francis et al., (2003).
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1.6 BBB dysfunction
Dysfunction of the BBB is believed to be one of the early events in MS pathogenesis, 
prior to lesion formation; this can be identified by MRI and through investigation of 
post-mortem tissue (Alvarez et ol., 2011; Larochelle et al., 2011). Numerous aspects of 
BBB dysfunction have been implicated in MS, including TJ abnormalities (McQuaid et 
al., 2009), degradation of the BBB by MMPs (Minagar & Alexander 2003; Daneman,
2012) and downregulation of laminin expression in the basal lamina (Oki et al., 2004). 
As mentioned previously, soluble mediators including, NO (Hill et al., 2004), mast-cell- 
derived histamine (Kruger, 2001), chemokines (Holman et al., 2011), 
metalloproteinases (Yang et al., 2007) and cytokines (Wojiciak-Stothard et al., 1998) 
act as inflammatory mediators in the breakdown of the BBB. For instance, infiltrating 
macrophages express IL-ip that has been shown to induce MMP-9 expression, an 
enzyme responsible for cleavage of TJ proteins (Lleo et al., 2007; Yang et al., 2007). 
Others consider breakdown of the BBB and increased permeability in MS to be 
advantageeous, enhancing self-repair, allowing anti-inflammatory cells into the CNS to 
reduce inflammation (Larochelle eta l., 2011).
1.7 Autoimmune mechanisms in MS
Leukocyte infiltration occurs in numerous disorders of the CNS, including intracerebral 
haemorrhage (Ma et al., 2011), hyperglycaemia following transient ischemia (Luitse et 
al., 2012) and autoimmune diseases such as MS (Tullman et al., 2013). The exact 
mechanisms involved in cell migration across the BBB are still not fully understood. But 
it is known that the exposure of the endothelial cells to pro-inflammatory cytokines 
such as interleukin (IL-ip), tumour necrosis factor (TNF) and interferon-y (IFN-y) 
disturb the BBB by disorganising cell-cell junctions, and enhance leukocyte and 
endothelial adhesion molecule expression at the BBB (Martins et al., 2011). Adhesion 
molecules expressed by ECs include E-selectin, intracellular adhesion molecule-1 
(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), which interact with ligands 
on peripheral blood mononuclear cell (PBMCs), namely carbohydrate epitopes, 
leukocyte function antigen-1 (LFA-1) and very late antigen-4 (VLA-4) respectively 
(Kohm & Miller, 2003; Serres et al., 2011; Linnartz et al., 2012), to enhance cell 
migration into the CNS.
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Chemokines and their receptors are also implicated in the chemoattaction of 
leukocytes into injured tissue. Chemokine receptors belong to the superfamily of 
seven-transmembrane domain receptors that signal through heterotrimeric GTP- 
binding proteins. One chemokine can activate more than one receptor and conversely. 
However, unique chemokine-chemokine receptor relationships do occur, e.g. CX3CL1- 
CX3CR1, CCL20-CCR6 and CXCL12-CXCR4 (Holman eta l., 2011; Roy eta l., 2014).
MMPs are proteolytic enzymes not only implicated in BBB disruption by degrading the 
ECM and basement membrane but also have a role in demyelination, cytokine 
activation and axonal damage (Comabella & Khoury, 2012). CSF and peripheral blood 
levels of MMP-2 and MMP-9 have been reported to be elevated in MS patients 
correlating with clinical and radiological disease activities (Alexander et al., 2010).
Until recently, MS research has mostly focused on the role of CD4+ T cells in disease 
pathogenesis. Myelin-specific CD4+ T cells are reactivated in the peripheral blood via 
myelin antigen presented in the context of HLA class II molecules in conjunction with 
accessory molecules on the surface of antigen presenting cells (APC) on macrophages 
and microglia (Comabella & Khoury, 2012). Reactivation triggers the release of pro- 
inflammatory cytokines, chemokines and soluble mediators that stimulate chemotaxis 
resulting in a second large wave of inflammatory cells recruitment into the CNS as 
described in figure (1-3).
Naive T cells differentiate into various T cell populations with different effector 
functions following activation. T h l cells release pro-inflammatory cytokines such as 
INF-y which activates macrophages to kill intracellular pathogens (Engelhardt et al., 
2005; Prat & Antel, 2005). IL-23 produced by macrophages and dendritic cells causes 
expansion of Th l7  cells that synthesis the pro-inflammatory cytokines IL-17, IL-21 and 
IL-22 (McFarland & Martin, 2007, Constantinescu et al., 2011).
CD8+ (cytotoxic) T cells increase tissue damage through further cytokine synthesis as 
well as granzyme and perforin production, leading to transection of axons (Fletcher et 
al., 2010). CD8+ T cells are present at the edge of lesions as well as in perivascular 
regions, while, CD4+ cell are generally only present at the lesion edge (McFarland & 
Martin, 2007). In addition, there is a higher frequency of CD8+ T cells recognising 
myelin proteins in patients with MS compared with healthy controls.
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It is indicated that CD4+ cells initiate the MS lesion, followed by clonal expansion of 
CD8 + T cells that amplify and mediate the damage (Medana et al., 2001, 
Constantinescu et al., 2011).
There is much evidence for an autoimmune pathogenesis in MS and the most likely 
targets are myelin proteins including myelin basic protein (MBP), myelin 
oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP). Indeed, increased 
circulating T cells with reactivity to amino acid residues 184-209 and 143-168 of both 
PLP and MBP respectively were found in patients with MS (Pender et al., 2007).
B cells are found within the perivascular space within inflammatory lesions, which 
release antibodies that in turn opsonise antigens expressed on oligodendrocytes and 
myelin (Alter et al., 2003). B cells also present antigens to T cells and secrete cytokines, 
which impact on the immune response within lesions. Several findings indicate that B 
cells undergo rapid division in the CNS in the affected areas, as short-lived 
plasmablasts are found in the inflammed CSF (Alter et al., 2003; Haider et al., 2011). 
Currently there is controversy over the presence of ectopic B cell follicles associated 
with the meninges, which are implicated in cortical demyelination (Aloisi et al., 2010).
1.8 The CNS extracellular matrix in MS
The extracellular matrix (ECM) is a complex structure which surrounds and supports 
cells in all tissue types and includes collagens, non-collagen protein, glycoproteins and 
proteoglycans. The components of the ECM vary greatly between tissue types and the 
CNS ECM lacks collagen, fibronectin and laminin, giving the brain a soft structure 
compared to other tissues (Yamaguchi, 2000; Barros et al., 2011). The ECM constitutes 
approximately 10-20% of the normal brain tissue and forms perineuronal nets (PNN). 
The ECM exists free or in aggregates bound to cell receptors, and is synthesised by 
both neurons and glial cells. It has been indicated that during maturation of the CNS, 
distinctive alterations in the composition of the molecules of ECM (lectican, tenascins 
and link protein) occurs in the brain (Mohan et al., 2010; Wiese et al., 2012). The ECM 
within PNNs helps regulate many physiological brain processes including development, 
migration of precursor cells, proliferation, repair and cell signalling (Bellail et al., 2004; 
Lau et al., 2013).
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The PNN consists of a condensed layer of mesh-like matrix composed largely of 
hyaluronan, proteoglycans (PGs), tenascin R (TR) and link proteins that surround 
neuronal bodies and proximal dendrites (Kwok et al., 2011). PGs consist of a core 
protein to which glycosaminoglycan (GAG) side chains attach. Individual PGs differ in 
the composition of either their core protein or the number and types of GAG side 
chains; that is, they determine whether the molecule is a dermatan sulphate 
proteoglycan (DSPGs), chondroitin sulphate proteoglycan (CSPGs), keratin sulphate 
proteoglycan (KSPGs) or a heparan sulphate proteoglycan (HSPGs) (Jones & Tuszynski, 
2002; Van Horssen et al., 2007; Shute, 2012).
1.8.1 Chondroitin Sulphate Proteoglycans
1.8.1.1 Structure and function in the CNS
Chondroitin sulphate proteoglycans (CSPGs) are expressed in various tissues; those 
expressed in the CNS fall into three families: lecticans (aggrecan, versican, neurocan 
and brevican), phosphacan known as protein tyrosine phosphatase-3 (RPTP-3) ar|d 
neuron-glial antigen 2 (NG2) (Sugahara et al., 2007; Pendleton et al., 2013). Three 
major nervous tissue specific CSPGs including, neurocan, phosphacan and brevican 
have been described (Kurazono et al., 2001; Inatani et al., 2001). CSPGs are a family of 
single-core protein PGs with attached side chains of GAG as shown in figure (1-4). 
Lecticans share a tridomain structure; an N-terminal domain (G l) that binds to 
hyaluronan through link proteins such as brain link protein-1 (BRAL-1), a central 
domain that can be glycanated to various degrees and a C-terminal domain (G3) that 
binds to other ECM proteins such as TR (Galtery et al., 2007; Lau et al., 2013).
The core protein of aggrecan has an additional domain, G2, consisting of two link 
proteins. GAGs have considerable heterogeneity within the lectican family and the full 
length core protein ranges in size from 90KDa to 400KDa, and the number of GAG side 
chains ranges from 20-200 (Table 1-1) (Schaefer et al., 2010). NG2 is the only 
transmembrane CSPG and is expressed on oligodendrocyte precursor cells (Biname et 
al., 2013). Alternative splicing of mRNA that encodes GAG binding regions generates 
versican into four isoforms including V0 (contains all domains), V I  (contains GAG-B), 
V2 (contains GAG-a), and V3 consist of G1/G2) (Zako et al., 1995; Wu et al., 2005).
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Table 1-1: CSPG isoforms and their interactions with hyaluronan 
receptors in CNS extracellular matrix
CSPGs GAGs
CNS-
Specific
Link Protein
GAG
number
core protein 
size KDa
Aggrecan CS/KS NO CRTL1 -1 0 0 224
Versican VO CS NO BRAL1 17-23 370
Versican V I CS NO BRAL1 12-15 262
Versican V2 CS NO BRAL1 5-8 180
Neurocan CS Yes BRAL1 3 133
Brevican CS Yes BRAL2 0-5 79
Phosphacan CS/KS Yes No HA binding 3-4 173
CS; Chondroitin sulphate, CSPGs; Chondroitin sulphate proteoglycan, GAGs; 
Glycosaminoglycans, KS; Keratin sulphate; CRTL; Cartilage link protein; BRAL; Brain link 
protein; HA; Hyaluronan. Table adapted from Galtrey e t a!., (2007).
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Besides the distribution of lectican indicated in figure (1-4), CSPGs are also present in 
the perinodal matrix surrounding nodes of Ranvier in myelinated axons (Bekku et a l, 
2010). It has been reported that there are distinctive changes in the ECM molecules 
during maturation of the CNS. In the adult brain, brevican, versican V2, aggrecan, 
Tenascin-R (TR) are major ECM components while neurocan, versican V I, and tenascin- 
C are characteristic components of developing brain ECM (Hirakawa et al., 2000). The 
main functions of CSPGs are dependent on their interactions with components of 
several receptor systems, including leukocyte common antigen-related phosphate 
(Fisher et al., 2011), protein tyrosine phosphate (Shen et al., 2009), epidermal growth 
factor receptors (Koprivica et al., 2005), Toll-like receptors (Jiang et al., 2007; Kim et al., 
2009), CD44 and Nogo receptor family members (Nogo receptors) NgRl and NgR3 
(Dickendesher et al., 2012). However, the roles of CSPGs in developing brain ECM 
might differ from that in the injured adult CNS and over expression in injured brain 
may lead to inhibition of neurite outgrowth and axonal regeneration (Nieto-Sampedro, 
1999; Deller et al., 2000; Schmalfeld et al., 2000; Levine et al., 2001. Lectican 
expression is affected by a variety of stimuli, including cytokines, chemokines and 
adhesion molecules (Jander et al., 2000; Asher et al., 2000; Viapiano & Matthews, 
2006).
1.8.2 CSPG expression changes in demyelination and remyelination in 
MS
Failure of remyelination is a critical impediment to recovery in demyelinating diseases 
such as MS (Patrikio et al., 2006; Albert et al., 2007). Within MS lesions, 
oligodendrocyte precursor cells (OPCs) can be found in areas with demyelinated axons, 
yet many of these do not go on to form compact myelin (Chang et al., 2002; Kuhlmann 
et a l, 2008). CSPGs have been reported to accumulate also in MS lesions and inhibit 
remyelination by impairing OPCs (Figure 1-5) (Back et a l,  2005; Gregg et a l,  2007; 
Sloane et a l,  2010). PNNs are also lost around neurons in demyelinated regions, and 
many of the affected neurons appear to be compromised, as indicated by 
accumulation of phosphorylated neurofilament protein in their cell bodies. It is 
unknown whether these changes in PNNs affect synaptic plasticity and function (Gray 
et a l,  2008).
20
(0
E
v._ro
_3
13ufU
+■*X0J
to
Z
u
Q )
J Z
to
0 )
■D
0
E
(DL_
34-*
u
3l.4-»to
1
rH
<Ul.
3
W>
O
(Ul_34-»u3
4-*to
O
'J7?
co
CQ
'to'
U
•3
cro
to
Co
*5bO)
c
CD
E
SZoro4->4-*ro
tocj
ro+->ro
SZ
_Q-
3to
-o
Co
x:u
croco
ro>•
s i
to-a
c
rox
o
‘ro
Eo-o
"ro
c
£
ro
■orotoo
a.
Eou
cro_u
uro
ro
■3o
£
"ros—
34—1u
3l_4->
to
crou
4-»u_ro
ro
CL >• 4—1 Iu
CDLU
C
‘ro
Eo
-a
ot_00
"ro
E
ro33
‘a.ro
toc
coo
ro
CD
ro
ro
Eo•3
CD —ro
J S
00
3
S3_o
00oo
3
E
E
cro
toc
‘ro4->cou
H
CD
ro
CD
ro
Eo
-a
"roc
ro
LO
tHoCM
ro
ro*aroro
*3ro4->Q.ro
*3ro
roi_
3
00
Q.
CO
Uro
— c 
‘ro
E o
”3
ro
c 
‘ro
Z  
Z
Cl
4-»ro cO —hr coc ororoo.ro
cro
EJTO
Q.
Eou
"3Cro
c
‘ro
Eo-3
ro_x
3ro
c
uroa
ro
o
£ro
’>
u
*3ro
Erox:uto
oroo
4->u_ro
ro
XH
to
"rou
15
"ob
"3
cro
"rocol_
3ro
c
ororo
>»
a.
3Uuo
"3
Cro
U
ro
c o
c
‘utoro
oro4->
■3Cro
< “
oroco
ro>*
torox_ro
a.
Eou
ro>-
o
S3
ororo
roXJ
toc
o
4-»Uroi_ro4->
c
a
u
>.X
to
"rou
ro x
toro u ro o.10
■S I
00 
"3c ro
"ro c ol_
3ro o
O .b=
■3ro
xuro4->4->ro
to
croco
ro>*sz
“3cro
to
3C
+-icu
Xrooco
CQ
Eo
■3ro4—1Q.ro
•3ro
roi-
3
00
‘ro
E0
-3
"ro
c
Ei—ro4->1u
t_
‘ro
>>
X
ro
>•
S3
Oroco
ro>.
to
*3
C
X
>
E.ro
to
CD
CL
tou
TJ
cro
toro
4—1to
‘xro
to
c o
\ -
toC
ro4-*O1_Q.
>*
S i
"3roM
15ro4->to
ro
ro
crou
4->u •
.22 cn
?  §E CN
CM
C\|
CN
i$ t
o
f U
2
S’
<~S>-x
-
Gli
a 
tra
ns
m
em
br
an
e 
re
ce
pt
or
s
There is now considerable evidence indicating that the CSPGs affect oligodendrocyte 
lineage cells, including their proliferation, survival, migration, differentiation, process 
extension and myelination (Sherman et al., 2008; Lin et al., 2011). Cell culture studies 
have emphasised that CSPGs inhibit the spreading and survival of oligodendrocytes by 
interacting with (31 integrin to trigger signalling cascades. Treatment of human 
neuronal cells with chondroitinase ABC increased the number of OPCs in the 
surrounding lesion, and the addition of growth factors promoted the differentiation of 
transplanted OPCs into mature oligodendrocytes (Karimi et al., 2012).
CSPG biosynthesis is catalysed by a series of intracellular enzymes including 
xylosyltransferase-1, which is required during CSPG synthesis to form xylose-galactose- 
galactose-glucuronic acid which initiates GAG polymerisation on the core protein. 
Notably, targeting of xylosyltransferase-1 mRNA with locally applied mRNA knockdown 
disrupted CSPG production in the ECM, resulting in increased axonal regeneration 
around lesion in mouse model of MS (Grimpe et al., 2004; Lau et al., 2013).
Another enzymatic approach are MMPs, a disintegrin and metalloproteinase (ADAM) 
and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTSs) that 
clear deposited CSPGs and maintain the dynamic nature of the PPNs which relies upon 
constitutive remodelling by numerous factors (Yong et al., 2005; Apte, 2009; Sorokin et 
al., 2010; Rodriguez e ta l., 2010; Kucharova eta l., 2011).
A subgroup of the ADAMTSs has glutamyl endopeptidase (GEP) activity and they have 
the ability to cleave CSPGs and are also upregulated in MS lesions (Westling et al., 
2004; Induklenmesi et al., 2014). These enzymes probably influence the lesion 
microenvironment during remyelination as several members of this protein family 
cleave laminin, CSPGs and ECM receptors such as integrins (Sternlicht & Werb et al., 
2001; Rodriguez et al., 2010). For instance; in mouse models of spinal cord injury, 
increased ADAMTS-4 expression reduced glial scaring and improved locomotor 
recovery associated with axon regeneration (Tauchi et al., 2012).
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Figure 1-5: Strategies to overcome the CSPG-mediated inhibition of 
remyelination
This schematic depicts a demyelinated CNS MS lesion (white circle), such as that 
observed in MS. Chondroitin sulphate proteoglycan (CSPG) is observed in the ECM at 
the lesion edge (red box), while macrophages containing CSPG immunoreactive 
material are encountered in the lesion core (Green box), presumably because these 
cells have phagocytosed CSPGs previously and because macrophages and activated 
microglia as well as reactive astrocytes can be a source of CSPGs. There is a high 
number of OPCs in normal appearing white matter, but these may be unable to 
repopulate in the lesion core owing in part to the non-permissive CSPG barrier. High 
levels of CSPGs are implicated in inhibition of re-myelination and digestion products o f  
CSPGs by particular proteases have been reported to retard myelin repair (Tauchi et al.,
2012). Several mechanisms have been proposed to enhance the repair of myelin and 
neurite outgrowth in demyelinating diseases such as MS. These include enzymatic 
clearance of deposited ECM [matrix metalloproteinase (MMPs), a disintegrin and 
metalloproteinase (ADAMs) and a disintegrin and metalloproteinase with 
thrombospondin motifs (ADAMTSs)], enzymatic removal of the GAG chains of CSPGs 
(chondroitinase ABC), reducing the synthesis of inhibitory molecules of neurite 
outgrowth by blocking of xylosyltransferase-1 which is required during CSPG synthesis. 
An increase in expression is indicated with a 1s arrow and a decrease in expression is 
indicated with a sf arrow. Figure adapted from Lau et al., (2013).
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1.8.3 Molecular mechanism of CSPG inhibition of neurite outgrowth
Neurite outgrowth is a key process during neuronal migration and differentiation, and 
is a complex process that occurs in three stages (1) "sprouting" initiation of neurite 
formation, (2) "path finding" elongation of neurite over long distances and guidance of 
their axons to the appropriate target and (3) synapse information and functional 
maturation of the newly formed connection (Johnson & Michell, 2015; Khodosevich & 
Monyer, 2010). Axon elongation, formation of synapses, axon regeneration and signal 
connection between neuronal cells are essential processes for maintenance of the CNS, 
and many molecules are involved in neurite outgrowth from cytoskeleton constituents 
to membrane receptors (Johnson & Michell, 2015). However, in the new-born and 
even in the mature animal, axon injury leads to severe functional deficits, as in patients 
with MS (Sharma et al., 2012).
The failure of destroyed axons to repair and regenerate after CNS injury has been 
described as due to two factors; a developmental reduction in the intrinsic growth 
factors and environmental factors (lbanze& Simi, 2012; Kwok et al., 2012; Dick et al., 
2013) . It is now clear that the intrinsic growth capacity relies on expression and 
activation of numerous independent cell molecules that are implicated in signalling by 
both classes of growth promoting and growth inhibitory environmental factors (Park et 
al., 2010). An important classes of extrinsic growth inhibitory is the CSPGs, myelin 
associated growth factors and chemo-repulsive guidance molecules which are 
components of the ECM comprising the PNNs (Liu et al., 2006; Piaton eta l., 2011; Tong 
eta l., 2013).
In fact, several general mechanisms involving receptors have been reported in the
inhibition of neurite outgrowth via GSPGs including, integrins (Asfari et al., 2010; Tan
et al., 2011), and leukocyte antigen receptors (LAR) (Fry et al., 2010; Takashashi et al.,
2013) and NgRl /  NgR3 (nogo-66 receptor-l/3)(Shen et al., 2009; Fisher et al., 2011;
Dickendesher et al., 2012). The intracellular effects of most axon growth-suppressing
proteins are mediated by activation of the GPI-binding protein, RhoA, which is a
signalling molecule regulating neuronal morphogenesis by interaction with several
other enzymes such as serine threonine kinases, lipid kinase, oxidase tyrosine kinase
(Luo, 2000; Mueller et al., 2005, Walker et al., 2005; Rollof et al., 2015). Reaction of
GPI-binding protein with RhoA leads immediately to activate Rho kinase (ROCK), which
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leads to phosphorylation of several target proteins, including myosin light chains and 
mediating cytoskeletal rearrangement and disassembly in neurons and collapse of 
growth cones (Mckerracher et al., 2012; Forgione & Fehling, 2014). Further strategies 
to overcome CSPG and hyaluronan-mediated inhibition of neurite outgrowth include 
semaphorins (Serna 5 A) (Hilario et al., 2009; Dick et al., 2013), neutrotrophins (Liu et 
al., 2010), and protein tyrosine phosphate (PTP) (Chien et al., 2013) and calcium 
channels (Ca++) (Hrabetova et al., 2009; Kadomatus & Sakamoto, 2014) as described in 
figure (1-6).
1.9 Matrix metalloproteinases
1.9.1 Matrix metalloproteinase family proteins
The matrix metalloproteinase (MMP) family consisting of 25 members is a group of 
Zn-dependent proteolytic enzymes that are implicated in the remodelling of the ECM 
in a variety of physiological and pathological processes (Rosenberg et al., 2002; Mandal 
et al., 2003; Lui & Rosenberg, 2005). Based upon their main substrate specificity, they 
are divided into collagenases, gelatinases, stromelysins and membrane type (MT)- 
MMPs, which are capable of degrading ECM components; collagen, proteoglycan, 
elastin, laminin and fibronectin (Leppert eta l., 2001; Szabo eta l., 2004).
MMPs are synthesised as preproenzymes secreted from cells as zymogens with an 
inhibitory N-terminal pro-peptide sequence which are activated in the ECM via 
cleavage by serine family protease enzymes such as plasmin (Gingras et al., 2000; 
Rosenberg, 2002). MMPs play pathological and detrimental roles in MS including 
breakdown of the BBB and myelin sheath (Chandler et al., 1997; Kouwenhoven et al., 
2001; Larochelle et al., 2011; Sato et al., 2012). MMPs can be regulated at four levels; 
pro-enzyme activation, gene expression, enzyme secretion and by tissue inhibitors of 
MMP (TIMPs) which are reported to be constitutively expressed in normal brain 
(Leppert et al., 2001).
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1.9.2 MMPs in MS
In the CNS, gelatinases, stromelysins and MT-MMPs make up the majority of MMPs 
present, with MMPs 2, 3 and 9, being the most significant (Muir et al., 2002; Verslegers 
et al., 2013). MMP3 is known to activate MMP-9 via causing removal of the peptidase 
that maintains the activity of the zinc binding site (Gu eta l., 2002). MMP2 and 9 act on 
fewer ECM substrates than MMP3, but process important components of the basal 
lamina (Yong et al., 2001; Yang & Rosenberg, 2011). It has been indicated that up- 
regulation of MMPs and a relative decrease in their TIMP inhibitor, may produce 
persistent proteolysis, resulting in the neuronal loss that represents the steady 
advance of symptoms of secondary chronic progression in MS (Lindberg et al., 2001). 
The serum, CSF and brain tissue of MS patients all showed an increase in MMPs 1, 2, 3, 
7, 9 and 12. MMPs in particular, are thought to assist with T cell migration into the CNS, 
high levels of MMPs are detected in astrocytes and macrophages in demyelinating 
lesions and in the CSF of MS patients (Szabo et al., 2004; Kurzepa et al., 2005; Brosnan 
et al., 2013).
1.10 ADAM family proteins
The ADAMs comprise the adamalysin subfamily of the metazincins (Killar et al., 1999; 
Rawling et al., 2013), and are important in regulating cell phenotype by their effect on 
growth factors, cytokines, cell adhesion molecules and cell immigration (Andreini et al., 
2005; Klein & Bischoff, 2011). ADAMs are transmembrane proteins which are 
implicated in pathological processes including cancer metastasis and inflammatory 
diseases such as MS (Plumb et al., 2006; Shiomi et al., 2010). The ADAM family of 
proteins include the adamalysin subfamily of the metzincins along with the snake 
venom metalloproteinase. ADAMs are similar to matrixins in that the 
metalloproteinase consists of a multi-domain protein with pro-domain, 
metalloproteinase, disintegrin, cysteine-rich, epidermal growth factor (EGF)-like, 
transmembrane and cytoplasmic tail domains (Weber et al., 2013) (Figure 1-7). ADAM 
17 is mainly implicated in CNS inflammatory disorders, through cleavage of a wide 
variety of proteins including; chemokine, amyloid precursor protein, transforming 
growth factors (TGF-a), TNF and TNF receptors (Garton et al., 2001; Allinson et al., 
2003; Scott et al, 2011).
30
1.10.1 ADAM-17 in MS
ADAM-17 is a membrane bound enzyme that cleaves cell surface proteins. It is a 
polypeptide of 824 amino acids and its gene is found on chromosome 2p25. ADAM-17 
has the ability to take part in a broad range of functions and has immune-mediated 
functions through modulation of shedding of proteins vital to the immune response 
(Holdt et al., 2008; Gooz, 2010). Within normal brain, ADAM-17 expression has been 
observed in both neuronal and endothelial cells (Goddard et al., 2001). In MS white 
matter, ADAM-17 expression is upregulated in neuronal cells, endothelial cells and 
macrophages and CD3 T lymphocytes (Keiseier et al., 2003; Plumb et al., 2006). 
Previous findings indicated that ADAM-17 is implicated in the pathogenesis of MS via 
cleavage of membrane bound TNF, releasing soluble TNF, which has several pro- 
inflammatory effects including, up regulation of cell adhesion leading to increased 
endothelial cell attachment of immune cells, induction of chemokines, and subsequent 
migration and BBB disruption (Scheller et al., 2011; Kaltsonoudis et al., 2014). 
Abnormally upregulated ADAM-17 may induce a beneficial immune response by 
producing apoptosis of autoreactive T cells (Probert & Akassoglou, 2001; Weishaupt et 
al., 2004).
1.11 ADAMTSs
1.11.1 Overview of ADAMTS
ADAMTSs (a disintegrin and metalloproteinase with thrombospondin motifs) were first 
described in mice by Kuno and colleagues in 1997. ADAMTSs are also part of the 
adamalysin subfamily of metalloproteinases, thus they contain zinc and have highly 
conserved thrombospondin motifs with some molecules having substantial 
proteoglycanase and anti-angiogenic activity (Andreini et al., 1997; Bornstein, 1992; 
Tang, 2001). Nineteen distinct human ADAMTS genes have been identified, numbered 
1-20, and their functions are limited to a few specific members in the CNS. Many 
orphan ADAMTSs, their substrates and activities are still not known. ADAMTS-1, -4, -5 
and -9 express strong proteoglycanase activity against large aggregating CSPGs and 
their activity can be inhibited by TIMP-3 (Porter et al., 2005; Rivera et al., 2010).
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1.11.2 Basic domain structure and functions of ADAMTSs
The structure of ADAMTSs and ADAMs is highly conserved and the main difference 
between them is that ADAMTSs are secreted proteins, while ADAMs are trans­
membrane proteins. As illustrated in Figure (1-8) the detailed structure of ADAMTS 
domains are shared with ADAMs, with the prodomain followed by the catalytic active 
site and metalloproteinase domain containing the zinc binding site. ADAMTS molecules 
are characterized by various numbers of thrombospondin like repeats (TSR-1) and at 
their C-terminal lack transmembrane and cytoplasmic domains (Paulissen et al., 2009; 
Lin & Liu, 2010).
ADAMTSs can be expressed in multiple isoforms due to their alternative gene splicing, 
and they are translated originally as inactive pre-proenzymes, whose structure 
includes; a signal peptide, a pro-domain, a catalytic domain, a disintegrin-like domain, 
a central thrombospondin type-1 like (TS) repeat, a cysteine-rich domain, a spacer 
region and a variable number of C-terminal TS repeats (Kuno et al., 2000; Porter et al., 
2005).
As seen in Figure (1-8), the C-terminal of ADAMTS-20 possesses a 14 TSR-1 repeat that 
is important for the ability of ADAMTS-20 to bind to different molecules of the ECM. 
ADAMTS-4 lacks the C-terminal (TS) repeat and has the ability to bind to ECM 
molecules by its spacer region (which correlates with the C-terminal of fibronectin) 
(Tortorella eta l., 2000; Hashimoto eta l., 2004).
1.11.2.1 Signal peptide and prodomain of ADAMTSs
The N-terminus of ADAMTSs contains a signal sequence that directs its post-translation 
transport into the secretory pathway by the endoplasmic reticulum. Signal peptides 
vary in length between the ADAMTSs (5-30 amino acids), very short in ADAMTS-13, 
and is removed from the protein prior to secretion (Dunn et al., 2006; Tauchi et al.,
2013).
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The signal peptide is followed by the pro-domain that keeps the metalloproteinase site 
of ADAMTSs in the inactive form. The pro-domain exhibits a high level of similarity 
between ADAMTSs (220-300 amino acids), the exclusion to this rule is ADAMTS-13 
which has 74 amino acids (Cao et al., 2000; Longpre & Leduc, 2004). The prodomain 
possesses cleavage sites for a furin cleavage consensus motif. Thus, it is generally 
believed that zymogen forms of ADAMTSs are cleaved intracellularly and then the 
protein is produced in its mature forms. This process of maturation was supported by 
studies of ADAMTS-1 and -4, which identified that furin interacts with the pro-form of 
these ADAMTSs to co-localise within the trans-Golgi network (Longpre & Leduc, 2004; 
Wang et al., 2004). However, not all ADAMTSs increase in catalytic activity when 
cleaved, as seen in ADAMTS-9, which is resistant to furin cleavage in the secretory 
pathway (Koo et al., 2007) as well as ADAMTS-13, which does not require prodomain 
cleavage for cleavage of von Willbrand factor (vWF) (Majerus et al., 2003).
1.11.2.2 Metalloproteinase domain of ADAMTSs
The catalytic domain of ADAMTSs shares a high degree of similarity and has a zinc- 
binding sequence HEXXHXXG that distinguishes the ADAMTS and ADAM family from 
MMPs ("X" = any amino acid residue). It is essential for the zinc ion to be bound to the 
histidine residues within the catalytic domain in order for ADAMTSs to be active, this 
known as the zinc binding motif (ZBM). The zinc activates water molecules by 
reduction of hydrogen atoms, rendering it a reactive nucleophile with the ability to 
attack peptide carbonyl groups. The glutamate (E) has been shown to have an essential 
role in this process by polarising the water molecules through hydrogen bonding 
(Andrein et al., 2005; Gottschall & Howell, 2015).
1.11.2.3 Ancillary domain of ADAMTSs
The C-terminal domains of the ADAMTSs are known as the ancillary domains. The 
catalytic domain of all ADAMTSs is followed by a highly conserved 60-90 amino acid 
domain with the primary sequence having similarity to snake venom disintegrins 
known as the disintegrin-like domain. These primary sequences have an integrin 
recognition sequence, arginine/glycine/aspartic acid (RGD), which binds to the 
superfamily adhesion molecule integrins. Unlike ADAMs, the C-terminal to the 
disintegrin like domain is highly conserved, with a 45-54 amino acid central TSP-1
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domain. TSP-1 is a glycoprotein proven to have an essential role in wound healing, 
inflammation and angioinhibition. This is followed by a cysteine rich domain and 
spacer regions (Porter et al., 2005; Takeda et al., 2012).
The cysteine rich domain (CRD) is highly homologous between all ADAMTSs and 
consists of ten cysteine residues. The CRD is believed to promote cell adhesion 
molecules through interacting with ECM proteins including fibronectin and syndecans 
(Rivera et al., 2010). The next domain downstream to the CRD is a cysteine-free spacer 
region; both are implicated in the binding to CSPGs (Stanton et al., 2011). The spacer 
domain on ADAMTS-4 is believed to interact with the GAG side chains on aggrecan 
allowing proteolysis to take place (Kashiwagi et al., 2004). Following the spacer region, 
a variable number of TSP repeats from 1 to 14 and further domains on certain ADAMTS 
enzymes are present (Figure 1-8).
1.11.3 Function of ADAMTSs subgroups
Phylogenetic tests of the ADAMTSs indicated that family members could be divided 
into three subgroups on the basis of their sequence similarities and, where known, 
their cleavage of target substrates, which are specific ECM macromolecules as follows 
(Lemarchant et al., 2013): proteoglycans (ADAMTS-1, -4, -5, -8, -9 and -15 and -20), 
pro-collagen (ADAMTS-2, -3 and -14), or von Willebrand factor (ADAMTS-13), which is 
implicated in blood coagulation homeostasis (Grawley et al., 2011). ADAMTS-13 is 
least like any other ADAMTSs as shown in figure (1-8). All members of the subgroup 
consisting of ADAMTS-1, -4, -5, -8, -9, -15 and -20 have all been shown to cleave 
lecticans and have thus been termed as hyalectanase "aggrecanases". There is 
subdivision into two further groups, one composed of ADAMTS-9 and 20 and the other 
of ADAMTS-1, -4, -5, -8 and -15. Though ADAMTS-9 is classified as Gon-ADAMTS with 
ADAMTS-20, it is able to cleave versican (Isik eta l., 2015).
Several ADAMTSs including ADAMTS-2, -3, -10, -14, -17 and -19 have protease and 
lacunin (PLAC) containing domains with six conserved cysteine resides that are found
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Figure 1-8: Domain structure of ADAMTS proteins
A schematic representation of the structure of the distinct human ADAMTS family. The 
ADAMTSs have the same general structure in that they all contain a signal peptide, a 
pro-domain, a metalloproteinase domain, disintegrin-like domain, a central TSP-1, a 
cysteine rich domain (CRD), a spacer domain and a variable number of C-terminus TSP- 
1 motifs. Additional domains are present at the C-terminal of particular ADAMTSs 
including protease and lacunin motif (PLAC), Gon-1 domain and cubulin domain motif 
(CUB). Figure adapted from Porter et al., (2005).
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in some protein convertases and their function is still not known (Gottschall & Howell, 
2015). A C-terminal extension comprising a distinctive embedded PLAC domain is 
found in ADAMTS-2, -3 and -14 (Colige, 2010; Jones& Riley, 2005). Additional C- 
terminal domains are present in ADAMTS-13 includs two cubilin domains (CUB). In 
addition to proteoglycan cleavage, ADAMTS-1 and -8 have the ability to regulate and 
inhibit angiogenesis via suppressing growth factors including fibroblast growth factor-2 
(FGF) and vascular endothelial growth factor (VEGF) (Vong & Kalluri, 2011; Kumer et al., 
2012).
1.11.4 ADAMTS proteoglycanases in the physiology of the CNS
ADAMTS proteoglycanases are present in several CNS structures including the cortex, 
the hippocampus, striatum and the spinal cord (Lemarchant et al., 2013). While it is 
clear that neurons and glia express ADAMTS proteoglycanases in vitro and in vivo> their 
presence in neuronal cells under physiological condition is controversial. Evidence 
exists for the presence of ADAMTS-1, -4 and ADAMTS-cleaved brevican fragment in 
physiological rat brain, particularly in regions such as the hippocampus, suggesting the 
involvement of the ADAMTS in the plasticity of PNNs (Gottschall & Matthew, 2015).
Hamel et al., (2008) indicated active ADAMTS-4 promoted neurite outgrowth of 
cortical neurons in vitro by; i) breakdown of CSPGs by its proteolytic activity, and by ii) 
activating the mitogen activated protein (MAP) and extracellular signal-regulated 
kinase (ERK) signalling pathways, presumably due to the activation of tyrosine kinase 
receptors by the TSP-1 domain of ADAMTS-4 (Hamel et al., 2008). The expression of 
synaptic proteins, such as synaptosomal associated protein 25 (SNAP-25), postsynaptic 
density protein (PSD-95) and synaptophysin, was down-regulated in developing frontal 
cortex of ADAMTS-1 deficient mice, suggesting specific involvement of ADAMTS-1 in 
synaptic plasticity (Howell et al., 2012). Others indicated that ADAMTS-4 and 
ADAMTS-5 are capable of cleaving Reelin, which is involved in neurodevelopment and 
in synaptic plasticity induced learning and memory processes (Krstic e ta i ,  2012).
1.11.5 ADAMTS proteoglycanases in the pathological CNS
ADAMTS breakdown of the ECM can be both beneficial and harmful in various 
pathological states of the CNS including, ischemic stroke and spinal cord injury 
(Lemarchant et al., 2013). An increased synthesis of ADAMTS-4, -5 and -9 by
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astrocytes was reported after transient middle cerebral artery occlusion (tMCAO) (Reid 
et al., 2009; Zamanian et al., 2012). Several cytokines including, IL-lp, IL-6, INF-y, 
transforming growth factor (TGF) and TNF have previously been described to 
upregulate the expression of ADAMTS proteoglycanases in CNS cell types. IL -la  in 
combination with the IL-1 receptor promoted ADAMTS-1 transcription in N1E-115 
neuroblastoma cell line in vitro and in motoneurons after nerve injury in vivo (Sasaki et 
al., 2001).
ADAMTS-4 mRNA and protein expression was increased by TNF in human astrocytes in 
vitro, whereas only up-regulation of ADAMTS-1 mRNA and ADAMTS-5 protein level 
was upregulated under the same conditions (Cross et al., 2006). TNF-a and INF-y 
increased the expression of ADAMTS-4 in macrophages induced by differentiation of 
human monocyte cell line THP1 (Wagsater et al., 2008). In experimental autoimmune 
encephalomyelitis (EAE), differential expression of ADAMTS-1, -4, -5 and TIMP-3 was 
seen at various stages of disease progression. There have been a limited number of 
reports in other CNS disorders focusing on ADAMTS involvement. ADAMTS-1 
expression was demonstrated to be up-regulated in Down's syndrome, Pick's and 
Alzheimer's disease (Miguel eta!., 2005).
1.11.6 ADAMTSs in MS
ADAMTS-1, -4, -5, -8, -9 and 15 are glutamate endopeptidase (GEPs), cleaving peptide
bonds at the carboxyl end of the glutamate residues, and can cleave the major
cartilage proteoglycan (Porter et al., 2005). ADAMTS-1 is expressed in all human
tissues with high expression in heart, thyroid, skeletal muscle and placenta. ADAMTS-1
can cleave both aggrecan and versican and is up-regulated by pro-inflammatory
cytokines (Demircan et al., 2013; Ren et al., 2013). Other reports indicate that
ADAMTS-1 cleaves aggrecan in vitro and the spacer region is essential for this (Kuno et
al., 2000). Most studies are reported on aggrecanases ADAMTS-4 and 5 which cleave
aggrecan at the GLu373-Ala374 bond, and at the four other sites within the GAG-
attachment region between The G2 and G3 globular domain including GLul480-
Glyl481, G lul667-Glyl668, G lul771-Alal772 and G lul871-Leul782 as shown in Figure
(1-9). Aggrecan neoepitopes produced by cleavage at all of these sites by ADAMTS-4
and ADAMTS-5 have been detected in bovine articular cartilage explants treated with
pro-inflammatory cytokines to enhance aggrecan release (Tortorella et al., 2001).
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ADAMTS-4 and 5 can also cleave brevican, predominantly expressed in CNS tissue 
(Matthews et al, 2000). In addition, differential expression of ADAMTS-1, 4 and 5 were 
identified during different lesion stages in MS which may contribute to ECM 
degradation in disease progression (Tauchi et al., 2012). Previous studies in our 
laboratory emphasise the up-regulation of ADAMTS-4 in active lesions of MS (Cross et 
al., 2006).
ADAMTS-9 was also identified as an aggrecanase and versicanase, cleaving aggrecan at 
the Glu373-Ala374 bond and versican at the Glu441- Ala442 bond (Somerville et al., 
2003). ADAMTS-9 was produced by astrocytes and was also up regulated after spinal 
cord injury in mice (Demircan eta l., 2013).
Despite the fact ADAMTS-9 is clearly expressed in abundance in the CNS (Ried et al., 
2009), no studies have focussed specifically on the protein expression in the brain.
ADAMTS-9 may also degrade other CSPGs proteins brevican and neurocan, on which 
the peptidase has yet to be tested. Therefore ADAMTS-9 could be implicated in normal 
ECM turnover e.g. cleaning a path for the migration of precursor cells. Other studies 
have demonstrated that ADAMTS-9 is up-regulated in response to pro-inflammatory 
cytokines, in particular IL-ip, TNF and INF-T (Reid et al., 2009). However, anti­
inflammatory mediators, for example TGF-01, have been shown to down-regulate 
ADAMTS-9 in neuronal cell lines (Cross et al., 2005). Following astrogliosis which 
accompanies neuronal injury, ADAMTS-9 has the ability to degrade HSPGs present in 
glial scars (Trendelenburg & Dirnagl, 2005). As ADAMTS-9 has a number of roles in 
both normal and injured CNS tissues, it is important to analyse the expression profile 
and modulation of ADAMTS-9 in the brain to provide a better understanding of its role 
in MS.
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Figure 1-9: Proteolytic cleavage sites of CSPG
Structural models of aggrecan and versican isoforms (VO, V I and V3) share the same
feature of large CSPGs with G1 and G3 domain with GAG region in between, ADAMTS 
cleavage site and binding regions of the polyclonal antibodies used in 
immunohistochemical studies in this thesis are displayed in the figures. Figure adapted 
from Zimmermann & Dours-Zimmermann (2008).
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1.12 The aims and objective of this study 
Hypotheses:
•  CSPGs are up-regulated in MS and contribute to lack of neuronal regeneration 
by preventing migration of oligodendrocyte precursor cells. Breakdown of 
CSPGs by ADAMTSs may enable axonal outgrowth and repair. Conversely, it 
may assist the access of inflammatory cells and the secretion of cytokines 
which may promote axonal damage.
•  Increased ADAMTS-9 activity in the brain causes breakdown of ECM 
components in MS
•  Neuronal ADAMTS-9 expression is modulated in response to proinflammatory 
cytokines in vitro.
Objectives
•  To determine the distribution of CSPGs; aggrecan and versican in CNS 
in vivo in control white matter, MS NAWM and MS lesions using 
immunohistochemistry (IHC) and western blotting (WB).
•  To detect CSPG degradation by ADAMTSs in vivo by the detection of 
neoepitopes of ECM components in normal and MS CNS tissue using 
IHC and WB.
•  Determination of expression of ADAMTS-9 within MS and control 
white matter at the protein level by immunofluorescence and western 
blotting and at the mRNA level by qRT-PCR.
•  To assess the impact of aggrecan on neurite outgrowth using in-cell 
ELISA, immunocytochemistry (ICC) and WB detection of neurofilament- 
L (NF-L) expression.
•  To analyse the modulation of ADAMTS-9 expression by cytokines 
relevant to CNS inflammation in MS in microglia, astrocytes and 
neuronal cells in vitro.
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Chapter 2
M a t e r i a l s  a n d  M e t h o d s
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Chapter 3
E x p r e s s i o n  o f  w h i t e  m a t t e r  e x t r a c e l l u l a r  
m a t r i x  c h o n d r o i t i n  s u l p h a t e  p r o t e o g l y c a n s  
a n d  t h e i r  n e o e p i t o p e s  i n  t h e  C N S  i n  m u l t i p l e  
s c l e r o s i s  a n d  c o n t r o l s
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2.1 Human brain tissue
The UK MS Society Tissue Bank, situated at Imperial College School of Medicine at 
Hammersmith Hospital, London, was established in 2007 by the Multiple Sclerosis 
Society to co-ordinate the collection of tissue from donors, and distributes high quality 
CNS tissue samples to MS researchers.
Snap-frozen autopsy brain tissue from twenty eight clinically and neuropathologically 
confirmed MS cases, together with eight normal control cases were received from the 
UK MS Society Tissue Bank. Informed consent and ethical approval for the MS Tissue 
Bank was obtained through multi-centre research ethics approval (MREC; 
08/MRE09/31) (Appendix I). Snap-frozen brain blocks were transported on dry ice, 
before being stored in airtight containers in a -80°C freezer until required. Control 
tissues were matched to MS tissue as closely as possible, in terms of the corresponding 
region of the brain.
The MS cases included 17 females, mean age 54.52 years (range 39-77) and 11 males 
with a mean age of 60.54 years (range 38-75), while control cases included five males, 
mean age of 67.8 (range 35-88) and 3 females, mean age of 68.3 (range 50-77). 24 of 
the MS cases had a confirmed diagnosis of secondary progressive MS (SPMS), 2 were 
diagnosed as primary progressive MS, one was diagnosed as relapsing-remitting MS 
and one was not specified, this study only included SPMS cases. Table (2-2) 
summarises the clinical details of all the individual cases used in this study and the 
mean time from death to freezing (post-mortem interval) for each case.
After the brain was removed from the deceased donor, it was dissected according to 
an approved protocol by staff at the tissue bank. Tissue blocks were prepared by 
cutting a whole brain into anterior and posterior halves by a single cut through the 
mammillary bodies. One centimetre thick coronal slices were then cut through the 
entire brain. The slices were then numbered, based on whether they were taken 
anteriorly (frontal pole) or posteriorly (occipital pole) to the mammillary bodies (Figure 
2-1). The former were numbered A l, A2 etc and the latter were numbered P I, P2 etc.
The coronal slices were laid on a grid and cut into two cm2 blocks, which were frozen 
by immersion in isopentane, precooled on dry ice and then stored at -80 °C.
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In addition, each patient was given an ID code and the four digits following that related 
to the coronal sections and the grid reference where the tissue blocks was taken from, 
e.g. MS076 A1E3, the patient's code is MS076, and the coronal slice is A l and 
therefore derived from the first section anterior to the mammillary bodies, and the 
block was taken from grid co-ordinate E3.
2.1.1 Histopathology of frozen brain tissue
2.1.1.1 Haematoxylin and Eosin staining
Haematoxylin and eosin (H&E) is a histological stain that uses the basic dye 
haematoxylin to stain basophilic structures, such as the nucleus, ribosomes, and RNA- 
rich cytoplasmic regions to produce a blue/purple colour shade. Whereas, the acidic 
dye, eosin Y stains eosinophilic structures, typically the cytoplasm, connective tissue 
and collagen pink (Ross & Pawlina, 2006).
Prior to staining, frozen tissue sections were fixed in 4% paraformaldehyde (PFA) 
(Appendix II) for 15 mins at room temperature (RT). Sections were immersed in filtered 
Harris's haematoxylin (Sigma-Aldrich, UK) for 2 mins followed by rinsing with running 
tap water until the water ran clear. Then sections were stained with eosin (1%) (Sigma- 
Aldrich, UK) for 1 min followed by rinsing in tap water. Following this, slides were 
subjected to dehydration in increasing concentrations of ethanol (50, 70, 80, 95, and 
100%) for 2 mins at each concentration. Slides were placed in xylene (Sigma-Aldrich, 
UK) for 5 mins and then mounted with Di-N-Butyl phthalate (DPX) in Xylene (Sigma- 
Aldrich, UK). Slides were then left to harden in the fume hood for at least lh  and then 
examined using light microscopy with an Olympus BX60 microscope with Cool SNAP- 
Pro (media Cybernetics) imaging system.
2.1.1.2 Oil Red O staining
Oil Red O (ORO) is a neutral lipid dye which indicates regions of myelin breakdown via 
staining myelin debris engulfed by macrophages (Suvarna et al., 2013). ORO solution 
was prepared by adding lg  of ORO powder (Sigma-Aldrich, UK) to 60mL of triethyl 
phosphate (TEP) (Sigma-Aldrich, UK) and 40mL of distilled water (dH20), heating to 
100°C for 5mins whilst stirring continuously on a magnetic stirrer. The ORO solution 
was filtered through filter paper (Fisher Scientific, UK) whilst hot, and again, when cold.
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Table 2-1: Case details of post mortem brains used in this study
Case Sex
Died Age 
(Yrs)
initial
symptoms
age(Yrs)
PMI
(firs)
Diagnosis Cause of death
MS049 Male 75 38 8 SPMS
Aspiration Pneumonia, Cerebrovascular 
accident, MS
MS050 Female 72 41 8 SPMS Bronchopneumonia, MS
MS051 Female 73 43 19 PPMS Bronchopneumonia
MS057 Female 77 44 9 SPMS
General deterioration, lung infection, 
treatment withheld
MS058 Female 51 21 15 PPMS MS
MS060 Male 55 43 16 SPMS Aspiration of gastric, MS
MS062 Female 49 19 10 SPMS Respiratory infection
MS074 Female 64 36 7 SPMS
Gastrointestinal bleed/obstruction, 
Aspiration Pneumonia
MS076 Female 49 18 31 SPMS Chronic renal failure, heart disease, 
general decline
MS079 Female 49 23 7 SPMS Bronchopneumonia, MS
MS080 Female 71 35 24 SPMS Bowel blockage then post-operative 
complication, heart failure
MS081 Male 72 47 23 SPMS Bronchopneumonia
MS090 Male 62 39 17 SPMS MS
MS092 Female 37 17 26 SPMS MS
MS094 Female 42 6 11 SPMS Bronchopneumonia, MS
MS100 Male 46 8 7 SPMS Pneumonia
MS102 Male 73 52 20 SPMS Left ventricular failure, Pneumonia, Pleural effusion
MS103 Female 77 21 7 SPMS Pneumonia
MS104 Male 53 11 12 No
Specified
Advanced Multiple Sclerosis, urinary 
tract infections
MS105 Male 73 46 8 SPMS Pneumonia
MS106 Female 39 21 18 | SPMS Bronchopneumonia
MS107 Male 38 16 19 PRMS Aspiration pneumonia, Pulmonary 
oedema
MS121 Female 49 14 24 | SPMS MS
MS122 Male 44 10 16 SPMS Bronchopneumonia
MS126 Male 75 32 22 SPMS Pneumonia ;
MS153 Female 50 - 12 SPMS MS |
MS154 Female 34 22 12 SPMS MS
MS160 Female 44 - 18 SPMS Aspiration pneumonia, MS ;
CO014 Male 64 Normal 18 Normal Cardiac failure
CO022 Female 77 Normal 20 Normal Pneumonia
CO025 Male 35 Normal 22 Normal Carcinoma of the tongue
CO026 Female 78 Normal 33 Normal Myeloid Leukaemia
CO032 Male 88 Normal 22 Normal Prostate cancer, bone metastases
CO036 Male 68 Normal 30 Normal Coronary artery, fibrosing alveolitis, 
heart failure
CO037 Male 84 Normal 5 Normal bladder cancer, Pneumonia
CO039 Female 50 Normal 8 Normal Cardiac failure
CO, control, PMI, post-mortem interval; SPMS, secondary progress sultiple sclerosis; PPMS, primary 
progress multiple sclerosis; PRMS, progress remitting multiple sclerosis.
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Frozen sections were prepared for ORO staining by fixation in 4% PFA at RT for 15 mins. 
Following fixation, slides were washed in tap water, briefly rinsed in 60% TEP, and 
stained in filtered ORO solution for 10-15 mins at room temperature (RT). Stained 
slides were then briefly rinsed in 60% TEP, and given a further rinse in tap water. 
Nuclei were counterstained with Harris's haematoxylin (diluted with dH20  to 20% v/v); 
the slides were washed in dH20 , and mounted using 22X50 mm coverslips (Fisher 
Scientific, UK) with the aqueous mountant glycerol gelatine (Sigma-Aldrich, UK).
2.1.2 Immunohistochemistry on normal and MS brain sections
2.1.2.1 Single label immunofluorescence stainings of brain sections
Prior to immuno staining, sections were fixed in ice-cold acetone in Coplin jars for 10 
mins at RT and then air-dried for 5 mins. After fixation, the tissue area of the slides was 
defined to contain the antibody solution by drawing a wax circle around it with an 
"ImmEdge" pen (Vector Lab, UK). Slides were then treated either with 3% goat serum 
(Abeam, UK) or donkey serum (Abeam, UK) or rabbit serum (Abeam, UK) dependent on 
the species of the antibodies used for stains diluted in 1% bovine serum albumin (BSA) 
(Sigma-Aldrich, UK) for 30 mins at RT to prevent non-specific binding of the primary 
and secondary antibodies. Table (2-2) provides a summary of the primary and 
secondary antibodies used in this study.
Tissue sections were characterized using antibodies to cell markers for the detection of 
endothelial cells of blood vessels using antibodies to Von Willebrand factor (VWF, 
Dako, UK), human leukocyte antigen (HLA-DR, Leica, UK) for activated 
macrophages/microglia, myelin oligodendrocyte glycoprotein (MOG, gift from Prof C 
Linington, Glasgow University) for regions of demyelination, glial fibrillary acidic 
protein (GFAP, Millipore, UK) for astrocytes, and neurofilaments (Cell Signalling, UK) 
for neurons. Primary antibodies were initially optimised by selecting a range of 
dilutions based on an initial recommendation by the manufacturer.
To identify CNS white matter CSPG alterations in normal control and MS sections, 
polyclonal rabbit anti-CSPG antibodies (Abeam, UK) to the core protein of two lecticans 
(aggrecan and versican), and their corresponding neoepitopes (Thermo, UK) were used. 
Prior to acetone fixation, a deglycosylation step was required for CSPGs to remove the
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glycosylation and unmask the antigen. Thus, sections were treated with chondroitinase 
ABC (0.25IU/ml, Appendix II) (Sigma-Aldrich, UK) for 90 mins at RT.
Primary antibodies (180pL) were applied in PBS, and slides incubated in a humid 
chamber for 2h at RT. Negative controls with omission of the primary antibodies were 
also performed. Unbound antibody was removed by 3 x 2min PBS washes, on an 
orbital shaker. Secondary antibodies were incubated and washed off in the same way 
as primary antibodies, and then Sudan Black B (SBB) staining was performed as 
described in (2.1.2.2), prior to mounting in DAPI mountant (Vector Labs, UK).
2.1.2.2 Sudan Black B
Brain tissue sections are susceptible to autofluorescence caused by the fluorescent 
pigment lipofuscin, which accumulates with age in the cytoplasm of cells, and is 
detrimental when using fluorescence microscopy, it is therefore often necessary to 
treat sections to reduce lipofusin-like autofluorescence to enable detection of specific 
fluorescence from antibody and antigen reaction (Yao et al., 2003; Viegas et al., 2009).
Sudan Black B (SBB) is a fat soluble dye used for staining neutral triglyceride and lipids 
blue black on frozen sections. SBB solution was prepared by adding lg  of SBB powder 
(Sigma-Aldrich, UK) to 70mL of ethanol and 30mL of dH20. The solution was stirred on 
a magnetic stirrer in the dark for 2h at RT. It was then filtered, and stored at 4°C for a 
maximum of one month. Following the final wash to remove unbound secondary 
antibody, slides were immersed in 1% SBB in the dark for 5 mins at RT, and mounted 
using 4', 6-diamidino-2-phenylindole (DAPI) mountant with a 22 X 50mm coverslip.
2.1.2.3 Dual label immunofluorescence
Dual-label immunofluorescence was performed with rabbit polyclonal antibodies to 
CSPGs (versican and aggrecan) and their neoepitopes together with mouse monoclonal 
anti-HLA-DR and anti-MOG antibodies for indication of inflammation and 
demyelination respectively. To determine the cellular origin of ADAMTS-9 expression; 
dual labelling immunofluorescence was also performed with specific cell markers (vWF, 
HLA-DR, GFAP and NF-L). Briefly, sections were incubated with goat polyclonal 
antibody to ADAMTS-9 overnight at 4°C and then detected by incubating in Alexa fluor 
568/488 conjugated secondary at RT for 90mins.
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Following 3 X 5min washes in PBS, sections were further incubated with monoclonal 
antibody for 2h at RT. Sections were washed in PBS as previously and incubated in 
Alexa fluor 568/488 conjugated secondary antibody for a further 90 mins (Table 2-2). 
After the final secondary antibody had been washed off, sections were treated with 
SBB (2.1.2.2) to quench autofluorescence of the tissue, and mounted using DAPI 
mountant.
Various controls were performed alongside the sections that were dual labelled, 
including single labelling with primary antibodies for serial sections, omission of the 
first or second primary antibodies in turn, and incubation of one primary antibody with 
both secondary antibodies.
2.1.3 Image capture and analysis
2.1.3.1 Light and fluorescence microscopy
Images of immunofluorescence on sections to assess expression of CSPGs were taken 
using an upright Olympus BX60 with cool-snap pro (cybernetics) digital camera. 
Fluorophores were excited at wavelengths of either 488 or 568nm. Composite images 
were stored and transferred into Microsoft PowerPoint without further manipulation.
2.1.3.2 Confocal scanning laser microscopy
Immunofluorescence images to determine co-localization of ADAMTS-9 were captured 
using a Zeiss 510 confocal scanning laser microscope (CSLM) equipped with a 
krypton/argon laser. Fluorophores were excited at wavelengths of either 488 or 
568nm. Co-localization studies of the dual-labelled sections utilized the co-localization 
software available with the Zeiss 510 CSLM. Individual pixels were scanned for each 
channel within set intensity thresholds, which were consistent for all analyses. Co­
localised pixels were represented as yellow in the composite image.
2.1.4 Quantitation of immunostaining and data analysis
Statistical significance of any increase or decrease in expression level of CSPGs and 
their neoepitopes in particular regions was performed using Image J software. The 
region of interest (ROI) was drawn with a drawing tool on captured images and then 
the mean density of staining was measured based on the MOG staining pattern on 
serial sections. All statistical analysis of data was performed via Kruskal-Wallis, where
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*P<0.05, **P<0.01 and P<0.001. All data was expressed as mean ± SEM for normal 
control samples and MS lesion brain tissue blocks.
2.2 Western Blotting
2.2.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS- 
PAGE)
A mixture of proteins in a sample can be separated by SDS-PAGE on the basis of 
molecular weight (M\N) via migration through a polyacrylamide gel as a support 
medium, in the presence of a current by electrostatic attraction of the negative charge 
(caused by SDS binding to the protein) to the anode. Negatively charged SDS coated 
proteins migrate in the gel relative to their size only and not to their charge. A M W  
marker containing proteins of known M W  is run in parallel to enable determination of 
the M W  of protein in the test sample (Figure 2-2). Following SDS-PAGE, the presence 
of a protein within a sample can be confirmed by using instant blue stain (Sigma- 
Aldrich, UK) (Schutz-Geschwender, 2004).
Western blotting (WB) is a well-established and widely used technique for the 
detection and analysis of specific proteins. The western blotting technique was first 
described in 1979 and has since become one of the most commonly used techniques in 
life science research (Renart et al., 1979). Proteins are separated by SDS-PAGE and are 
then transferred onto nitrocellulose or polyvinylidene difluoride (PVDF) membrane 
where they are probed with antibodies specific to a target protein. Although there are 
a number of membrane types, nitrocellulose is the most commonly used. PVDF 
membranes have high protein binding capacity and are strong; however they are 
expensive and have a short shelf-life. A nitrocellulose membrane has a low binding 
capacity and is often brittle when dry, but is relatively inexpensive and has the longest 
shelf-life. Supported nitrocellulose membrane such as Hybond-C-extra (GE Healthcare 
LTD, UK), have improved mechanical strength thereby making them less brittle (Figure 
2-2). Specific antibody binding is then detected using a range of methods, e.g. 
chemiluminescence with an enzyme labelled secondary antibody, or a fluorescently 
labelled secondary antibody (Figure 2-2) (Kurien et al., 2011).
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2.2.2 Protein Extraction
2.2.2.1 Tissue protein extraction
The human brain tissue blocks were stored at -80°C immediately after collection from 
the MS Society Tissue Bank. The region brain tissue of interest (ROI) was cut based on 
IHC results for active lesions, NAWM and normal control white matter. The tissues 
were then weighted and an appropriate amount of celLytic™ Mammalian Tissue 
Lysis/Extraction Reagent (Sigma-Aldrich, UK) and protease inhibitor cocktail (Sigma- 
Aldrich, UK) used. For this procedure, a ratio of tissue to celLytic™ reagent of 1:10 
(lgram of tissue/ 10 ml of reagent) was used. Each tissue sample was transferred to a 
pre-chilled microhomogenizer, where it was homogenized at 4°C. The pellet was 
discarded and the supernatant was centrifuged at 20,000 g for 10 mins at 4°C. The 
supernatant was stored at-20°C in 500pl aliquots.
2.2.2.2 Cellular protein extraction
In accordance with the manufacturer's protocol (Sigma-Aldrich, UK) protein was 
extracted from neuroblastoma cells line (SHSY-5Y), human foetal microglia cell line 
(CHME3) and human primary astrocytes using CelLytic™ reagent. Cells were grown on 
24 well plate in triplicate and 150pl of CelLytic™ reagent added to each well (4X105 
cells per/well). Prior to adding CelLytic™ reagent, the growth medium were removed 
from the cells and then cells rinsed once with DPBS, being careful not to dislodge the 
cells attached to the plate. The cells were incubated for 15 mins on shaker at RT and 
the lysed cells centrifuged for 10 mins at 12,000 g to pellet the cellular debris. Finally, 
the protein-containing supernatant was transferred to a chilled Eppendorf tube and 
stored at -20°C until used.
2.2.3 Estimation of total protein concentration by using Bradford assay
Following protein extraction, the protein concentration was determined using a quick 
start Bradford dye ™reagent kit (Bio-Rad, UK) according to the manufacturer's 
instructions. 5pL of bovine serum albumin (BSA, Sigma Aldrich, UK) protein standard in 
PBS (ranging from 0.1 to 200mg/ml) along side 5pl of extracted protein sample in 
triplicate were pipetted into a 96 well plate. 200pL of Bradford dye reagent was added 
to each well. The plate was incubated for 30 mins at RT and the absorbance was read
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with a Victor Wallac2 plate reader at 570nm. A standard curve was drawn in excel and 
protein concentration was determined using the trend line of the equation of the 
standard curve (Figure 2-3):
Y= aX + b where (Y) corresponds to absorbance, (a) corresponds to the slope of the 
trend line; (X) corresponds to the concentration of protein in the sample and (b) 
corresponds to the intercept point with the X-axis.
2.2.4 SDS-PAGE
All reagents and materials were from Invitrogen, Paisley, UK, unless stated otherwise. 
The extracted proteins from tissue blocks were fractionated on pre-cast 1% Tris 
acetate gels, 1mm thick with 10 wells, in the presence of Nupage Tris Acetate running 
buffer (Appendix II). 15-30pg of each protein sample was loaded per well along side 
10pl of multicolour high molecular weight markers standard (range 40-300kDa, 
Thermo Scientific, UK) and electrophoresis carried out at 130 voltages and 200 mA for 
approximately lh , until the dye front reached the bottom of the gel.
2.2.5 Protein electroblotting
Separated proteins were transferred onto Hybond-C nitrocellulose membrane (GE 
Healthcare, UK) in order to make the proteins accessible to antibody. A piece of 
nitrocellulose membrane was soaked for 5 mins in cold transfer buffer (Appendix II), 
along with two pieces of blotting paper and two pieces of sponge per mini-gel. One 
sponge was placed on the open transfer cassette, followed by a piece of blotting paper 
and the gel, nitrocellulose membrane (NCM), a second piece of blotting paper and 
another sponge.
Proteins were transferred from the SDS-PAGE gel to the NCM at 100 V for lh  (Figure 2- 
2). To verify the protein had transferred successfully onto the membrane, the gel was 
immersed in instant blue (Sigma Aldrich, UK) and the NCM in Ponceau red (Sigma 
Aldrich, UK) in order to visualise the protein.
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Figure 2-3: Bradford assay standard curve
An example of a standard curve used in the determination of protein concentration of 
an unknown cell or tissue extract sample using bovine serum albumin (BSA) as 
standard. Sample absorbances at 570nm were read and plotted as illustrated in the 
graph above. Equation of chart line and R2 value of the chart are given.
5 9
2.2.6 Immunoprobing the membrane
Following transfer of protein to the NCM, it was immediately placed in blocking 
solution [5% non-fat milk in PBS-T (phosphate buffered saline containing 0.02% 
Tween)]. Following this, the membrane was washed three times for 5 mins each in PBS, 
with gentle agitation on a platform shaker. The primary antibodies were then diluted 
in lOmL of PBS and added to the membrane and incubated overnight at 4°C (Table 2-3). 
For negative controls, primary antibody was omitted and the membrane was 
incubated with PBS alone. Following three washes of the membrane with PBS for 5 
mins each, labelled secondary antibody was then diluted in PBS (Table 2-3) and 
incubated for lh  with gentle agitation at RT. The membrane was then washed twice 
for 5 mins each in PBS on the shaker followed by one final wash for 5 mins in PBS only 
with gentle agitation.
2.2.7 Determination of molecular weight of proteins migrated on SDS- 
PAGE
Molecular weight markers (spectra multicolour high range protein ladder (40-300kDa), 
Thermo, UK) were used to identify the approximate mass of a protein run on a gel; 
using the principle that molecular weight is inversely proportion to migration distance 
through a gel matrix. Consequently, once used in gel electrophoresis, markers 
effectively provide a logarithmic scale by which to estimate the size of the protein 
(Figure 2-4) (Choi et al., 2009). In order to determine the mass of a protein band on 
western blotting, a marker lane was always included. The distance migrated by the 
protein markers was measured and a standard curve constructed using a plot of log10 
mass versus relative mobility (distance migrated by band/distance migrated by dye). 
The molecular weight (MW ) of the unknown protein band was then determined by 
using the equation of the line using Microsoft Excel.
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Figure 2-4: Measurement of the molecular weight of sample protein
Determination of the MW of the protein sample on SDS-PAGE using a known 
molecular weight marker (spectra multicolour high range protein ladder, Thermo 
Scientific, UK). A standard curve generated by plotting log molecular weight (MW) 
versus migration distance (Rf) o f each band of the protein ladder marker through an 
SDS-PAGE gel.
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2.3 Quantitative Reverse Transcriptase Polymerase Chain Reaction 
(qRT-PCR)
2.3.1 Overview of qRT-PCR
Quantitative reverse transcriptase polymerase chain reaction is widely used in gene 
expression studies in order to detect and quantify expression specific genes of interest. 
Prior to PCR, mRNA is converted to complementary DNA (cDNA) through the action of 
the enzyme reverse transcriptase, which elongates and copies the single-stranded RNA 
using deoxynucleotide triphosphates (dNTPs) to make single cDNA sequences of the 
entire length of RNA (Bustin et a i, 2002). This double-stranded DNA product, or 
amplicon, then undergoes many repeats of thermal cycling, which consist of heating to 
denature the hydrogen bonds of the alpha-DNA helix thus separating the strands, and 
cooling to anneal primers and encouraging polymerization, resulting in the synthesis of 
copies of target DNA exponentially (Wong & Medrano, 2006).
2.3.2 The amplification plot
As amplification proceeds, the amplification is plotted by the instrument after every 
cycle using fluorescent intensity related to the amount of amplicon, and is converted 
into a RT-PCR graph. qRT-PCR consists of three amplification stages, exponential, linear 
and plateau (cycles 28-40) (Figure 2-5). The amount of product doubles in each cycle of 
PCR, resulting in an exponential increase in fluorescence throughout the amplification 
reaction. However, as the reaction progresses the reagents are consumed and the 
reaction slows and thus at an endpoint the reaction stops (plateau phase). qRT-PCR 
allows accurate and precise detection and quantification of product during the 
exponential phase (Wong & Medrano, 2006).
Within the exponential phase, a threshold is set; the RT-PCR cycle at which the sample 
reaches this threshold is called the cycle threshold (CT). The CT value is used in 
downstream quantitation and depends on the amount of target, the larger the amount 
of template DNA in the reaction the fewer amplification cycles is needed to form a 
significant fluorescent signal. In contrast, a small amount of target will require more 
amplification cycles for the fluorescence signal to generate a detectable fluorescence 
signal (Orlando e ta i ,  1998).
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10
CT value Exponential
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0.01
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Figure 2-5: qRT-PCR amplification plot
This plot shows the exponential and plateau phases of qRT-PCR amplification. The PCR 
cycle number is shown on the X-axis and changes in fluorescence from the 
amplification, which is proportional to the amount of the amplified products, is shown 
on the Y-axis. In the exponential phase, reagents are in abundance with PCR product 
doubling every cycle. During the plateau phase these reagents begin to deplete and 
the PCR reaction begins to slow down.
Key: CT; cycle threshold
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2.3.3 Total RNA Extraction
2.3.3.1 Brain tissue RNA extraction
RNA was extracted from characterized human brain tissue blocks using Tri-reagent 
following the manufacturer's instructions (Sigma Aldrich, UK). Samples were left in Tri­
reagent for 5 minutes at room temperature to dissociate nucleoprotein complexes.
2.3.3.2 RNA extraction from cell culture
In accordance with the manufacturer's protocol (Sigma-Aldrich, UK) mRNA was 
extracted from SHSY-5Y cells using Tri-reagent. Cells were grown in 24 well plates in 
triplicate and lm L of Tri-reagent added to each well (4X105 cells/well). Prior to 
addition of Tri- reagent, the growth medium was removed from the cells, and then the 
cells rinsed once with DPBS, being careful not to dislodge any of the cells. RNA 
extraction was performed as described below (2.3.3.3).
2.3.3.3 RNA extraction using Tri-reagent
Following incubation of cells/tissue with Tri-reagent for 5mins, 0.2ml of chloroform 
was added; samples were mixed by vortexing for 15 seconds and incubated at room 
temperature for 3 mins prior to centrifugation at 12,000g for 15 mins at 4°C. Following 
centrifugation the upper aqueous phase (RNA containing) was removed to a clean 
1.5ml Eppendorf tube and 500pl isopropanol added. RNA samples were incubated for 
10 mins at RT and then centrifuged at 12,000g for 10 mins. The supernatant was 
carefully removed and discarded, and then 1ml of 75% was ethanol added to each 
pellet. Tubes were centrifuged at 8,000g for 5 mins. 75% ethanol was removed and the 
pellet re-suspended in nuclease free water (30pl) (Sigma Aldrich, UK). The RNA 
samples were stored at -80°C prior to use.
2.3.4 Agarose gel electrophoresis of RNA products
A 1% agarose gel was made up by heating 0.5g of agarose (Bioline, UK) in 50ml Tris- 
acetate-EDTA (TAE) buffer (89mM Tris-HCL pH 7.8, 89 mM borate, 2mM EDTA) for 2 
mins or until the agarose had dissolved entirely. The 1% gel solution was allowed to 
cool for several minutes and lOpI of ethidium bromide (lOmg/ml-stock solution) 
(Sigma Aldrich, UK) was added. The solution was then poured into a casting tray and an 
8 well comb inserted. The gel was allowed to set for 30 mins. Once the gel had set, the
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comb was removed and the gel was placed in an electrophoresis tank filled with lx  TAE 
buffer. 2.5pl of loading buffer (Thermo Scientific, UK) was added to 2.5pl of RNA 
products and carefully loaded into each well of the agarose gel. The electrophoresis 
was then run at 100 volts for 40 mins. Images were captured by UVP Bio-imaging 
system Epi II in the dark room using LabWorks software version 4.0.
2.3.5 cDNA Synthesis
Extracted mRNA cannot serve as a template for real-time PCR and therefore it is used 
to synthesise cDNA with the enzyme reverse transcriptase (RT). All reagents were from 
Invitrogen, unless otherwise specified. The synthesis of the first stand of cDNA requires 
a primer in order for the RT to extend the cDNA. The cDNA synthesis was performed 
with RNAse/DNAse free tips, tubes, gloves and surfaces were cleaned with alcohol 
wipes. The total reaction volume for each RNA sample was 19pl including: Superscript 
II RT (lpL), 5X first strand buffer (4pL), dithiothreitol (DTT) (2pL), RNAseout 
ribonuclease inhibitor (0.5pL), random hexamers (0.5pL) and lpL dNTP mix containing 
12.5% dATP, 12.5% dCTP, 12.5% dGTP and 12.5% dTTP (Bioline, London, UK), RNA 
sample (lpL) and molecular grade water (9pL). The reaction was performed at 42°C for 
1 h in a heat block. The reaction was stopped by heating the samples at 95°C for 5 mins 
in a heat block, to inactivate the enzyme. For each cDNA synthesis preparation, two 
samples were included as negative controls, one lacking RT and the other mRNA 
template (replaced by RNAse/DNAse free water) (Sigma Aldrich, UK). The prepared 
cDNA samples were stored at -20°C prior to use as a template for real-time PCR.
2.3.6 Primer design and housekeeping genes for qRT-PCR validation
PCR primers for the RT-PCR step should ideally be designed to span exon-exon 
junctions, with one of the amplification primers potentially spanning the actual exon- 
intron boundary. This design plays a crucial role in reducing the risk of false positives 
from amplification of contaminating genomic DNA. If primers cannot be designed to 
separate exons or exons boundaries, it is necessary to treat the RNA samples with 
RNase-free DNase in order to remove contaminating genomic DNA (Gunson et a i,  
2006). The primers utilized in this study were designed using primer express and 
purchased from Applied Biosystems, UK. To achieve accurate relative quantification of 
an mRNA target, it is necessary to normalise to at least one reference gene, which is
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constitutively expressed and is not affected by the experimental treatment under 
study, and therefore can be used to correct for differences in the amount of total 
nucleic acid added to each reaction (Vandesompele et a i,  2002). Table (2-4) lists 
details of the fully optimised and validated primers utilized in this study. Human 
housekeeping genes, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 
hypoxanthine phosphoribosyltransferase 1 (HPRT-1), cyclophilin A (PPIA) as well as 
human ADAMTS-9 were validated and optimised previously by Cross et a i,  2006, Ried 
et a i,  2009 and Gibrel, 2012), and expression of ADAMTS-9 was normalized against 
expression of these housekeeping genes. According to the manufacturer's information 
primer efficiencies of the target and reference genes were approximately 100%.
Synthesised cDNA was used as a template for qRT-PCR and was diluted 1:10 in 
nuclease free water. All qRT-PCR reactions were prepared on ice. Amplification was 
carried out using the ABI Prism sequence detection system (Applied Biosystems, UK). 
Real-time PCR was carried out with lOpL reaction volume in triplicate. The reaction 
mixture consisted of 5pL 2X Taqman mastermix, 3.5pL nuclease free water, 0.5pL of 
forward and reverse primers and lpLcDNA.
2.3.7 Comparative CT method of data analysis
Real-time PCR data was expressed as an amplification plot for each individual gene 
detected. Baseline and threshold values were manually determined on each 
amplification plot for each target and reference gene. Thresholds were set within the 
exponential phase of the amplification plot and maintained across all samples 
investigated. Measured CT values of the mean of each triplicate target and 
housekeeping gene was exported to an excel file for analysis by the 2’ AACT method 
(Livak et a i,  2001). Briefly, analysis was performed by the arithmetical mean target CT 
value of each sample being normalized to the mean CT values of three housekeeping 
genes resulting in the CT value, as follows:
Calculation: Step 1: ACT = CT target gene - CT reference gene
Step 2: AACj values = ACTof test sample - ACTcontrol sample 
Step 3: 2 'AACT = relative fold increase
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In order to perform statistical analysis on RT-PCR data, statistical significance of 2 'AACT 
values representing the relative levels of ADAMTS-9 expression between samples was 
compared using Stats Direct software (Kruskal-Wallis). Results were considered 
statistically significant when *P<0.05, **P<0.01 and ***P<0.001.
2.4 Cell culture
2.4.1 Overview
The growth of particular mammalian cells in vitro allows the analysis of target 
protein/mRNA (e.g. ADAMTS-9) expression levels to be measured under experimental 
conditions, which mimic a particular physiological or pathological state. By controlling 
or modifying the culture medium, the effect on the cell of one variable from a complex 
disease process can be analysed e.g. a cytokine. All cell culture procedures were 
carried out under sterile conditions in a Hera Safe class II laminar flow cabinet. Three 
human CNS cell types [primary astrocytes, neuroblastoma cell line (SHSY-5Y) and foetal 
microglia cell line (CHME3)] were used in this study and details including culture 
medium are listed in Table (2-5). All cell types have an adherent mode of growth and 
were incubated at 37°C in 5% C02/95% air in a humid environment in a Hera cell 
incubator (Heraeus Instruments, Kandro Laboratory Products, Germany). Culture 
media was changed every 3 days.
2.4.2 Sub-culture of cells
Monolayer cultures were maintained up to 80-90% confluence before passaging. 
Culture media was removed and cells were washed twice with sterile PBS to remove 
any remaining serum. Cultures were incubated for 3 mins at 37°C with 3mL 0.05% 
trypsin-ethylene diamine tetra acetic acid (EDTA) (Gibco, UK) until the cells began to 
detach from the surface of the flask. The addition of an equivalent volume of complete 
media caused inactivation of the trypsin. Cells and media were harvested and then 
centrifuged in Sorvall RT7 plus centrifuge (Kandro Laboratory Products, Germany) at 
1,200 rpm for 10 mins and the pellet was re-suspended in fresh media. Cells were 
either divided into new flasks or counted for plating out in experiments.
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2.4.3 Cell counting
Trypan blue stain was used to quantify the number of live and dead cells in the 
suspension. Trypan blue is based on the principle that live cells have an intact cell 
membrane and therefore do not take up certain dyes. In contrast dead cells do not 
have an intact and functional membrane and therefore do take up the dye from their 
surrounding medium (Strober et al., 2001). lOpI of the cell suspension was mixed 
thoroughly with lOpI trypan blue solution (0.4%) (Sigma, Aldrich, Uk) and lOpI of the 
mixture was pipetted carefully onto a Countess® slide. Cells were counted using a 
Countess® Automated Cell Counter (Invitrogen, UK) and total cell count value, live cell 
count, dead cell count and viability percentage were obtained. From the results a 
dilution factor was calculated to obtain a live cell concentration of 5 x l0 4 cells/ml.
2.4.4 Cryopreservation of cells
Harvested cells were resuspended in freezing medium of 10% dimethyl sulphoxide 
(DMSO)(Sigma Aldrich, UK), 90% (v/v) growth media prior to pipetting 1X106 cells into 
cryovials, which were placed in a Cryo 1°C freezing container (Nalgene, Hereford, UK) 
containing isopropanol in a -80°C freezer. Once cells were at -80°C, cryovials were 
transferred to liquid nitrogen storage. Cells were thawed by placing a cryovial in a 37°C 
incubator before adding cells to 5 mL of growth media prior to centrifugation at 1,200 
rpm to remove DMSO. 1ml of pre-warmed complete medium was added to the cells 
and then quickly transferred to cell culture flasks (75cm2) containing 15mL pre-warmed 
complete culture media.
2.4.5 Aggrecan coating of plasticware for cell culture
For culture of SHSY-5Y cell line, recombinant human aggrecan G1-IGD-G2 domain (R&D 
Systems, UK) was used to coat 24 well plates and 8 well chamber slides. The aggrecan 
stock solution was prepared by reconstituting of 25pg of aggrecan in 1 mL of sterile 
DPBS which was then filtered using a 0.2pm filter. Aggrecan solution (300pl) was 
added to wells to produce final concentrations ranging from 0 to 2.5pg/mL to cover 
the bottom of the wells and the plate then incubated at room temperature for 3 h. 
After this time the aggrecan/DPBS was removed and SHSY-5Y cells were seeded into 
the wells.
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2.4.6 Cytokine treatment of cells
Cells were seeded into 24-well plates at density of 5 x l0 4 cells/well in Im L of medium 
and left for 48 h to adhere. Recombinant cytokines IL-ip, IFN-Y and TNF (Peprotech,
UK) were diluted in serum-free media at concentrations of 0, 1, 10, 100 ng/mL 
(Appendix II). Media was removed and cells washed in serum free media prior to the 
addition of Im L of each cytokine in triplicate wells for 24h. All experiments were 
repeated three times.
2.4.7 Mycoplasma Testing
Mycoplasma is a class of Mollicutes that represent a large group of specialized bacteria, 
distinguished by the absence of a cell well. Mycoplasma are small and flexible, which 
make them able to pass through conventional microbiological filters (0.2pm). They 
depend on their hosts for many nutrients due to their limited biosynthetic capabilities 
(Drexler et al., 2002). Mycoplasma has long been recognized as a common 
contaminant of cell lines in continuous culture and their presence may go undetected 
for months. As the mycoplasma competes with the cell lines for nutrients in complete 
culture media, this causes a reduction in the rate of cell proliferation and changes in 
cellular responses including gene expression (Dvorakova et al., 2007).
The MycoAlert™ assay (Lonza, UK) was used to exploit the activity of certain 
mycoplasmal enzymes. The presence of these enzymes allows a rapid screening 
procedure, providing sensitive detection of contaminating bacteria in the test sample 
(Figure 2-6). The viable mycoplasma are lysed and the enzymes react with MycoAlert™  
substrate catalysing the conversion of adenosine diphosphate (ADP) to adenosine 
triphosphate (ATP). The mycoplasma positive or negative samples can be detected by 
measuring ATP in specimens both before and after the addition of the MycoAlertTM  
substrate. If no mycoplasma enzymes are present, the second reading displays no 
increase over the first, while reaction of mycoplasma enzymes with their specific 
substrates leads to raised ATP levels, giving a positive result.
Luciferase
ATP + Luciferin + 02------------ :--------> Oxyluciferin + AMP + PP, + C02 + Light
Mg2+
Figure 2-6: Modified from Promega. Luminescent reaction to detect ATP in mycoplasma test.
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2.4.7.1 Methodology
MycoAlert™ reagent and substrate were reconstituted in MycoAlert™ assay buffer. 
5mL of complete culture medium were transferred into a centrifuge tube, and spun at 
200 X g for 10 mins. lOOpI of cleared supernatant was transferred into white 96 well 
plates (Fisher Scientific), and lOOpI MycoAlert™ reagent was added to each sample 
and incubated for 5 mins at room temperature. Following the incubation the plate was 
measured for luminescence (Reading A) using a Wallac Victor 21420 luminescence 
system. Following this, lOOpI of MycoAlert™ substrate was added to each sample and 
incubated for a further 10 mins before re-measuring the luminescence (Reading B). 
The ratio was calculated for each well by dividing reading A by reading B (Ratio= 
Reading A/Reading B).
2.4.8 Determination of cell viability by MTT assay
Investigating the effect of specific conditions on the behaviour of cell lines in vitro, it is 
vital to determine if treatments have an effect on cell viability and proliferation. Cell 
viability was determined by a mitochondria enzyme dependent reaction of 3-(4, 5- 
dimethylthiazol-2yl)-2, 5- diphenyltetrazolium bromide, tetrazole (MTT) (Datki et al., 
2003: Cheung et al., 2009). Briefly, all cell lines at a density of 5x l04 cells per well in 
200pl media were cultured in 96-plates for 24h, after treatment, lOpI of MTT stock 
solution (5mg/ml) (Sigma, Aldrich, Uk) was added to each well (lOOpI) and left to 
incubate at 37°C for 3 hours. Metabolically active cells cleaved the yellow tetrazolium  
salt (MTT) to purple formazan crystal. At the end of the incubation time, the medium 
was removed and the formazan crystals were solubilized with 150pL of DMSO. The 
absorbance of the wells was measured at 570nm using Wallac Victor2 plate reader 
spectrophotometer. These absorbance readings were then used in order to calculate 
fold-changes in cell number following treatment compared with untreated cells. All 
MTT assays were performed in triplicate.
2.4.9 Immunocytochemistry of the CNS cells
Immunocytochemistry is dependent on the affinity of an antibody for an antigen in a 
cell, where immunohistochemistry applies the same process, but in tissue sections. 
The antigen and antibody are held together by forces such as hydrogen bonding, 
hydrophobic interactions and ionic interactions and are reversible (Ramos-Vara, 2005).
73
The part of the antigen that is recognised by the antibody is known as the epitope and 
polyclonal antibodies can bind to more than one epitope, whereas monoclonal 
antibodies recognise a single epitope. Each antibody forms a complex which only 
occurs with the specific antigen, but some cross-reactivity can occur, however, in order 
to test the specificity of the antibodies used, immunoglobulin of the same class, 
namely isotype controls, can be used under the same experimental conditions (Delves 
et al., 2006; Buchwalow et al., 2011).
Cells were plated out into 24 well plates at a density of 5X104 cells well/mL. Prior to ICC, 
cells were washed with two changes of PBS and then fixed in 4% (w/v) 
paraformaldehyde (PFA) for 10 mins. After 2 x 2  mins washes with PBS, the cells were 
placed in ice-cold acetone for 4 mins and subsequently left to air dry for 10-15 mins at 
RT. To enable permeabilisation of the cells for intracellular staining following acetone 
fixation, all antibodies were diluted in 0.5% Triton X-100 (Sigma, Aldrich, UK) in PBS. 
The neuroblastoma cell line (SHSY-5Y) and primary human astrocytes were labelled for 
specific phenotypic markers by indirect immunofluorescence. SHSY-5Y was labelled for 
neurofilaments (NF-L) and primary human astrocytes for GFAP, using monoclonal 
rabbit anti-human NF-L (1:100) and mouse anti-human GFAP directly conjugated 
(1:500) (Table 2-7). Fixed cells were also labelled for ADAMTS-9 using a polyclonal anti­
goat antibody (1:100, Santa Cruz).
Cells were incubated in primary antibody (200pl, per well) overnight in the 4°C. The 
negative controls without the primary antibody were incubated with 20pl PBS with 
0.5% Triton X-100 as for the primary antibody. After 2 x 2  mins washes with PBS, Alexa 
conjugated secondary antibodies (200pl per well, diluted in PBS) were applied to each 
well for 90 minutes. Table (2-6) provides the details of the primary antibodies used in 
this study and the secondary antibodies used were the same as in IHC for either 
monoclonal or polyclonal antibodies. Following a further 2 X 2  mins washes in PBS, cell 
nuclei were counterstained in a Vectashield mounting medium containing DAPI (Vector 
Labs, UK). Images were captured on an inverted stage fluorescence microscope 
(Olympus 1X81) with Cool Snap digital camera (Olympus Media Cybernetics, Silver 
Spring, USA).
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3.1 Introduction
The glial scar consists predominately of reactive astrocytes, microglia/macrophages 
and extracellular matrix molecules, especially CSPGs (Cregg et al., 2014). CSPG 
aggrecan (Schmalfeldt et al., 2000), versican (Schmalfeldt et al., 2000), neurocan 
(Friedlander et al., 1994) and phosphacan (Bovolenta et al., 2000) are known to have 
growth-inhibitory effects, and are produced by almost all cell types at sites of CNS 
injury (especially by neurons and astrocytes) (Glatrey et al., 2007). Recently, research 
groups provided grounds for optimism when they recognised growth-inhibitory 
components in CNS injury including CSPGs and myelin-derived proteins such as myelin 
associated glycoprotein (MAG), and myelin oligodendrocyte glycoprotein (MOG) which 
inhibits axonal growth. These molecules have been associated with glial scar that is 
actively formed following spinal cord injury (Rolls et al., 2009; Sharma et al., 2012).
The inhibitory nature of CSPGs on oligodendrocytes has also been shown in in vivo 
studies, in rat models of traumatic spinal cord injury, the accumulation of CSPGs is 
thought to inhibit OPC migration and their maturation into oligodendrocytes (Karimi et 
al., 2012; Harlow et al., 2014). CSPGs are found at the edge of active and expanding 
white matter lesions in MS (Sobel et al, 2001). One study showed that the number of 
OPC outside such lesions is increased and that this change in OPC number may be an 
attempt at repair (Kuhlmann et al., 2008). Various therapeutic approaches have been 
assessed to eliminate and reorganize the chemical components of the glial scar or 
regulate its negative effects. These include using degrading enzymes to eliminate scar 
components (especially CSPGs). Blocking by CSPGs can be reduced, but not eliminated, 
by removing chondroitin sulphate chains, indicating that multiple domains of CSPGs 
are involved in controlling axon regeneration (Bradbury eta l., 2002; Kwok eta l., 2008).
It is likely that cellular interactions between resident and inflammatory cells involved 
in glial scar formation are mediated by pro-inflammatory cytokines in MS. This leads to 
the production of increased amounts of proteolytic enzymes, which are the major 
effectors of the subsequent axon demyelination and resulting clinical symptoms 
(Kasper& Shoemarker, 2010). ADAMTS-mediated cleavage of aggrecan and versican in 
CNS ECM, via their glutamyl endopeptidase activity, could have a role in ECM
oyo
degradation in glial scar formation in MS. The main aggrecanase cleavage site is Glu -
Ala374, and there are four additional cleavages sites in the GAG attachment region at
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Glu1480-Gly1481, Glu1667-Gly1668, Glu1771-Ala1772 and Glu1871-Leu1872 (Figure 3-1) (Jones et 
al., 2005; Porter et al., 2005; Troeberg et al., 2012). Westling and colleagues indicated 
that ADAMTS-4 could cleave versican V I and V2 within GAGs (Glu405-GLu406) and 
(Glu441-Ala442) in neural tissue, which produced 70KDa and 64KDa fragments 
respectively (Westling eta l., 2004).
Previous studies in our laboratory reported the expression of ADAMTS-1, -4, -5 and 
TIMP-3 in MS CNS, and highlighted a possible role for ADAMTSs in lesion development 
in MS (Haddock et al., 2006). This present study investigated intact CSPG expression 
and their breakdown by ADAMTSs, via production of aggrecan and versican fragments 
as an indicator of enzyme activity in MS tissue. Antibodies that recognize the 
neoepitopes produced by cleavage at specific sites, generated by proteolysis of the 
aggrecan and versican by glutamyl endopeptidases such as ADAMTS-4 and -9 
neoepitopes antibodies, are now commercially available, and allow identification of 
regions of active enzyme activity within the CNS.
Our current state of knowledge suggests that glutamyl endopeptidases (GEP- 
ADAMTSs) may be important in MS pathogenesis because of their site of expression 
and their known and potential substrate specificities. Their effects may be detrimental 
in terms of the CNS ECM breakdown, enabling infiltration of immune and inflammatory 
cells and in myelin breakdown. Alternatively, they may be beneficial by enabling 
neurite outgrowth and neuronal repair. This chapter describes the detailed 
investigation of the expression of aggrecan, versican and their neoepitopes in both 
normal control and MS brain tissue (active, chronic inactive, chronic active lesions and 
NAWM), to further elucidate the role of CSPGs in MS pathogenesis.
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3.1.1 Aims of the study
The aims of this study were:
•  To determine whether the expression levels of aggrecan and versican showed 
any differences in MS post-mortem tissue compared to normal control brain 
tissue using immunohistochemistry and western blotting.
•  To study CSPG breakdown by ADAMTSs in ex vivo via the production of 
aggrecan and versican neoepitopes of ECM components in MS post-mortem 
tissue, compared to normal control brain tissue using immunohistochemistry 
and western blotting.
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Figure 3-1: Aggrecan structure and ADAMTS cleavage sites
Diagrammatic representation of aggrecan and its known cleavage sites; aggrecan has 
two cleavages sites located within the G1/G2 interglobular domain (IGD) (a). The 
Asn341-Phe342 is the main MMP cleavage site, whereas the Glu373-Ala374 is cleaved by 
aggrecanases including ADAMTS-9 (b). There are also four cleavage sites within the 
CSPG-rich region of aggrecan for ADAMTS-4 and ADAMTS-5; arrows indicate cleavage 
sites (c). Figure Adapted from Proter et al, (2005).
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3.2 Results
3.2.1 Tissue grading
3.2.1.1 H&E and ORO stains for the extent of inflammation and 
demyelination
H&E staining was used to detect areas of inflammatory perivascular cuffs, within the 
brain tissue used for this study, and ORO was used to identify areas of demyelination. 
H&E and ORO stained sections were graded according to the extent of perivascular 
cuffing observed and myelin loss respectively, using a four point scale (Negative, +, ++ 
and +++). No inflammation or demyelination was seen in the majority of control brain 
tissues which were graded as negative (-). Tissue blocks graded from + through to +++ 
demonstrate immune cell infiltration and demyelination within MS lesions. These 
sections were also scored by Prof Nicola Woodroofe, following the initial scoring of the 
80 blocks, scores were then compared and any results that did not match were re­
assessed together to reach a consensus on the scoring. There was agreement of the 
scoring in > 90% of cases. The grading results for all tissue samples were further 
confirmed by immunohistochemistry investigations on serial sections using antibodies 
to HLA-DR and MOG, to demonstrate activated macrophages and loss of myelin 
respectively. Results of characterization of the blocks used, based on grading is 
illustrated in Figures (3-2) and (3-3), and are summarised in Table (3-1).
3.2.1.2 HLA-DR expression for the extent of microglia activation
Human leukocyte antigen (HLA) is expressed at the cell surface of antigen presenting 
cells and consists of a 34kDa (alpha) subunit and one of several 28kDa (beta) subunits, 
encoded by the MHC class II genes on chromosome 6 region 6p21.31 (Zephir et al., 
2009). The complex of HLA-DR and its ligands, peptides of 9 amino acids in length or 
longer, constitutes a ligand for T cell receptors (TCR). Several MHC class II genes are 
linked to autoimmune conditions, disease susceptibility and disease resistance. The 
primary function of HLA-DR is to present peptide antigen, potentially foreign in origin, 
to the immune system for the purpose of eliciting or suppressing T helper cell 
responses that eventually lead to T cell activation and production of antibodies by B 
cell against the same foreign peptide antigen (Racke, 2009).
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CD8+ T cells use the CD8 molecules (in conjunction with their TCR) to recognize 
peptide MHC class I molecules HLA A, B or C in association with peptide and develop 
into cytotoxic T cells. CD4+ T cells develop into Thl or Th2 cells; use the CD4 molecules 
to stabilize interactions with the peptide HLA-DR complex. Th l7  are also differentiated 
from CD4+ in the presence of IL-6, TGF-P and IL-21, they are characterised by the 
production of pro-inflammatory cytokines including IL-17, IL-21 and IL-23 (Christensen 
et al., 2013). There are usually very low levels of HLA-DR expression in normal brain 
tissue, whereas in response to inflammatory stimuli in MS, microglia become activated 
and up regulate HLA-DR antigen expression (Handunnetthi et al., 2010; Comabella & 
Khoury, 2012).
MS and control tissues used in this study were classified based on the criteria of Sobel 
et al., (2001). In actively demyelinating lesions, HLA-DR positive cells were evenly 
distributed within the lesion, whereas in chronic active lesion HLA-DR positive cells 
were located at lesion edges rather than centrally. In chronic inactive lesions there 
were no HLA-DR positive cells either inside the lesion, at the edges of, or outside the 
demyelinating lesions. Lastly, in normal control and NAWM this was few HLA-DR 
positive cells. Results of human brain tissue classification according to HLA-DR 
immunostaining is illustrated in Figure (3-4), and summarised in Table (3-1).
3.2.1.3 MOG expression as a marker for the extent of demyelination
MOG is a useful marker for classifying the type of lesion in MS based on the extent of 
demyelination and re-myelination (Lucchinetti eta l., 2005). In an active lesion, there is 
substantial reduction in MOG staining, whereas in chronic lesions there was no 
evidence of MOG staining in the centre (Sobel & Ahmed, 2001). Results of human 
brain tissue classification according to MOG immunostaining is illustrated in Figure (3- 
4), and summarised in Table (3-1).
3.2.2 Classification of the human brain tissue blocks
Characterisation of the 89 blocks of MS and normal controls examined revealed 16 
contained active lesions, 20 had chronic inactive lesions, 11 had chronic active lesions, 
19 were NAWM, 16 were normal controls and 7 were poor structure (Table 3-1). 
Initially MS blocks were assessed for level of inflammation and 14 MS blocks displayed 
cuffs graded as (+). Control blocks also were assessed for inflammation and the
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majority of blocks displayed no inflammation however 4 blocks displayed sparse 
perivascular lymphocytes and were graded as (+). The majority of MS tissue blocks 
showed varying degrees of inflammation and displayed cuffs at (++) except 9 blocks 
which displayed cuffs grade (+++). Figure (3-2) shows the varying degrees of 
inflammation (A) and (E) for normal control brain (NC014 P1E3) which shows a 
negative score (-), B and F were graded as there were a small numbers of cells in the 
perivascular region (+) and described as CAL (MS103 P1E4), D and H show (+++) H&E 
staining for a MS lesion with perivascular cellular infiltrate classified as an active 
lesions (MS092 P1E3).
All sections were stained with ORO, and the majority of tissue blocks were negative for 
ORO lipid-laden macrophages (Table 3-1). 9 MS blocks displayed weak ORO positive 
staining which was very sparse and graded as (+), while 18 blocks had one or more foci 
or cluster of ORO positive cells graded as (++) and were classified as active lesions. In 7 
blocks however, ORO positive cells were abundant throughout the entire section 
graded (+++) and were also classified as active lesions (Figure 3-3).
16 blocks were classified as containing active lesions i.e. ongoing demyelination with or 
without ORO positive macrophages and increased HLA-DR staining in the absence of a 
hypo-cellular region. 11 blocks were classified as containing chronic-active lesions i.e. 
MOG loss entirely within the lesional centre with ORO positive macrophages and a rim 
of HLA-DR positive cells bordering the lesion with hyper-cellularity. 19 blocks were 
classified as NAWM i.e. displayed minimal inflammation, no ORO positive 
macrophages, normal MOG staining and resting microglia as indicating by HLA-DR 
staining. Figure (3-4) compares the expression of MOG and HLA-DR in NAWM and an 
active lesion to demonstrate the extent of demyelination and inflammation 
respectively.
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Figure 3-4: MOG and HLA-DR expression in normal control (NC) and active 
MS lesion brain tissue
Expression of MOG and HLA-DR assessed by IHC in NC and MS active lesion tissue to
determine the extent of demyelination and inflammation respectively. (A-B) Normal
control (CO037 A1B3) showed uniform expression of MOG and small numbers of
evenly distributed HLA-DR+ cells respectively, whereas (C-D) active lesion (MS051
A1B3) shows disrupted MOG staining and positive HLA-DR immunoreactivity on
abundant activated macrophages.
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Table 3-1: Human CNS tissue classification of MS and control blocks
based on immunohistochemical studies used in this study
A1B6 - - M ostly resting microglia Negative in lesion CL
MS049
A1D6 - - Resting microglia Normal NAWM
P2C2 - + Resting microglia Normal CL
MS050
P7C3 - - Resting m icroglia Normal NAWM
A1B3 ++ ++
Activated rounded up m icroglia
Disrupted in 
lesion
Small region AL, m ost 
o f block is GM.
MS051
M ostly resting m icroglia, w ith
P5C6 ++ ++ small area o f activated m icroglia 
at border
Negative in lesion
Small area is CAL
P4C1 ++ ++ M ostly resting m icroglia, some
Disrupted in 
lesion
Small region AL, M ost
rounded up m icroglia o f block is GM.
MS057
A2A3 - - Resting microglia
Normal
NAW M
A4E3 ++ ++ M ostly resting, some rounded up Disrupted
very small AL
microglia
AL
P1C1 +++ +++ Activated rounded up microglia Disrupted
MS058
A2D2 + - Resting microglia Negative in lesion
Small area CL, M ostly 
GM
A2A4 - -- -- -- Poor structure
A2F5 + - Resting microglia Negative in lesion CL
MS060 A2E5 + - Resting m icroglia Negative in lesion CL
A4D4 . . Resting microglia Normal NAW M
P1C3 +++ ++ Activated rounded up microglia
Disrupted in 
lesion
AL
MS062
P5D5 ++ ++ Activated rounded m icroglia and 
fla ttened  in lesion
Negative in lesion
CAL
A2C2 ++ + Resting m icroglia
Negative in lesion
CL
A4C3 - - Resting m icroglia
Normal
NAW M
P1E2 ++ ++ Activated rounded up microglia Disrupted AL
P2D2 +++ +++ Activated rounded up microglia Disrupted AL
MS074
A5B5 + - Resting m icroglia Normal NAW M
A4B6 - . Not clear Not clear Poor structure
P5B6 + +
Resting m icroglia
Negative in lesion CL
MS076 A1B3 - -
Resting m icroglia
Normal NAW M
P2A4 ++ ++
Activated rounded m icroglia at 
border
Negative in lesion CAL
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Table 3-1: (Continued) Human CNS tissue classification of MS and control
blocks based on immunohistochemical studies used in this study
P2D2 + +/- Resting m icroglia Negative in lesion CL
MS079 P3E4 + +/BV Resting m icroglia Negative in lesion CL, M ainly GM
P4B4 ++ ++ Activated rounded microglia Disrupted AL
MS080
P2B2
P7C3
+++
++
++
++
Activated rounded microglia at 
border
Activated rounded m icroglia
Disrupted 
Negative in lesion
AL
CAL
A2C2 . . Resting microglia Normal NAW M, M ostly  GM
A2B3
P5C3
+
++ ++
Resting microglia 
Activated rounded microglia
Negative in lesion 
D isrupted in lesion
CL
Very small AL, 
M ostly  GM
MS081
P2C2 ++ ++ Activated rounded microglia, 
fla ttened  w ith in  lesion center
Negative in lesion CAL.
A4D4 ++ ++ Activated rounded m icroglia Disrupted in lesion M ainly AL, M ostly 
GM
P4C3 ++ -/+ Resting m icroglia Negative in lesion CL
P3D3 +++ ++ Activated rounded up microglia Disrupted in lesion
AL
MS090
P3E3 ++ ++ Activated rounded up microglia Disrupted in lesion AL
P1B4 + -/+ Resting microglia Negative in lesion
CL
MS092
P1E3
P4B3
+++ +++ Activated rounded m icroglia 
Resting microglia
D isrupted in lesion 
Normal
AL
NAW M
P2C4 + - Resting m icroglia Negative in lesion
M ainly CL, M ostly 
GM
MS094 P3C7 ++ - Resting microglia Negative in lesion CL
P4C2 - - Resting microglia Normal NAW M
MS100
P5D3
A4C2
++
+
+++ Activated rounded up m icroglia 
at border 
Resting microglia
Negative in lesion 
Normal
CAL
NAW M
MS102
P5C6
A2C5
+ Resting m icroglia 
Resting m icroglia
Negative in lesion 
Normal
CL
NAW M
MS103
P1E4 + ++ M ostly resting, w ith  small area o f 
activated m icroglia at border
ND CAL
P3C4 - - Resting m icroglia Normal NAW M, M ostly  GM
P1B3 - - ND ND Poor s tructure
MS104
P3E2
P1E1
- - ND
ND
ND
ND
Poor s tructu re  
Poor s tructure
P3E3 . . ND ND Poor s tructu re
MS105
P1D3
A4B3 _ -
Resting m icroglia 
Resting microglia
Normal
Normal
NAW M
NAW M
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Table 3-1: (Continued) Human CNS tissue classification of MS and control
blocks based on immunohistochemical studies used in this study
P6D1 + + Resting microglia Negative in lesion
CL
MS106 P4B3 +++ ++ Activated rounded microglia at Negative in lesion
CAL
A2D1 ++ -/+
border 
Resting m icroglia Negative in lesion
CL Hyper cellu lar at 
border
P2E2 - - ND ND Poor structure
MS107
P5C7 - - Resting microglia Normal NAWM
MS121
P5B2 +++ +++ Activated rounded microglia Disrupted AL
A5B3 ++ ++ Activated rounded microglia, 
fla ttened  w ith in  lesion centre
Negative in lesion CAL.
MS122 P5B7 ++ ++ Activated rounded m icroglia, 
fla ttened  w ith in  lesion centre
Negative in lesion CAL.
A2E3 . . Resting microglia Normal NAW M
P4D2 - - Resting microglia Normal NAW M
MS126
P5B3 - - Resting microglia Normal NAW M
MS153 P1C3 ++ +
Activated rounded microglia and 
fla ttened  in lesion
Negative in lesion CAL
A2E6 - Resting microglia Negative in lesion CL
MS154
P3D5 + - Resting microglia Negative in lesion CL
P5A1 +++ +++ Activated rounded up microglia Disru pted AL
MS160
A2D2 ++ - Resting m icroglia Negative in lesion CL
P1E3 - - Resting microglia Normal NAWM
CO014
P2D2 - - Resting m icroglia Normal NAW M
P3D3 - - Resting m icroglia Normal NAW M
CO022
P4C3 - - Resting m icroglia Normal NAW M
A4D4 + - Resting m icroglia Normal NAW M
CO025
P3D4 - - Resting m icroglia Normal NAW M
A2D2 - - Resting m icroglia Normal NAW M
CO026 P1A2 - - Resting m icroglia Normal NAW M
P2A1 . Resting m icroglia Normal NAW M
P5A2 - - Resting m icroglia Normal NAW M
CO032
P1A1 - Resting m icroglia Normal NAW M
P2A3 + - Resting m icroglia Normal NAW M
CO036
P5A5 - - Resting m icroglia Normal NAW M
A1B3 + - Resting m icroglia Normal NAW M
CO037
P5B2 + - Resting m icroglia Normal NAW M
CO039 A4B5 — - Resting m icroglia Normal NAW M
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3.2.2.1 Immunohistochemical analysis of aggrecan and aggrecan 
neoepitope expression in MS and control CNS tissue
Aggrecan and aggrecan neoepitope immunoreactivity were consistently demonstrated 
in normal control and MS tissue sections. Intense immunoreactivity for aggrecan and 
its neoepitope were seen in both active and chronic active lesions of MS tissue blocks 
as compared to NAWM, CLs and normal control white matter. In this study the 
expression of MOG in human brain tissue was used to determine the extent of 
demyelination. Omission of primary antibodies resulted in negative staining for all 
samples for aggrecan and its fragments indicating specificity of the antibodies used. 
Aggrecan and its neoepitope immunoreactivity were detected in 54 blocks of MS (44) 
and normal control (10). Aggrecan and its neoepitope immunostaining appeared 
heterogeneous in distribution both between samples and within the same section 
dependent on the contribution of AL, CL and CAL within the MS blocks.
Strong aggrecan immunoreactivity was observed in active lesions with ongoing 
demyelination and was associated with areas of activated microglia. Figure 3-5 shows 
normal control and NAWM with a uniform pattern of expression of MOG indicating 
intact myelin, low level of HLA-DR+ cells in areas where there was decreased 
expression of aggrecan and aggrecan neoepitope. In contrast, strong aggrecan and 
aggrecan neoepitope immunoreactivity were observed in areas of active lesions, 
assessed by increased HLA-DR expression, and the presence of myelin breakdown with 
ongoing demyelination evidenced by lack of MOG staining. Expression of aggrecan and 
its neoepitope within regions of interest on individual sections was quantified by 
Image J software on immunohistochemical staining for aggrecan and its neoepitope in 
control, NAWM and active lesion. As shown in Figure (3-5, d) much greater expression 
of aggrecan and aggrecan neoepitope in active lesions compared to NAWM and 
normal controls. Data are represented as the mean (control white matter, n=10; MS 
NAWM, n=10; MS active lesion, n=10) ± SEM. A statistically significant differences 
between control white matter, MS NAWM and MS lesional tissue are indicated by 
asterisks (*P< 0.05, **P<0.01, ***P<0.001) (Kruskal-Wallis test) (Figure 3-5, d).
In chronic active lesions, aggrecan and its neoepitope expression was either weakly 
expressed or absent in areas of complete myelin loss and in the absence of microglia,
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with strongest immunoreactivity observed in areas with thinning myelin and activated 
microglia at the lesion edge (Figure 3-6). In contrast, in chronic inactive lesions, 
aggrecan and its neoepitope expression was weak or absent in areas of complete 
myelin loss as well as in areas with thinning myelin and activated microglia (Figure 3-6). 
Image J software analysis of the level of aggrecan protein density from each region of 
CAL, CL, NAWM and NC showed much greater expression of aggrecan in active lesions 
compared to chronic lesions, NAWM and normal control brain tissue. Data 
represented as mean ± SEM (10 blocks each CL and CAL).
3.2.2.2 Western blot analysis of aggrecan and aggrecan neoepitope 
expression in MS and control tissue
Following initial optimisation, SDS-PAGE was performed with 20pg protein/well before 
transferring separated proteins onto nitrocellulose membrane. Western blotting 
demonstrated that aggrecan and its neoepitope were present in all samples of MS 
active, NAWM and normal control brain tissue studied. Immunoblotting for p-actin 
(42kDa) was used as a reference protein. Two bands of 250 kDa and 70 kDa were 
observed for aggrecan and aggrecan neoepitope respectively, with the relevant 
antibodies. Figure 3-7 shows the variation in aggrecan and its neoepitope expression 
for all MS and normal brain samples examined, as determined by densitometry. 
Although expression was variable, overall there was a significant increase in aggrecan 
and aggrecan neoepitope expression in active lesions compared to NAWM and normal 
brain samples (***P<0.001, n=7). Increase in levels of these proteins was due to 
increases in both the 250 kDa and 70 kDa bands. Densitometric analysis values are 
expressed as the density ratio of target (aggrecan or aggrecan neoepitope) to loading 
3-actin in arbitrary units for aggrecan and its fragment in control white matter, MS 
NAWM and MS active lesional brain tissue. As shown in figure 3-7, there was much 
greater expression of aggrecan and its neoepitope in active lesions compared to 
NAWM and normal control brain. Data was represented as the mean ± SEM using 
Kruskal-Wallis analysis.
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Figure 3-5: Comparison of expression of aggrecan and its neoepitope 
between MS and control brain tissue by IHC
Single and dual staining immunofluorescence microscopy of serial tissue sections
stained with DAPI (blue) demonstrated cell nuclei, aggrecan and aggrecan neoepitope 
(green), MOG (red) and HLA-DR (red). Low levels of HLA-DR were observed in NAWM 
(MS094 P4C2) and normal control (NC022 P4C2) (a, i) and (b, i) respectively. Low levels 
of aggrecan and its neoepitope expression are seen in the same blocks as (a, iii) and (b, 
iii) respectively. In comparison to the active lesion (MS057 P4C1) (c, iii) showed high 
levels of these proteins in ongoing demyelination along with activated microglia (c, i) 
and (c, ii) respectively. Image J software analysis shows expression of aggrecan and its 
neoepitope in NC, NAWM and AL brain tissue (d). There is a greater expression of 
aggrecan and its neoepitope in the active lesion compared to NAWM and NC. Data 
represented as mean ± SEM using Kruskal-Wallis, n=10, five readings for each region 
for each section (**P<0.01, ***P<0.001, n=10). Scale bar 100pm
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Figure 3-6: Expression of aggrecan and its neoepitope in CAL and CL brain 
tissue by IHC
Immunofluorescence microscopy of serial tissue sections stained with DAPI (blue) 
demonstrated cell nuclei, aggrecan and aggrecan neoepitope (green), MOG (red) and 
HLA-DR (red). Low levels of HLA-DR were observed in areas of intact myelin in both 
CAL (MS051 P5C6) and CL (MS102 P5C6) (a, i) and (b, i) respectively. High levels of 
aggrecan and its neoepitope are present at the lesion edge in CAL (a; iii, iv) compared 
to CL (b; iii, iv). Areas of complete myelin loss were associated with absence of both 
microglia evidenced by HL-DR and loss of aggrecan and aggrecan neoepitope in both 
CAL and CL. An abundance of aggrecan and aggrecan neoepitope are present at the 
lesion border in ongoing demyelination in CAL compared to the CL border. Low levels 
of aggrecan and its neoepitope at the lesional centre in both CAL and CL are associated 
with low levels of HLA-DR staining and absence entirely of MOG. Data is presented as 
Mean ± SEM using Kruskal-Wallis, n= 10, five readings for each region for each section 
(c and d). Scale bar 100pm
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Figure 3-7: Western blotting analysis of expression of aggrecan and its 
neoepitope in MS and control brain tissue
Western blot of aggrecan (green), its neoepitope (green) and (3-actin (red) from an
active MS lesion (MS090 P3D3)( lanes 2, 3); control white matter (NC022 P3D3)( lane
4) and MS NAWM (MS103 P3C4)( lane 5). (Lane 1 and 6) represent standard molecular
weight markers (40-300KDa) (Thermo Scientific, UK), (a) and (c) demonstrate
expression of aggrecan (M W  250kDa) and aggrecan neoepitope (M W  70kDa)
respectively in an active lesion, normal control and normal appearing white matter.
Densitometric quantification shows much greater expression of aggrecan and its
neoepitope in AL compared to NC and MS NAWM using Kruskal-Wallis (***P<0.001,
n=7 blocks) (b) and (d).
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3.2.3 Expression of versican isoforms and versican neoepitope in human 
brain tissue
3.2.3.1 Immunohistochemical analysis of versican and versican 
neoepitope expression in MS and control tissue
Intact versican and its fragment were identified using antibodies raised in rabbit; the 
immunogen for the neoepitope was a synthetic peptide corresponding to residue 
Glu405-Glu406 which is a product of cleavage of versican V0/V2 generated by ADAMTSs. 
Intense immunoreactivity for both versican and the neoepitope was seen in active 
lesions of MS tissue blocks, as compared to NAWM, MS CL and control white matter 
tissue. Strong versican and neoepitope immunoreactivity was observed in active 
lesions with ongoing demyelination, evidenced by thinning of the myelin sheath, 
shown by disrupted MOG staining, and associated with areas of activated HLA-DR 
foamy macrophages/microglia. Figure (3-8, a) shows a normal control tissue (C037 
P5B2) with a uniform pattern of expression of MOG. Figure (3-8, c) lesional MS tissue 
(MS121 P5B2) shows loss and disruption of MOG. Loss of MOG staining was found in 
areas where there was increased expression of versican neoepitope, indicative of 
increased ADAMTS activity in lesional MS tissue (Figure 3-8, d).
MOG staining was absent within lesion centres and there was loss of ECM staining for 
versican, with dense intra-cytoplasmic granular staining in foamy macrophages. 
NAWM from MS blocks showed weak versican and versican neoepitope 
immunoreactivity, MOG staining was intact and normal in these cases. In chronic 
active lesions an increased gradient of versican immunoreactivity was observed 
starting at the inner edge of the hypercellular rim surrounding the hypocellular centre 
(Fig 3-9, a). There was less staining in chronic inactive lesions, although there was still 
an elevated expression compared to areas of NAWM (Figure 3-9, b). Furthermore, 
immunohistochemical analysis of versican and its neoepitope expression indicated 
much greater expression of versican isoforms (VO, V I and V3) in active lesions 
compared to chronic and NAWM (Figure 3-9, c). Data represented as mean ± SEM (10 
blocks each CL and CAL). Statistically significant difference between control white 
matter, MS NAWM and MS AL tissue are marked by asterisks (***P<0.001) using 
Kruskal-Wallis.
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3.2.3.2 Western blot analysis of aggrecan and aggrecan neoepitope 
expression in MS and control CNS tissue
Western blotting analysis demonstrated that versican and its neoepitope were present 
in all samples of MS and normal control brain tissue studied. The versican antibody 
produced a triplet of bands at 300, 270 and 180 kDa. Figure (3-10, a) shows the 
variation in versican isoform expression for all the MS and normal brain samples 
examined (n=7), as determined by densitometry. Though expression was variable, 
overall there was a significant increase in versican isoform (V0, V I  and V2) expression 
in the MS active lesions compared to the NAWM and normal control brain samples. 
Increases in versican isoforms was due to increase in the 300, 270 and 180 kDa bands 
Figure (3-10, c).
Versican neoepitope bands at 64kDa represent the neoepitope sequence generated by 
the aggrecanase-mediated cleavage for versican V0/V2 in human samples (Westling et 
al., 2004). This study was to determine whether lesional MS differed from NAWM and 
NC tissues in their ADAMTSs activity as determined by the presence of versican 
(V0/V2) neoepitopes by western blotting. Figure (3-10, b) shows that the expected 
64kDa versican (V0/V2) neoepitope fragment (Westling et al, 2004) is present and 
densitometric analysis values are expressed as the density ratio of target (versican 
neoepitope) to loading (3-actin in arbitrary units for versican neoepitope and control 
white matter, MS NAWM and MS active lesional brain tissue. Much greater expression 
of versican neoepitope in active lesions is seen compared to NAWM and normal 
control (Figure 3-10, d). Data was represented as the mean ± SEM using Kruskal-Wallis 
test (***P<0.001).
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Figure 3-8: Comparison of expression of versican and its neoepitope 
between MS and control brain tissue by IHC
Single and dual staining immunofluorescence microscopy of serial tissue sections 
stained with DAPI (blue) demonstrating cell nuclei, versican and versican neoepitope 
(green), MOG (red) and HLA-DR (red). Low levels of HLA-DR were observed in normal 
control (NC037 P5B2) and NAWM (MS126 P5B3) (a, i) and (b, i) respectively. Low levels 
of versican and its neoepitope expression in the same blocks (a; ii, iii) and (b; ii, iii) is 
shown. In comparison to active lesion (MS121 P5B2) (c; ii, iii, iv), which shows high 
levels of versican and versican neoepitope in areas of ongoing demyelination along 
with activated microglia (c, i) and (c, ii) respectively. Image J software analysis shows 
expression of these proteins in NC, NAWM and AL brain tissue. There is a much greater 
expression of versican and its neoepitope in active lesions compared to NAWM and NC. 
Data represented as Mean ± SEM using Kruskal-Wallis, n= 10, five readings for each 
region for each section (***P<0.001). Scale bar 100pm
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Figure 3-9: Expression of versican and its neoepitope in CAL and CL MS 
brain tissue by IHC
Immunofluorescence microscopy of serial tissue sections stained with DAPI (blue) 
demonstrated cell nuclei, versican and versican neoepitope (green), MOG (red) and 
HLA-DR (red). Low levels of HLA-DR staining were observed in areas of intact myelin in 
both CAL (MS050 P2C2) and CL (MS081 P2C2) (a, i) and (b, i) respectively. High levels of 
versican and its neoepitope at the lesion edge in CAL (a; iii, iv) compared to CL (b; iii, iv). 
Areas of complete MOG loss were associated with absence of both microglia 
evidenced by HLA-DR and loss of versican and versican neoepitope in both CAL and CL. 
Abundance of versican and versican neoepitope are present at the lesion border in 
ongoing demyelination in CAL compared to the chronic border lesion. Low levels of 
versican and its neoepitope are observed at the lesion centre in both CAL and CL, 
associated with low levels of HLA-DR staining and absence entirely of MOG. Data 
represented as Mean ± SEM using Kruskal-Wallis, n= 10, five readings for each regions 
for each section (c and d). Scale bar 100pm
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Figure 3-10: Western blotting analysis of expression of versican isoforms 
and its neoepitope in MS and control brain tissue
Western blot of versican isoforms and versican neoepitope (green) and P-actin (red) 
from an active MS lesion (MS090 P3D3) (lanes 2, 3); control white matter (NC022 
P3D3) (lane 4) and MS NAWM (MS103 P3C4) (lane 5). (Lane 1 and 6) represent 
standard molecular weight markers (40-300KDa) (Thermo Scientific, UK), (a) and (c) 
demonstrated expression of versican isoforms (VO, V I  and V2) and versican 
neoepitope respectively in active lesion, normal control and normal appearing white 
matter. Densitometric quantification shows much greater expression of versican 
isoforms and its neoepitope in AL compared to NC and MS NAWM using Kruskal-Wallis, 
Mann Whitney (***P<0.001, n=7 blocks) (b) and (d).
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3.3 Discussion
Aggrecan and versican, two major components of the ECM in the CNS are widely 
expressed throughout the developing and adult CNS and have a role in guiding or 
limiting neurite outgrowth and cell migration (Sandy et al., 2001; Sharma et al., 2012). 
Alteration in the synthesis or breakdown of the ECM may contribute to disease 
processes (Asher et al., 2001; Smith et al., 2005). Thus, ADAMTS-mediated cleavage of 
CSPGs aggrecan and versican in CNS ECM, via their glutamyl endopeptidase activity, 
could have a role in normal turnover and ECM breakdown in MS (Westling et al., 2004). 
To investigate this, here we demonstrated CSPG breakdown by ADAMTSs via 
production of aggrecan and versican neoepitopes as an indicator of enzyme activity. 
The objective in this project was to study CSPG protein expression and their 
breakdown by ADAMTSs ex vivo via the production of aggrecan and versican 
neoepitopes of ECM components in brain tissue. This was done by 
immunohistochemistry and western blotting. Also to show any differences, MS post­
mortem tissue was compared to normal control brain tissue in terms of intact 
aggrecan and versican.
In this study, high levels of aggrecan, versican and their neoepitopes were found in 
areas of ongoing demyelination by immunohistochemistry, which has not previously 
been reported in MS compared to normal brain tissue. In comparison, much lower 
levels of these proteins were consistently found in NAWM of MS and control white 
matter tissue where there was no demyelination (Table 3-2). From a previous study, 
using the same anti-versican neoepitope antibody, a 64 KDa band indicated the 
presence of this neoepitope in MS active lesions (Westling et al., 2004; Port et al., 
2005). Aggrecan and versican neoepitopes were increased, as observed by IHC and WB, 
in lesional tissue relative to normal control tissue, indicating that changes in ECM 
degradation may result from changes in ADAMTS activity level. The data provided 
cannot be used conclusively that aggrecan and versican neoepitopes present in active 
lesion were generated by ADAMTS-mediated cleavage. In this regard, there are two  
possible major cleavage sites at the C-termini on both aggrecan and versican G1 
domains, which have been termed the "aggrecanase" site and the "MMP" site; 
however, these cleavage sites are approximately 30 residues apart in each case, and 
they generate species that are readily separated electrophorectically. An alignment of
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this region of human versican VO, V I  and V2 domains suggests that there is no obvious 
equivalent MMP cleavage sites in these proteins, therefore most, or all of versicans 
from different species terminates at Glu 405-Ala406 following ADAMTS activity (Westling 
et al., 2002; Demircan et al., 2014). Since ADAMTS-4 cleaves brain aggrecan and 
versican, it is possible that this enzyme, as well as other aggrecanases including, 
ADAMTS-9 may play an important role in the processing of these molecules and other 
lecticans such as brevican, phosphacan and neurocan. It has been previously 
demonstrated that ADAMTS-4 is expressed in the CNS and shows an increased 
expression in MS active lesions compared to normal control white matter (Haddock et 
al., 2006). Also further work from our group demonstrated that TIMP-3, which is an 
endogenous inhibitor for ADAMTSs is decreased in MS (Haddock et al, 2006) and EAE 
(Plumb et al., 2005). Sobel and Ahmed, (2001) demonstrated that intact versican was 
decreased in central lesions, in keeping with the observation of increased versican 
neoepitope expression in lesional MS described in this thesis.
In view of the abundance of ADAMTS enzymes and other ECM molecule-degrading 
enzymes in demyelinating areas, loss of aggrecan and versican in MS plaques is in line 
with previous observations (Lemons et al., 2001; Westling et al., 2004). We did not, 
however, anticipate identifying large granules of versican and its neoepitope within 
cells in active lesions. These granules likely are aggregates of the versican or products 
of its extracellular degradation by ADAMTS that is phagocytosed either by activated 
microglia or macrophages (Figure 3-8). Alternately, this staining pattern may represent 
synthesised versican prior to secretion by the cells (Sobel & Ahmed, 2001).
The striking increase in ECM proteoglycan immunostaining of the aggrecan and 
versican in active plaque edges suggests that their expression is increased as a 
consequence of the pro-inflammatory milieu of the borders of expanding acute lesions 
(Siebert et al., 2014; Burda et al., 2014). These increases are consistent with numerous 
studies which show enhancement of both mRNA and immunoreactivity of the lecticans 
and the major dermatan sulphate PGs, biglycan and decorin accompanying 
astrocytosis in CNS injury (Thon et al., 2000; Jones et al., 2002; Lau et al., 2013). 
Furthermore, it has been indicated that TLRs are expressed by a variety of peripheral 
immune cells and resident cells of the CNS. TLRs play an important role in linking the 
innate to the adaptive immune response (Bell et al., 2005). They have a significant role
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in remodelling molecules in the CNS MS, as well as in EAE (Racke & Drew, 2009). In 
addition to lymphocytes that control adaptive immune responses, dendritic cells and 
tissue macrophages that regulate innate immune responses also play a crucial role in 
controlling MS pathogenesis (Takeda & Akira, 2005, Hacker et al., 2006; Amor et al., 
2014). TLRs may be activated by fragments of the ECM molecules generated by 
proteolytic cleavage. The aggrecan neoepitope, versican neoepitope and short 
hyaluronan fragment could be a candidate for this binding to TLR on macrophages. 
Activation of TLRs induces the expression of proinflamatory cytokines such as IL-1, TNF, 
chemokines and adhesion molecules, which could induce production of ADAMTSs, 
amplifying ECM breakdown (Piccinini & Midwood, 2010).
Studies have emphasized that CSPGs can interact with adhesion molecules expressed 
on various cell types (Asfari et al., 2010; Tan et al., 2011). When axonal growth cones 
come into contact with CSPGs, they retract and collapse. This might be the reason for 
the abortive regenerative sprouting observed in spinal cord injury lesions (Profyris et 
al., 2004; Fleming et al., 2006). The interaction of CSPGs and neurons stimulates the 
Rho-associated protein kinase Rho-ROCK and/or protein kinase C (PKC) intracellular 
signalling cascades, which inhibit process extension. Also by blocking activation of the 
Rho-ROCK and PKC signalling pathways, the inhibitory effect of CSPGs could be 
observed (Lim et al., 2013). While CSPGs are widely accepted to be inhibitory to axonal 
regeneration, the inhibitory nature of individual lectican molecules varies amongst the 
CSPGs. In vitro, purified brevican has been shown to be inhibitory to both axonal 
attachment and growth, while neurocan has been shown to interact with neuronal cell 
adhesion molecules (N-CAM) similarly inhibiting neurite outgrowth (Jones et al., 2003; 
Yuan et al., 2013).
At the molecular level, the inhibitory activity of CSPGs on neurite outgrowth and axon 
re-growth is mediated mainly by GAGs and their structural motifs. Treatment with 
chondroitinase ABC, an enzyme able to cleave the sugar side chains without altering 
the core protein structure, promotes axon re-growth both in vivo and in vitro (Properzi 
et al., 2003). The ECM of the glial scar contains high level of CSPGs, Yiu et al., (2006) 
demonstrated that neurons cannot cross the glial scar, in which CSPG levels are 
increased. Similarly, the increased expression of intact aggrecan and versican around 
sites of injury in MS lesions in this study might be involved in the inhibition of neuite
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re-growth and axon elongation. The precise relationship of CSPG deposition to glial 
scarring and axon re-growth inhibition, binding to other ECM components and cell 
migration in the mature CNS are currently poorly understood. Previous studies 
performed in our laboratory demonstrated evidence for expression of ADAMTS-1, 4 
and 5 in both normal and MS lesion with up-regulation of ADAMTS-4 at the protein 
level in MS lesions (Haddock et al., 2006). Current knowledge suggests that these 
alterations may be beneficial, enabling neurite outgrowth and neuronal repair, since 
CSPGs inhibit neurite outgrowth, axonal regeneration and promote neural cell death. 
However, ADAMTS mediated degradation of CSPGs may increase access of 
inflammatory cells to sites of tissue destruction leading to detrimental outcomes 
(Inatani et a l,  2001; Cross et a l,  2006).
3.4 Conclusion
Cleavage of white matter ECM components, versican and aggrecan, in MS plaques is 
up-regulated, in particular in active lesions and at chronic active border. This study 
provides evidence to suggest that CSPG breakdown is involved in MS pathogenesis; 
CSPGs are likely to contribute to the failure of axon regeneration and neurite 
outgrowth. ECM lectican abnormalities in the CNS of MS patients should be considered 
in the design of future interventional therapies and their breakdown by glutamyl 
endopeptidase ADAMTSs may be beneficial, enabling neurite outgrowth and neuronal 
repair.
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Chapter 4
Expression of ADAMTS-9 in the CNS in MS:
a pathological role
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4.1 Introduction
The ADAMTS enzyme family contains 20 individual gene products (Apte, 2004). Certain 
members of this family (ADAMTS-1, -4, -5, -8, -9 and 15) can proteolytically process 
aggrecan within the interglobulin domain (IGD) separating its globular G1 and G2 
domains at a specific Glu373-Ala374 bond or at one or more sites within the C-terminal 
glycosaminoglycan (GAG)-bearing region (Kuno et al., 2000; Tortorella et al., 1999). 
ADAMTS-9 was originally cloned by Clark et al., (2000) who localized the gene to 
chromosome 3P14.2-P14.3. Of all ADAMTSs, ADAMTS-9 comprises the highest number 
of C-terminal TSP-1 like domains (Gottschall & Howell, 2015). This is indicative of a 
protein with the ability to bind to heparan sulphate proteoglycans (HSPGs) of the BBB 
basement membrane and glial scars as well as glycosphingolipid sulphatide, a lipid 
predominantly expressed in the brain (Zeng et al., 2006).
ADAMTS-9 is widely expressed throughout the adult human body organs including 
brain, heart, placenta and others (Somerville et al., 2003). Levels of pro-inflammatory 
cytokines TNF and IL-1 are up-regulated in the CNS in MS (Di Penta et al., 2013) and 
ADAMTS-9 has been shown to be increased in response to these in chondrocytes and 
chondrosarcoma cells (Demircan et al., 2005; Yaykasli et al., 2009). Though, anti­
inflammatory mediators such as TGFpl down-regulated ADAMTS-9 expression in 
prostate cells (Cross et al., 2005).
Unlike other ADAMTSs, such as ADAMTS-1 and ADAMTS-4, pro-domain cleavage of 
ADAMTS-9 leads to reduced versicanase activity rather than enhancing the catalytic 
function, and pro-domain processing occurs outside the cytoplasm on the cell surface 
(Kumar et al., 2012). It has been suggested that ADAMTS-9 degradation of CSPGs may 
increase access of inflammatory cells to the CNS and lead to axonal damage. 
Alternatively, breakdown of CSPGs, by ADAMTS-9 may enable axonal regeneration and 
neurite outgrowth, which is inhibited by CSPGs (Tauchi et al., 2012). Several ADAMTSs 
have been shown to be elevated in human neurodegenerative disease and animal 
models of brain injury. ADAMTS-1, but not ADAMTS-5, appears to be up-regulated in 
Down's syndrome, Pick's disease and Alzheimer's disease (Miguel et al., 2005) and 
ADAMTS-4 in MS (Haddock et al., 2006).
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4.1.1 Aim of study
Since in chapter 3, enzymatic degradation of aggrecan and versican was observed in 
MS lesions, the key aim of this study was to determine whether ADAMTS-9 is 
implicated in this ECM degradation; to develop an understanding of its activity by 
assessing its substrates ex vivo, which may then subsequently be exploited 
therapeutically through the design and application of molecules to increase or inhibit 
its activity. This study was designed to establish a reproducible protocol for the 
examination of ADAMTS-9 expression together with phenotypic markers of specific 
CNS cells. Snap-frozen autopsy brain tissue from the same blocks was used and 
classified as described in Chapter 3 (section 3.3.2). Image J software analysis of 
ADAMTS-9 expression by immunofluorescence was applied to establish differences in 
extent of ADAMTS-9 expression between NC, MS NAWM and MS AL. The major 
objectives addressed were:
•  To determine whether ADAMTS-9 immunoreactivity is detectable in human 
snap frozen brain autopsy material.
•  To investigate levels of ADAMTS-9 mRNA expression in MS AL brain tissue 
compared to levels in MS NAWM and control brain, using qRT-PCR.
•  To Investigate the expression of ADAMTS-9 protein in MS AL compared to MS 
NAWM and normal control human brain tissue, using immunohistochemistry 
and western blotting.
•  To identify the cell types within the brain associated with ADAMTS-9 expression, 
using dual staining immunohistochemistry.
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4.2 Results
4.2.1 ADAMTS-9 immunoreactivity within control and MS CNS white 
matter
4.2.1.1 Immunohistochemistry analysis of ADAMTS-9 in CNS tissue from 
MS and control
Upon microscopic examination, ADAMTS-9 expression appeared to be associated with 
the cell body and elongated processes of parenchymal cells. Strong ADAMTS-9 
immunoreactivity was observed in active MS lesions with ongoing demyelination and 
was associated with areas of activated microglia. Staining was quite extensive around 
some blood vessels (vWF+), which may indicate ADAMTS-9 is secreted by endothelial 
cells and binds to connective tissue components.
In normal control and NAWM with a uniform pattern of MOG staining, low levels of 
HLA-DR+ cells were found in areas where there were low levels of ADAMTS-9 
expression (Figure 4-1). In contrast, strong ADAMTS-9 immunostaining was observed in 
areas with active lesions, assessed by increased HLA-DR+ cells, and myelin breakdown 
with ongoing demyelination. Expression of ADAMTS-9 within the region of interest on 
individual sections was quantified by image J software. Immunohistochemical analysis 
emphasized that ADAMTS-9 expression in NC, NAWM and AL. Much greater expression 
of ADAMTS-9 was observed in active lesion compared to NC and MS NAWM (Figure 4- 
1, d). Data are presented as the mean (n=10 each NC, NAWM and MS AL) ± SEM. 
Statistically significant differences between control white matter, MS NAWM and MS 
active lesion are marked by asterisks ***P<0.001.
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Figure 4-1: Detection of ADAMTS-9 in MS and control human brain tissue 
using IHC
Single and dual staining immunofluorescence microscopy of serial tissue sections 
stained with DAPI (blue) demonstrating cell nuclei, ADAMTS-9 (red), MOG (green) and 
HLA-DR (green). Low levels of HLA-DR were observed in NAWM (MS076 A1B3) and 
normal control (NC37 A1B3) (a, ii) and (b, ii) respectively. Low levels of ADAMTS-9 
expression in the same blocks (a, iii) and (b, iii) respectively. In comparison, active 
lesion (MS051 A1B3) shows high levels of ADAMTS-9 (c, iii) in areas of ongoing 
demyelination along with activated microglia (c, i) and (c, ii) respectively. Image J 
software analysis shows expression of ADAMTS-9 in control, NAWM and lesion brain 
tissue (d). Note the difference in graph, much greater expression of ADAMTS-9 in 
active lesions compared to NAWM and NC. Data represented as mean ± SEM using 
Kruskal-Wallis, n=10, five reading for each region for each section (**P<0.01, 
***P<0.001, n=10). Scale bar 100pm
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4.2.1.2 Cellular localisation of ADAMTS-9 within MS active lesion
ADAMTS-9 expression appeared to be associated with the cell body and the elongated 
processes of parenchymal astrocytes in active MS lesion. There were also increased 
levels of blood vessel associated ADAMTS-9 expression compared to NAWM and NC 
white matter, which appeared to be both endothelial and astrocytic-end-feet in origin. 
To determine the exact cellular distribution of ADAMTS-9, dual label 
immunofluoresence was carried out with polyclonal goat anti-ADAMTS-9 antibody and 
rabbit anti-NF or mouse anti HLA-DR or mouse anti-vWF or mouse anti-GFAP 
antibodies for identification of neurons, microglia/macrophages, endothelial cells and 
astrocytes respectively as described in chapter 2 (section 2.1.2.3). 
Immunofluorescence was carried out following the application of three different 
commercially available anti-GFAP antibodies to determine the cellular location of 
ADAMTS-9 protein expression within astrocytes cells, and to ensure there were no 
cross reactions (anti-GFAP, abeam, UK; anti-GFAP, Millipore, UK; anti-GFAP, invitrogen, 
UK). Following initial optimisation, mouse anti-GFAP antibody from Millipore was 
carried forward for use in this experiment.
Utilisation of the Zeiss 510 software enabled individual pixels to be scanned and 
viewed as a yellow colour if true co-localization existed between the two channels of 
interest. Co-localisation was observed with ADAMTS-9 and cerebral vascular 
endothelium in the lesion (Figure 4-2), compared to normal control human brain tissue 
(Appendix III). Co-localisation was also observed in the foamy macrophages and 
activated microglia in MS active lesion (Figure 4-3). Co-localisation of the astrocytic 
phenotypic marker (GFAP) with ADAMTS-9 provided definitive evidence of ADAMTS-9 
expression by astrocyte cells within MS active lesions as shown in (Figure 4-5).
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ADAMTS-9
Figure 4-2: Dual label immunofluorescence of ADAMTS-9 and vWF in 
MS AL brain tissue sections
Dual label immunofluorescence for (a) vWF (green) and (b) ADAMTS-9 (red) in MS 
active lesion white matter (MS062 P1C3) with high levels of parenchymal ADAMTS-9 
immunoreactivity. (C) Co-localisation is represented by the pixels in quadrant 3 on the 
graph and is demonstrated as yellow pixels in the composite image (d) following Zeiss 
510 CSLM software reading of individual pixels for each fluorophore. V= vessel.
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Figure 4-3: Dual label immunofluorescence of ADAMTS-9 and HLA-DR 
in MS AL brain tissue
Dual label immunofluorescence for (a) HLA-DR (green) and (b) ADAMTS-9 (red) in MS 
active lesion white matter (MS062 P1C3) with high levels of parenchymal ADAMTS-9 
immunoreactivity. (c) Co-localization is represented by the pixels in quadrant 3 on the 
graph and is demonstrated as yellow pixels in the composite image (d) following Zeiss 
510 CSLM software reading of individual pixels for each fluorphore. Areas circled 
indicate co-localisation of ADAMTS-9 to macrophages aand activated microglia 
(stained yellow).
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Figure 4-4: Dual label immunofluorescence of ADAMTS-9 and NF in MS 
AL brain tissue
Dual label immunofluorescence for (a) NF (green) and (b) ADAMTS-9 (red) in MS active 
lesion white matter (MS062 P1C3) with high levels of parenchymal ADAMTS-9 
immunoreactivity. (c) Co-localization is represented by the pixels in quadrant 3 on the 
graph and is demonstrated as yellow pixels in the composite image (d) following Zeiss 
510 CSLM software reading of individual pixels for each fluorphore. Arrows indicate co­
localisation of ADAMTS-9 and NF on a few axons. V= vessel.
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Figure 4-5 Dual label immunofluorescence of ADAMTS-9 and GFAP in MS 
AL brain tissue
Dual label immunofluorescence for (a) GFAP (red) and (b) ADAMTS-9 (green) in MS 
active lesion white matter (MS062 P1C3) with high levels of parenchymal ADAMTS-9 
immunoreactivity. (C) Co-localization is represented by the pixels in quadrant 3 on the 
graph and is demonstrated as yellow pixels in the composite image (d) following Zeiss 
510 CSLM software reading of individual pixels for each fluorphore. Areas circled 
indicate co-localisation of ADAMTS-9 to astrocytes (stained yellow). V= vessel.
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4.2.1.3 Western blot analysis of ADAMTS-9 in CNS tissue from MS and 
control brain
Western blotting of protein samples from CNS tissue homogenates indicated that 
ADAMTS-9 is constitutively expressed within MS and normal control tissue (Figure 4-6). 
As variations in the extent of ADAMTS-9 staining were detected within the white 
matter using IHC, and was not the grey matter, quantitation of protein samples were 
carried out due to the varying amount of white matter in the tissue blocks used. Anti- 
ADAMTS-9 antibody revealed a single band at approximately 180kDa, is an affinity 
purified goat polyclonal antibody raised against peptide mapping within internal region 
of ADAMTS-9 of human tissue (Cal et a l,  2002). The P-actin band (42 kDa) was used to 
verify the equal loading of the samples (Figure 4-6, a). The results demonstrated that 
ADAMTS-9 protein was present in both normal control and in MS human brain tissue. 
Densitometry analysis of this band showed a significant increase in ADAMTS-9 protein 
in the MS sample "active lesion" compared to the NAWM and normal control brain 
samples (Figure 4-6, b).
4.2.2 qRT-PCR analysis of mRNA expression of ADAMTS-9 in MS AL, MS 
NAWM and normal control brain tissue
4.2.2.1 Case selection
A total of 30 tissue blocks were initially characterised for the study based on the 
histological and immunohistochemical assessment as described in chapter 3 (section 
3.3.2). Histological evaluation identified 10 cases as having evidence of inflammation 
and ongoing demyelination considered as active lesions. Another 20 blocks identified 
as having no evidence of inflammation or demyelination were considered as normal 
control and NAWM samples (Table 3-1). RNA was extracted as described in chapter 2 
(section 2.3.3.1), and then all samples were checked by agarose gel electrophoresis for 
RNA integrity as described in chapter 2 (section 2.3.4). Figure (4-7) shows a 
representative gel for extracted RNA with intact and good quality RNA as determined 
by the presence of 28S and 18s RNA subunit.
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4.2.2.2 qRT-PCR validation, normalisation and housekeeping genes
It is essential to rule out variation between samples when detecting mRNA expression 
[(reverse transcription into cDNA as described in chapter 2 (section 2.3.5)]. Three 
widely used housekeeping genes (GAPDH, PPIA and HPRT-1) were tested for their 
stability across experimental samples and hence suitability as reference genes for 
normalisation of target gene expression in qRT-PCR as described in chapter 2 (section 
2.3.6) (Vandesompele et al., 2002). The expression of stability measure of CT values of 
the three stable genes was determined in each sample following cDNA synthesis. This 
demonstrated the suitability of PPIA, HPRT-1 and GAPDH to be used as reference 
genes; therefore all three genes were used in subsequent qRT-PCR experiments. Figure 
(4-8) shows representative amplification plots of qRT-PCR for housekeeping genes, all 
housekeeping gene CT values were between 18 -25 and for ADAMTS-9 CT values were 
> 30 indicating that the expression ADAMTS-9 was much lower than that of the 
housekeeping genes.
4.2.2.3 Expression of ADAMTS-9 mRNA in human brain tissue
qRT-PCR amplification of mRNA from normal and MS tissue blocks revealed that 
ADAMTS-9 was constitutively expressed at the mRNA level (Figure 4-8) in all samples 
studied. ADAMTS-9 was shown to be expressed at the mRNA level in control white 
matter, MS NAWM and MS AL. There was significantly higher ADAMTS-9 mRNA 
expression in the MS lesions compared to both NAWM and control white matter brain 
tissue using Kruskal-Wallis, n=7 (Figure 4-9).
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Figure 4-6: Western blot analysis of ADAMTS-9 protein expression in MS 
and control CNS white matter protein extracts
(a) Western blot of ADAMTS-9 (green 180KDa) and (3-actin (red 42KDa) from; control 
white matter (lane 2) MS NAWM (lane 3) and active lesion (lanes 4 and 5). Lanes 1 and 
6 represent standard molecular weight markers (40-300KDa) (Thermo Scientific, UK).
(b) Densitometric quantification of ADAMTS-9 expression in active lesion, normal 
control and normal appearing white shows much greater expression of ADAMTS-9 in 
AL compared to NC and MS NAWM using Kruskal-Wallis, n=7 (***P<0.001).
b
3
2
0
1 2 7
Figure 4-7: Agarose gel electrophoresis pattern of total RNA extracted 
from control and MS human brain tissue
Lanes (1 and 2) and (3 and 4) represent duplicate samples of RNA extracted from NC 
and MS white matter blocks respectively. 28S rRNA and 18S rRNA bands confirm RNA 
integrity. DNA marker contains thirteen markers between 250 and 10,000 bp, 
(Invitrogen, UK). bp= base pairs.
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Figure 4-9: Expression of ADAMTS-9 mRNA in human control and MS 
brain tissue assessed by qRT-PCR
Real Time PCR (qRT-PCR) analysis showing ADAMTS-9 mRNA expression in NC, NAWM 
and MS active lesions. Much greater expression of ADAMTS-9 mRNA in MS lesions is 
seen compared to NC and MS NAWM. Data are presented as the mean (n=10 samples 
each NC, NAWM and MS AL) ± SEM. Statistically significant difference between control 
white matter, MS NAWM and MS active lesion are marked by asterisks ***P<0.001.
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4.3 Discussion
The results presented here demonstrate the spectrum of ADAMTS-9 distribution in 
CNS tissue by IHC, along with image J software analysis of the relative level of 
ADAMTS-9 expression in normal control white matter, NAWM and the active lesions. 
Tissue was classified based on evidence of recent myelin breakdown and extent of 
cellular activation as determined by ORO staining and HLA-DR immunoreactivity, 
classification parameters as described by other authors (Sanders et al., 1993; Van der 
Valk & De Groot, 2000). The first objective of this study was to determine whether 
ADAMTS-9 was expressed and then to establish a reproducible protocol for 
identification of ADAMTS-9 by immunofluorescence in snap frozen human autopsy 
brain material. Protein expression of ADAMTS-9 was further confirmed by western 
blotting following separation of proteins extracted from tissue homogenates by SDS 
PAGE as described in chapter 2 (section 2.2.4). Gene transcription for this protein was 
also demonstrated by reverse transcribing mRNA into cDNA followed by qRT-PCR.
High levels of ADAMTS-9 were found in areas of ongoing demyelination, which has not 
previously been reported in MS immunohistochemically. In comparison, much lower 
levels of this protein were consistently found in NAWM of MS and control white 
matter tissue where there was no evidence of demyelination. Previous studies using 
qRT-PCR indicated that ADAMTS-9 was expressed by differentiated neuroblastoma 
cells in vitro and significantly up-regulated following transient middle cerebral artery 
occlusion (tMCAo) in the rat (Reid et al., 2009). ADAMTS-9 expression was associated 
with the endothelium of blood vessels and with the cell body and elongated processes 
of parenchymal astrocytes and the astrocytic end feet that encompass the cerebral 
vasculature. Co-localisation of ADAMTS-9 with the astrocyte phenotypic marker, GFAP, 
or the endothelial marker, vWF or neuronal marker, NF-L following dual labelled 
immunofluorescence, confirmed the morphological observations and clearly 
demonstrated that these three cell types are responsible for ADAMTS-9 expression. 
These observations confirm ADAMTS-9 expression within MS active lesions is similar to 
that for other MMPs reported previously e.g. ADAMTS-4 and ADAM 17 (Haddock et al., 
2006; Goddard et al., 2001). ADAMTS-9 was also demonstrated to be expressed by 
activated macrophages/microglia cells in MS tissue and was upregulated in MS.
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particularly in active lesions where ADAMTS-9 immunreactivity is evident in numerous 
large foamy macrophages, implicating a possible role in the disease process.
The presence of ADAMTS-9 protein and mRNA was analysed by western blotting and 
qRT-PCR using protein and RNA extracted from 30 blocks (10 each NAWM, AL and NC). 
ADAMTS-9 was detected in all samples by a band at 180 kDa, probably corresponding 
to the mature form of the protein (Cal eta l., 2002). ADAMTS-9 protein expression was 
significantly increased, as observed by western blotting in MS active lesions. In 
addition, ADAMTS-9 mRNA was up-regulated in MS active lesion tissue; this suggests 
that translation of ADAMTS-9 increases in MS active lesions.
Changes in ADAMTS-9 reported in human chondrocytes in rheumatoid arthritis (RA) 
result from transcriptional changes in ADAMTS-9 or changes in protein activity due to 
up-regulation of aggrecan within injury sites (Demircan et al., 2005). ADAMTS-9 may 
be involved in the loss of ECM by cleaving proteoglycans, as demonstrated for other 
ADAMTSs and other tissues (Sandy et al., 2001; Lemanrchant et al., 2014) and as 
described here in chapter 3. Sobel and Ahmed, (2001) demonstrated that in active 
plaque centre and active lesions, CSPGs were decreased in the ECM and accumulated 
in foamy macrophages which is similar to our findings in chapter 3. This loss of CSPGs is 
related to the high levels of ADAMTS-9 observed in active MS plaques.
Transcriptional induction of ADAMTSs e.g. ADAMTS-1 and 9 in neurons and astrocytes 
following physical or toxic injury in the CNS has been reported and it was suggested 
that this expression at the site of injury may favour neurite outgrowth (Lemons et al., 
2001; Cau et al., 2013). It has been reported that ADAMTS-4 cleaves versican in vivo, 
in a manner similar to the ADAMTS-mediated cleavage of aggrecan and versican in 
cartilage (Tortorella et al., 2001; Demircan et al., 2005), spinal cord (Fawcett, 2006; 
Lemons et al., 2001) and brain tissue (Matthews et al., 2000; Westling et a!., 2004). It 
was also reported that ADAMTS-4 was abundant in MS active lesions (Haddock et al., 
2006), in agreement with our reported observations for ADAMTS-9. Thus, ADAMTS-9 
together with ADAMTS-4 expression in the CNS, may contribute to remodelling of the 
ECM in the brain in MS patients. On the other hand, others also suggest that the level 
of endogenous ADAMTSs is not sufficient to recover plasticity and functional recovery 
after human brain injury. The cleavage of CSPGs induced by glial cells may be achieved
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not only by ADAMTS-9 but also by other ADAMTSs and MMPs, which are also 
upregulated after neuronal injuries (Nakamura et al., 2000; Tauchi et al., 2012). MMPs 
also cleave other matrix proteins, such as laminin and collagen, leading to loss of blood 
brain barrier integrity; enhancing the infiltration of immune cells which may worsen 
the pathology of MS (Rosenberg et al., 1998).
ADAMTS-9 may play a role in a number of ways in the development of MS; proteolytic 
cleavages of ECM Heparan sulphate proteoglycan (HSPGs) of the BBB basement 
membrane and glial scar as well as cleavage of HGSPs into their soluble form, may 
create a chemotatic gradient for inflammatory cells to enter the CNS (Chen et al., 
2000; Zeng et al., 2006). ADAMTSs are reported to cleave CSPGs and adhesion 
molecules from the luminal surface of blood vessels; however in MS, increased 
expression of CSPGs has been reported, suggesting an imbalance in enzyme/inhibitor 
activity. ADAMTS-9 expression has been demonstrated to be associated with 
astrocytes and activated macrophages/microglia and expressed at high levels in lesions 
with high level of cellular activity as gauged by HLA-DR and ORO expression. ADAMTS- 
9 cleaves CSPGs thereby possibly subjecting neurons to its cytotoxic effects (Cau et al., 
2013). CSPGs have been reported to inhibit myelin repair (Lau et al., 2013) neurite 
outgrowth (Barrit et al., 2006) and axon regeneration (Shen et al., 2009; Brown et al., 
2012), which is investigated in chapter 5.
Following upregulation, ADAMTS-9 could be contributing to neuronal regeneration by 
two potential mechanisms; 1) promotion of neuronal differentiation/proliferation by 
enzymatic activity in the nucleus (Somerville et al, 2003) or 2) operating as a peptidase 
on the cell surface of migrating CNS cells and clearing a path through the ECM or glial 
scar by degradation of CSPGs (Somerville et al, 2003), enabling migration of 
oligodendrocyte precursor cells. Alternatively, the breakdown of CSPGs by ADAMTS-9 
could have a damaging effect on the CNS by allowing the migration of inflammatory 
cells and activated macrophages to susceptible neurons. The efficiency by which 
ADAMTSs cleaves CSPGs does not appear to be as high as MMPs, perhaps limiting the 
impact of the peptidase as proteoglycanase in ex vivo (Somerville et al, 2003). 
Therefore the up-regulation of ADAMTS-9 expression following stroke is not 
necessarily a bad thing because it is unlikely that the normal ECM structure will be 
significantly degraded by the peptidase.
134
The identification of the cells responsible for the synthesis of ADAMTS-9 is important 
when analysing the functional aspects of ADAMTS-9. ADAMTS-9 could be the sheddase 
responsible not only for CSPGs breakdown, but also for release of growth factors and 
adhesion molecules (Luan et al., 2008). Moreover, astrocytes and macrophages can 
contribute to immune regulation through their role in resealing of the BBB and their 
direct effects on immune cell modulation molecules, such as TGF|3, and TNF and 
proteoglycans (Faulkner et al., 2004; Rolls et al., 2009). Proteoglycan, and principally 
CSPGs, are known for their immune-related activity in peripheral tissue. Owing to their 
adhesiveness to chemo-attractive agents and growth factors that are required for 
recruiting and activating immune cells, proteoglycans can capture these factors 
increasing their focal concentration and thereby targeting the immune response to the 
injured areas (Nandini eta l., 2006; Rolls eta l., 2009).
Reid et al., (2009) provided evidence that IL-1(3 and TNF-a potentially up-regulated 
ADAMTS-9 in an astrocytic cell line (U373-MG) by activating transcription factor NF|<B. 
This study provided strong evidence that ADAMTS-9 expression is modulated by 
pathological conditions that occur in response to CNS injury. The ADAMTS-9 data 
described here are consistent with previous studies of ADAMTS-1 and -4 expressions, 
which were both upregulated in MS. In contrast to ADAMTS-5 and -8, levels which 
were not significantly raised in response to experimental stroke or in MS (Chen et al., 
2000; Haddock et al., 2006; Tian et al., 2007). However, Luan et al., (2008) indicated 
that specific blocking antibodies against IL-lp and TNF-a dramatically inhibited 
ADAMTS-7 and ADAMTS-12 induction in chondrocytes in vitro, and the suppression of 
TNF-a and IL-ip expression by siRNA in human chondrocytes prevented ADAMTS-7 
and ADAMTS-12 mediated degradation of cartilage oligomeric matrix protein (COMP). 
Regardless of cell source, ADAMTS-9 expression by astrocytes and 
macrophages/microglia would allow cleavage of CSPGs resulting in promotion of a pro- 
inflammatory after acute CNS injury. These suggestions are in agreement with other 
reports indicating that, in the periphery, CSPGs regulate the motility and activation of 
macrophages (Hayashi et al., 2001; Rolls et al., 2008), dendritic cells (Kodaira et al., 
2000) and other immune cell types (Rolls et al., 2006).
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4.4 Conclusion
In chapter 3 was reported that CSPGs including aggrecan and versican are up regulated 
in MS active lesions as were their neoepitopes indicative of ADAMTS-9 activity. Here 
we report the cellular origin and distribution of ADAMTS-9 expression within clinically 
and neuropathologically confirmed MS and normal control white matter, assessed by 
qRT-PCR, IHC and WB. ADAMTS-9 expression was associated predominantly with 
activated macrophages/microglia, parenchymal astrocytes and to lesser extent with 
blood vessel endothelium and axons in MS white matter. We demonstrated here that 
ADAMTS-9 expression at the mRNA and protein level was also increased in active 
inflammatory lesions with evidence of myelin breakdown, suggesting that up- 
regulation of ADAMTS-9 may be a general phenomenon induced by CNS injuries. 
ADAMTS-9 could degrade aggrecan and versican and reverse the neurite outgrowth 
inhibition mediated by human brain proteoglycans allowing OPCs to cross the glial scar 
to repair axons. However, as repair in MS is limited; this degradation of ECM proteins 
deposited in lesions does not allow the repair process to be complete. Further studies 
on this enzyme are now required to define its function in normal CNS physiology and in 
the pathological process of MS (See chapter 5).
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Chapter 5 
ADAMTS-9 expression and modulation 
in CNS cells in vitro
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5.1 Introduction
In the CNS, inflammation is not a phenomenon that occurs spontaneously, it requires a 
stimulus (inflammatory or infection), to initiate pathways including intercellular 
communication by pro-inflammatory mediators such as cytokines and chemokines 
(Comabella & Khoury, 2012). Some of these molecules, such as interleukin-1 (IL-1), IL-2, 
IL-6, TNF-a and IFN-y are produced by many cell types such as monocytes, 
macrophages, NK cells, astrocytes and microglia (Imitola et al., 2005; Ramesh et al., 
2013; Rossi et al., 2013). They are all known proinflammatory factors and are found to 
be upregulated in MS (Lim & Constantinescu, 2010; Carminero et al., 2011; Di Penta et 
al., 2013). Additionally, when these molecules, especially IL-1, TNF-a and IFN-y, were 
injected into normal brain tissue, a significant amount of reactive astrogliosis was 
observed around the injection site (Abdelbassat eta l., 2011; Burda et al., 2014; Siebert 
et al., 2014).
Damage to the CNS, either by trauma or inflammation, initiates an increase in pro- 
inflammatory cytokines, which stimulate the upregulation of CSPGs expression, due to 
the induction of reactive gliosis (Yu et al., 2012; Siebert et al., 2014). Reactive 
astrocytes synthesise brevican, neurocan and phosphacan, while vascular 
macrophages, activated microglia and endogenous OPCs account for the increased 
expression of aggrecan, versican and NG2 (Asher et al., 2002; Jones et al., 2002; 
Viapiano et al., 2006). CSPGs inhibit neurite outgrowth from embryonic chick and 
rodent neurons in vitro but the role of CSPGs on human neurons has been largely 
untested. Here, the effect of aggrecan on neurite outgrowth was investigated using 
neuroblastoma cell line (SHSY-5Y), cells grown on varying concentration of aggrecan to 
assess neurite extension (Hynds eta l., 1996; Cua eta l., 2013).
Enzymatic removal of the GAG chain from ECM core proteins by chondroitinase ABC 
permits some axonal regrowth; however the remaining intact core protein also 
possesses an inhibitory domain (Karimi et al., 2012; Cua et al., 2013). Because 
ADAMTSs can degrade the core protein of CSPGs, ADAMTS-9 was investigated for its 
capacity to overcome CSPG inhibition of neurite outgrowth in culture. ADAMTS-9 was 
selected for its known expression following inflammation in the CNS in MS as 
described in chapter 4.
138
Aggrecanase activity was previously described in rat astrocytes treated with IL-1(3, and 
was also enhanced by TNF-a (Cross et al., 2006; Rogerson et al., 2010). Another study 
indicated that transforming growth factor alpha (TGF-a) expressed by macrophages 
and transforming growth factor beta (TGF-|3) expressed by both microglia and 
macrophages, resulted in the up-regulation and synthesis of both ADAMTS and their 
substrates CSPGs (Properzi et al., 2005; Reid et al., 2009).These data support the 
hypothesis that aggrecanases are active early in the disease process in MS or during 
acute inflammatory episodes (Merson et al., 2010). In cartilage, ADAMTS-5 mRNA is 
strongly up-regulated by IL-ip, whereas ADAMTS-4 mRNA shows only a small degree 
of up-regulation (llic et al., 2007).There is limited evidence as to the cellular source of 
ADAMTS-9 in the human brain. Furthermore, little is known about transcriptional 
regulation of ADAMTS-9 in the CNS, though in other tissues it appears to be modulated 
by pro-inflammatory mediators (Bevitt et al., 2003; Demircan et al., 2005).
In this study, the effect of pro-inflammatory cytokines (IL-lp, IFN-Y and TNF-a) on 
expression and modulation of ADAMTS-9 in astrocytes (primary human astrocytes), 
microglia (CHME3 human foetal cell line) and neuronal cells (SHSY-5Y) differentiated 
with RetA was assessed by ICC and WB. This may enable our understanding of the 
transcriptional initiators of ADAMTS-9 expression in the CNS in MS.
5.1.1 Aims of the study
•  To confirm the effects of the RetA on neuroblastoma cell line SHSY-5Y
differentiation
•  To determine effects of varying concentrations of aggrecan on neurite 
outgrowth using in cell ELISA, ICC and WB detection of NF-L expression
•  To optimise and validate methods to study ADAMTS-9 expression in SHSY-5Y 
cells grown on varying concentrations of aggrecan, at the mRNA level (qRT-PCR) 
and the protein level (ICC and WB).
•  To determine the modulating effect of cytokine treatment on expression of 
ADAMTS-9 in all the cell types utilised in this study.
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5.2 Methods
5.2.1 Neuroblastoma cell line differentiation with retinoic acid
Retinoic acid (RetA) is a metabolite of vitamin A that mediates the functions of vitamin 
A, which is required for cell growth and development and can control the expression of 
genes in the CNS (Clagett-Dame et al., 2005). RetA treatment of SHSY-5Y cells has been 
shown to increase extension of neurites to produce a more neuronal phenotype 
comparable to in vivo neurons (Encinas et al., 2000). Cells were cultured as described 
in chapter 2 (section 2.4.1). To induce differentiation of human neuroblastoma SH- 
SY5Y cells to become more mature neuronal cells, cells were seeded into 24 well plates 
at a density of 5X104cells/well in lm L culture medium containing lOpM RetA for 7 days 
(Cheung et al., 2000). To confirm whether the cells had differentiated neuronal 
features, ICC was performed with anti-NF-L antibody as described in chapter 2 (section 
2.4.9). NF-L is one of the intermediate filament protein subunits present in neurons, 
neuronal processes, and peripheral nerves and is a specific neuronal cell marker (Wang 
et al., 2012). Figure 5.1 shows the difference in cell morphology between untreated 
and RetA treatment of the SFISY-5Y cells.
5.2.2 The effect of aggrecan on expression of ADAMTS-9 in the SHSY-5Y 
cells using in cell ELISA
After coating of aggrecan on plasticware as described in chapter 2.4.5, neuroblastoma 
cell line SHSY-5Y was plated into 96-well plates at a density of 5 x l0 4/200pl m edia/ well 
containing lOpM RetA for 7 days. Media were removed from the cells and then cells 
were washed with two changes of PBS. Following this, cells were fixed with 4% PFA for 
10 mins and ice cold acetone for 4 mins. Cells were incubated with primary antibody to 
NF-L (1:1000), P-actin (1:1000) and ADAMTS-9 (1:100) overnight followed by 
appropriate secondary antibodies (Table 2-6) for 90mins. Nuclei were counterstained 
using DAPI. The double labelled in Cell-ELISA of NF-L with P-actin and ADAMTS-9 with 
p-actin were identified and imaged on the Odyssey infrared imaging system (LI-COR 
Bioscience, USA).
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Figure 5-1: Morphological effects of RetA on neuroblastoma cell line SHSY-5Y
SHSY-5Y cell morphology A) untreated B) treated with RetA. Characterization o f the 
neuroblastoma cell line SHSY-5Y with NF-L antibody staining (green). C) Untreated D) 
treated with RetA. White arrows indicate that RetA has enhanced neurite outgrowth. 
Images were captured on an inverted stage microscope (Olympus 1X81 fluorescence 
microscope with Cool Snap digital camera (Olympus Media Cybernetics, Silver Spring, 
USA).
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5.3 Results
5.3.1 The effect of CSPGs on neurite outgrowth of the neuroblastoma 
cell line
5.3.1.1 Effect of aggrecan on the viability of differentiated SHSY-5Y cells
The cell viability of differentiated SH-SY5Y cells grown on various concentrations of 
aggrecan on at 0 pg/ml, 0.5, 1 ,1 .5 ,1 .75 , 2 and 2.5pg/ml was determined by MTT assay 
and is shown as the percentage of values obtained for uncoated control wells at each 
concentration. The highest concentration of aggrecan that could be used in the 
experiment was determined as when cell viability was greater than 80% of their 
untreated controls (Datki et al., 2003; Cheung et al., 2009). The results showed that 
the highest concentration of aggrecan that could be used was 2pg/ml. Treatment of 
neuroblastoma cell line with aggrecan at 0.5, 1 and 1.5pg/ml resulted in smaller 
reductions of less than 8% in cell viability, whereas treatment with 2.5pg/ml caused 
more than 20% loss of cell viability compared to control untreated cells (Figure 5-2).
5.3.1.2 The effect of aggrecan on expression of ADAMTS-9 in the 
differentiated SHSY-5Y cells using qRT-PCR
5.3.1.2.1 RNA integrity
After growing cells on aggrecan as described in chapter 2.4.5, RNA was extracted from 
SHSY-5Y cells and the concentration was determined using a Nanodrop-1000 
spectrophotometer. The absorbance ratios of A260/A280 were between 0.8 and 1.4 
(data not shown) that reflected the purity of extracted RNA as described in chapter 2 
(section 2.3.3). The RNA samples were separated by agarose gel electrophoresis as 
described in chapter 2 (section 2.3.4). All RNA samples showed two bands indicating 
28S and 18S ribosomal RNA in a ratio of 2:1 by ethidium bromide staining indicating no 
degradation or contamination of extracted RNA had occurred (Figure 5-3).
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Figure 5-2: Effect of aggrecan coating concentration on the viability of 
SHSY-5Y differentiated cells
The percentage of viable cells on wells coated with aggrecan at different 
concentrations compared to control cells is shown. A decrease in cell viability was 
observed following coating with aggrecan at a concentration o f 0.5pg/ml 3.6%, w ith a 
maximal decrease of 39.3% at 2.5pg/ml aggrecan coating. Data represented as mean ± 
SEM, n= 4 experiments in triplicate.
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Figure 5-3: Agarose gel electrophoresis of total RNA extracted from 
differentiated SHSY-5Y cells
Visible bands of 28S and 18S ribosomal RNA indicating the integrity of RNA extracted 
from differentiated SHSY-5Y cells grown on coated and uncoated plates. Lanes 1, 2, 3,
4, 5 and 6 represent samples extracted from SHSY-5Y grown on aggrecan at varying 
concentrations 0, 0.5, 1, 1.5, 1.75 and 2pg/mL respectively. DNA marker contains 
thirteen markers between 250-10, 000, (Invitrogen). bp= base pairs.
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5.3.1.2.2 Selection of housekeeping genes as internal control genes
The strategy here in this study to validate the qRT-PCR was by comparing mRNA 
expression of three housekeeping genes GAPDH, Cyclophilin-A and HPRT-1 in SHSY-5Y 
cells under the same conditions i.e. cells grown on varying concentrations of aggrecan 
from 0 to 2pg/mL as described in chapter 2 (section 2.4.5). The expression of ADAMTS- 
9 gene was also analysed in differentiated SHSY-5Y cells grown on aggrecan compared 
to uncoated control. Data showed that GAPDH was the most stable housekeeping gene 
as its relative mRNA expression was constant either when used as reference or as 
target gene compared to cells on control uncoated wells. When using HPRT-1 and 
Cyclophilin-A small changes in gene expression of HPRT-1 and Cyclophilin-A was 
observed under different test conditions although these were not statically significant 
with these housekeeping genes (data not shown). Statistical analysis for GAPDH gene 
expression was performed by Kruskal-Wallis test as described in the following section.
5.3.1.2.3 Comparison of ADAMTS-9 mRNA expression in SHSY-5Y in 
the presence of various concentrations of aggrecan
The expression of ADAMTS-9 mRNA in differentiated cells grown on aggrecan was 
determined by qRT-PCR following 7 days in vitro exposed to 0.5pg/ml and 
lpg/ml.There was an apparent increase in ribosomal RNA yield following aggrecan 
treatment of SHSY-5Y cells compared to those grown on uncoated plastic. This 
however, did not affect the real time PCR data as all target gene expression was 
normalised to housekeeping gene expression. No effect on the expression of the 
ADAMTS-9 mRNA relative to cells grown on control un-coated plates was seen. 
However, coating wells with aggrecan at 1.5pg/ml resulted in increased expression of 
ADAMTS-9 transcript, but this did not reach significant levels (P>0.05) after 7 days in 
vitro. However, high levels of ADAMTS-9 mRNA transcript were observed in SHSY-5Y 
cells plated on aggrecan at 1.75pg/ml and 2pg/ml compared to untreated cells 
respectively using Kruskal-Wallis test, (**P<0.01 and ***P<0.001) (Figure 5-4).
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Figure 5-4: ADAMTS-9 mRNA expression when differentiated SHSY-5Y 
cells were grown on various concentrations of aggrecan
Relative fold change in ADAMTS-9 mRNA expression in SHSY-5Ycells following growth 
on aggrecan for 7 days (0-2|ig/mL). Expression was normalised to GAPDH mRNA level. 
An increase in ADAMTS-9 expression was observed following growth on aggrecan at 
concentrations 1.75 and 2 pg/mL using Kruskal-Wallis (**P<0.01, ***P<0.001). Data 
represented as mean ± SEM, n=3 experiments with each one done in triplicate.
1 4 6
5.3.1.3 Immunocytochemical detection of NF-L and ADAMTS-9 in 
differentiated SHSY-5Y cells grown on aggrecan
ICC was performed on differentiated SHSY-5Y cells in order to study the effect of 
aggrecan on neurite outgrowth and ADAMTS-9 expression following fixation in acetone 
to enable the intracellular localization of cell marker NF-L and ADAMTS-9. Negative 
controls were also performed whereby the primary antibody for both NF-L and 
ADAMTS-9 was omitted. With regards to the coating of plasticware with varying 
concentrations of aggrecan to assess neurite outgrowth and ADAMTS-9 expression, 
figure (5-5) illustrates the differences between the effects of varying aggrecan 
concentrations. There appears to be more neurofilament in the absence of aggrecan in 
image A, B and C compared with the cells grown on higher aggrecan concentration 
2|ig/ml in figure (5-5 J, K and L).
Images in figure (5-5) visualised using fluorescent microscopy showed that SFISY-5Y 
cells grown on wells coated with aggrecan at 0.5 and 1 pg/mL concentrations had no 
effect on the expression of ADAMTS-9 and NF-L proteins compared to control cells in 
uncoated wells. Flowever, SFISY-5Y cells in wells coated with aggrecan at 2pg/mL had a 
higher abundance of ADAMTS-9 and lacked neurite outgrowth, with cells growing as 
clusters.
5.3.1.4 In cell-ELISA detection of NF-L and ADAMTS-9 in differentiated 
SHSY-5Y cell
The expression of both ADAMTS-9 and NF-L in differentiated cells was also determined
by in cell-ELISA and the results were similar to previous experiment 5.3.1.3. No staining
was observed when primary antibody was omitted (replaced by PBS). Cells grown on
wells coated with aggrecan at 0.5pg/ml and lpg /m l had no effect on neurite
outgrowth and ADAMTS-9 protein expression within SFISY-5Y cells relative to control
cells in uncoated wells at day 7. In contrast, wells with aggrecan coating at 1.5pg/ml
showed significant increase in ADAMTS-9 protein and low level expression of NF-L
protein within SFISY-5Y cells as shown in Figure (5-6, B and E). Highest concentrations
of aggrecan produced high level expression of ADAMTS-9 and low level expression of
NF-L using Kruskal-Wallis (**P<0.01, ***P<0.001) (Figure 5-6 C and F).
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Figure 5-5: Immunocytochemical detection of NF-L and ADAMTS-9 in 
differentiated SHSY-5Y cells grown on aggrecan
Dual label immunofluorescence of the differentiated SHSY-5Y cells before and after 
growth on varying concentrations of aggrecan and expression of ADAMTS-9 (red). 
Differentiated SHSY-5Y cells stained (green) with anti-NF-L antibody. (A, B and C) cells 
were grown in the absence of aggrecan and showed normal expression of both NF-L 
and ADAMTS-9 respectively. (D, E and F) Cells were grown on aggrecan at lpg /m l and 
showed no changes in both neurite outgrowth and ADAMTS-9 expression. (G, H and I) 
cells were grown on aggrecan at 1.5pg/ml and showed a lack of neurite outgrowth and 
no effect on ADAMTS-9. (J, K and L) cells that were grown on aggrecan at 2pg/ml had a 
higher level of ADAMTS-9 and lacked neurite outgrowth, cells grew as clusters 
compared to control SHSY-Y5 cells on uncoated wells. Nuclei of the cells were 
counterstained using DAPI. Images were captured on an inverted stage microscope 
(Olympus 1X81 fluorescence microscope with Cool Snap digital camera (Olympus Media 
Cybernetics, Silver Spring, USA).
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Figure 5-6: Effect of aggrecan on ADAMTS-9 and NF-L protein 
expression using an in cell ELISA
The double labelled in cell ELISA for P-actin (red) (A, B), ADAMTS-9 (green) (C) and NF-L
(green) (D). Columns represent varying concentration of aggrecan 0, 0 .5 ,1 , 1.5,1.75, 2 
and 2.5|ig/ml respectively, each done in triplicate. The top row of each figure (A-D) 
shows no staining observed when primary antibody was omitted; the lower three rows 
show the primary antibody against ADAMTS-9 and NF-L (C) and (D) respectively. Not 
the difference in graphs (E) and (F), showing much greater expression of ADAMTS-9 is 
related to low levels of NF-L in cells grow on aggrecan at 1.5, 1.75 and 2pg/ml 
respectively, compared to control uncoated cells using Kruskal-Wallis, (*P<0.05, 
**P<0.01, ***P<0.001).Data presented as mean ± SEM, n=3 experiments, each one 
done in triplicate.
150
AD
A
M
TS
-9
/P
-a
ct
in * * *
Agg Cone (ng/mL)Agg Cone (ng/mL)
E F
15 1
5.3.2 Effect of pro-inflammatory cytokines on ADAMTS-9 protein
expression in CNS cells
5.3.2.1 Effect of pro-inflammatory cytokines on cell viability
5.3.2.1.1 Human foetal microglial cell line CHME3
Treatment of CHME3 cells with IL-lp at lOOng/mL resulted in a 15% decrease in viable 
cells compared to control untreated cells, similarly for 48h treatment with TNF-a at 
lOOng/mL an 11.3% decrease in viable cells compared to control was observed. 
Treatment with lOOng/mL IFN-y resulted in a 12.6% decrease in viable cells. A 
decrease in the percentage of viable cells was also observed following dual treatment 
of CHME3 cells with IL-1|3 and TNF-a at 10 and lOOng/mL, with maximal 10.3% 
reduction observed at lOOng/mL with both cytokines (Figure 5-7, a).
5.3.2.1.2 Primary human astrocytes
Treatment of primary astrocytes with Ing/m L IL-1|3 for 48hr resulted in a small 2.7% 
decrease in the percentage of viable cells compared to untreated control cells, 
whereas dual treatment with Ing/m L of IL-1|3 and TNF-a resulted in an 11.9% decrease 
in the number of viable cells compared to controls. Treatment of astrocytes with 
lOOng/mL of IL-ip + TNF-a or IL-1(3 alone for 48hrs resulted in a 14.7% decrease in the 
number of viable cells, whereas lOOng/mL of IFN-Y caused a 15.6% reduction in the 
number of viable cells (Figure 5-7, b).
5.3.2.1.3 SHSY-5Y differentiated cells
TNF-a treatment of differentiated SFISY-5Y cells resulted in a decrease in cell number, 
with a maximal 15.5% decrease observed at lOOng/mL, similarly IFN-Y treatm ent 
resulted in a decrease in viable cells, with maximal 15.9% decrease at lOOng/mL. Dual 
treatment of TNF-a and IL-ip resulted in a decrease in viable cells at all concentrations, 
with a maximal 16.0% decrease observed at lOOng/mL. Treatment of SHSY-5Y with IL- 
1(3 did not alter the viability of cells and percentage was less than 7% (Figure 5-7, c).
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Figure 5-7: Effect of pro-inflammatory cytokines on the viability of CNS
cells in vitro
Effect of pro-inflammatory cytokines on the viability of CHME3 cells, (a) human 
astrocytes (b) and differentiated SHSY-5Y cells (c). 48hrs treatment with single and 
dual cytokines IL-lp, TNF-a and IFN-T at 0-100ng/ml. Data represented as mean ± SEM, 
n=3 experiments, each done in triplicate.
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5.3.2.2 Effect of pro-inflammatory cytokines on ADAMTS-9 protein
expression in CNS cells using ICC
To detect the modulation of ADAMTS-9 expression in CHME3, human primary 
astrocytes and SHSY-5Y cells, they were treated with pro-inflammatory cytokines (IL-1(3, 
TNF-a and IFN-y) which have been implicated in the pathogenesis of MS.
5.3.2.2.1 Human foetal microglial cell line CHME3
On treatment of human foetal microglia cell line (CFIME3) with varying concentrations 
of pro-inflammatory cytokines to assess expression of ADAMTS-9, qualitative analysis 
via image J software showed that treatment of CFIME3 with single pro-inflammatory 
cytokine IL-1(3 and IFN-y had no effect on the expression of ADAMTS-9 protein. 
Whereas, dual treatment of IL-lp and TNF-a at concentrations 10 and 100 ng/mL 
down-regulated ADAMTS-9 protein expression (figure 5-8).
5.3.2.2.2 Primary human astrocytes
Primary human astrocytes treated with single and dual cytokines IL-ip and TNF-a at all 
concentrations tested had no effect on expression of ADAMTS-9 (Appendix V). In 
comparison, IFN-Y initiated an increase in ADAMTS-9 protein expression by primary 
astrocytes at 10 and lOOng/mL (Figure 5-9). Statistical analysis using Image J software 
confirmed this increase in ADAMTS-9 when astrocytes were treated with IFN-Y at 10 
and 100 ng/ml (Figure 5-10, b).
5.3.2.2.3 SHSY-5Y differentiated cells
Treatment of SFISY-5Y cell line with IL-ip, TNF-a and IFN-Y had no statically significant 
effect on ADAMTS-9 expression at all concentrations tested (Data not shown). 
Culturing of cells, treatment of cells and ICC experimental procedure were identical to 
those adopted for the human primary astrocyte and CFIME3 cells.
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Figure 5-10: Statistical analysis of the effect of pro-inflammatory 
cytokines on ADAMTS-9 expression in CHME3 cells and human primary 
astrocytes using ICC
The effect of pro-inflammatory cytokines on ADAMTS-9 expression in CHME3 cells (a) 
and human astrocytes (b), after 48hrs treatment with single and dual cytokines with 
varying concentrations (0, 1, 10, lOOng/ml). Much lower expression of ADAMTS-9 in 
CHME3 treated with dual pro-inflammatory (IL-1J3 and TNF-a) at concentrations 10 and 
lOOng/mL were seen (a). Treatment of astrocytes with IFN-y at 10 and lOOng/mL 
resulted in up-regulation of ADAMTS-9 expression (b). Data presented as mean ± SEM, 
n=3 experiments, each done in triplicate, using Kruskal-Wallis, (**P<0.01, ***P<0.001).
160
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5.3.2.3 Effect of pro-inflammatory cytokines on ADAMTS-9 protein in
CNS cell using WB
The extracted proteins from CNS cells were quantified by Bradford assay as described 
in chapter 2.2.3, and the same amount of protein (20pg) was loaded per well on SDS- 
PAGE gels. Western blot analysis for all CNS cells utilised in this study was described in 
2.2.4-2.2.7. The expression levels of ADAMTS-9 were investigated using quantitative 
two colour staining IRDye® 680 LT goat anti-mouse IgG for (3-actin (red) and IRDye® 
CW donkey anti-goat IgG for ADAMTS-9 (green). Western blot analysis demonstrated 
that ADAMTS-9 was present in CHME3 cells (Figure 5-11, a), primary human astrocytes 
(Figure 5-11, b) and SHSY-5Y (Figure 5-11, c), and produced single bands at ~180KDa.
5.3.2.3.1 Human foetal microglial cell line CHME3
Treatment of CHME3 cells with TNF-a and IL-1(3 for 48hrs at concentration of 1 ,1 0  and 
lOOng/ml and treatment with IFN-T at concentration of 1, 10 and lOOng/ml had no 
effect on the expression of ADAMTS-9 relative to control untreated cells (Figure a). 
Flowever, the expression of ADAMTS-9 in the CHME3 was significantly down-regulated 
following dual treatment with IL-lp and TNF-a at 10 and lOOng/ml (P<0.05, Kruskal- 
Wallis as shown in Figure 5-12, a).
5.3.2.3.2 Human primary astrocytes
Dual treatment of human primary astrocytes with IL-ip for 48hrs at varying 
concentration (0-100ng/ml) had no effect on expression of ADAMTS-9. Flowever, 
treatment with TNF-a at concentrations 10 and lOOng/ml resulted in an increase of 
ADAMTS-9, but this did not reach significant levels P>0.05 after 48hrs of treatment. 
High levels of ADAMTS-9 were expressed in astrocytes treated with IFN-T at 
concentrations 10 and lOOng/ml (P<0.001) (Figure 5-12, b).
5.3.2.3.3 SHSY-5Y cells
No statistically significant effect on ADAMTS-9 protein level expression was observed 
in differentiated SHSY-5Y cells following 0-100ng/ml of single or dual treatm ent with 
IL-1P, TNF-a and IFN-Y (Figure 5-12, c).
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Figure 5-12: Statistical analysis of the effect of pro-inflammatory 
cytokine treatment on expression of ADAMTS-9 in CNS cells assessed by 
WB
The effect of pro-inflammatory cytokines on ADAMTS-9 expression in CHME3 (a), 
human astrocytes (b) and differentiated SHSY-5Y (c). Cells were treated for 48hrs with 
single and dual cytokines (IL-lp, TNF-a and IFN-Y) with varying concentrations (0 ,1 ,1 0 , 
lOOng/ml). Lower expression of ADAMTS-9 in CHME3 cells treated with dual pro- 
inflammatory (IL-lp and TNF-a) at concentrations 10 and lOOng/mL was observed (a). 
Treatment of astrocytes with INF-y at 10 and lOOng/mL resulted in up-regulation of 
ADAMTS-9 (b). Data presented as mean ± SEM, n=3 experiments each done in 
triplicate, using Kruskal-Wallis test.
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5.4 Discussion
5.4.1 Effect of aggrecan on neuronal phenotype; impact of ADAMTS-9
Neuronal growth cones integrate signals from outgrowth promoting molecules, e.g. 
laminin or fibronectin, and outgrowth-inhibiting molecules, e.g. CSPGs (Dickendesher 
et al., 2012: Mammadov et al., 2012; Tonge et al., 2012). The CSPGs can inhibit neurite 
growth by several mechanisms such as binding to adhesion molecules (integrin P) 
which are a bridge for cell-cell and cell ECM interactions (Tan et al., 2011). Enzymatic 
cleavage of CSPG core protein has been reported to permit some axonal regrowth in 
CNS injury (Cua et al., 2013). The objective of this current study was to determine 
whether ADAMTS-9 is expressed in CNS cells microglia (CHME3), primary astrocytes 
and differentiated neuronal cells (SHSY-5Y), under basal conditions. All the three cell 
types expressed ADAMTS-9 at the protein level. Previous studies in our laboratory 
revealed that CHME3, SHSY-5Y and primary astrocytes expressed mRNA for ADAMTS-1, 
-4, -5 and -9 (Cross et ol., 2006; Reid et al., 2009).
The SHSY-5Y cell line has been widely used as an In vitro model of neurons since the 
early 1980s as these cells have many functional properties of neurons. They express 
neuronal marker enzyme activity tyrosine and dopamine-P hydroxylases and express 
NF proteins (Skotake et al., 2012). RetA is a metabolite of vitamin A that mediates 
functions of vitamin A, which are required for development and differentiation of 
neuronal cells and was used to differentiate (Clagett et al., 2006). The SHSY-5Y cells 
were treated with RetA and visualised using light microscopy, showing a significant 
increase in the length of neurites containing neurofiliaments compared to the control 
untreated cells, which supports results generated by other studies, regarding 
alterations in cellular morphology with RetA treatment (Encinas et al., 2000; Clagett et 
al., 2006).
Tucholski et al., (2001) also reported increased neurite outgrowth with regards to 
number and length of neurites, and the necessary component of RetA-induced SHSY- 
5Y cell differentiation was simultaneously increased expression of active tissue 
transglutaminase which creates an inter or intramolecular bonds that are highly 
resistant to proteolysis (protein degradation)(Dwane et al., 2013). Other studies in our 
group indicated that RetA differentiated SHSY-5Y cells showed a statistically significant
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increase in ADAMTS-1 and -9 expression when compared to cells cultured without 
RetA (Reid et al., 2009: Gibrel, 2012). A study by East et al, (2007) showed increased 
ADAMTS-5 mRNA in cartilage explants treated with RetA. The increase in ADAMTS-9 in 
differentiated neuronal cells could lead to an increase in breakdown of CSPGs and 
allow neurite outgrowth as CSPGs are normally inhibitory. However, this study did not 
show any difference in levels of aggrecan expression or its neoepitope, in RetA treated 
SHSY-5Y cells compared to control untreated cells, thus suggesting that neuronal 
phenotype SHSY-5Y was not linked to increase ADAMTS-9 activity on aggrecan to 
generate the neoepitope. CSPG expression could be regulated at different stages 
including pre-transcriptional (e.g. cytokine modulation of mRNA expression) or post- 
transcriptional. Stability of the CSPG expression level in normal physiology prevents 
any changes that could result in neurodegenerative disease (Siebert et al., 2014).
The response of neurons from animal models to the ECM molecules, LN and CSPGs, 
has been well studied in vivo and in vitro (Hynds et al, 1999; Hynds et al, 2001; Lau et 
al, 2012; Cua et al., 2013). In the present study, the effects of aggrecan on SHSY-5Y 
human neuroblastoma cell line, a well-accepted model of human neuronal 
differentiation, demonstrated CSPG was not permissive for neurite outgrowth from 
these cells at higher concentrations (2pg/ml), confirming previous studies (Hynds et al., 
1999; Lau et al., 2013). Important and novel to this inquiry is the finding that aggrecan 
inhibited expression of NF-L and increased expression of ADAMTS-9 within these cells 
at concentrations of 2pg/ml. it is also similar to other studies which indicated that 
CSPGs decreased neurite initiation (number of neurites/cell, percentage of neurite- 
bearing cells) compared with cells plated on LN or control uncoated coverslip in SHSY- 
5Y cells (Hynds et al., 1999). Many studies have established that CSPGs inhibit neurite 
outgrowth in vitro and they restrict axonal regeneration in vivo (Hynds et al., 2001; 
Sandving et al., 2004; Cua et al., 2013).
Intrinsic attempts by axons to overcome CSPG inhibition through local ADAMTS-4 
expression have been documented in CNS injury (Hamel et al., 2008; Tauchi et al.,
2012), while there is no literature for ADAMTS-9 at this time. The results from in-cell 
ELISA analysis were interesting with regards to the cells in aggrecan coated wells 
having higher levels of ADAMTS-9 and lower levels of NF-L; this confirms that aggrecan 
is affecting neuronfilament subunit expression as well as ADAMTS-9 protein expression
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by differentiated SHSY-5Y cells. Comparing data generated from qRT-PCR of SHSY-5Y 
cells with the data in figure (5-5/ICC) as well as Licor images of in-cell ELISA data in 
figure (5-6) with regards to expression of ADAMTS-9 and NF-L, shows that results were 
similar to those previously published (Schmalfedt et al, 2000; Yamada et al, 1997; Cua 
et al, 2013). They found that several MMPs as well as ADAMTS-4 were effective in 
degrading CSPGs and overcoming the promotion of neurite outgrowth observed on 
purified CSPGs and the neuronal ECM. The differences may be related to relative 
insensitivity of the neurite outgrowth where a large difference in aggrecan degradation 
may be required before an impact on neurite outgrowth can be observed. 
Alternatively, as different ADAMTSs can cleave the same substrates at different sites 
producing a different set of peptide fragments (Overall et al., 2002); ADAMTS-9 could 
have produced aggrecan fragments, undetectable through the antibodies used in 
current western blotting that has growth-promoting properties reminiscent of certain 
CS-GAG chains (Clement et al., 1999).
A previous study indicated that ADAMTS-4 could enhance neurite outgrowth from 
cultured rat neurons on both permissive and inhibitory substrates through a non- 
proteolytic mechanism that implicated the ErKl/2 MAP kinase cascade (Hamel et al.,
2008). This mechanism might not be a possibility in this study, where active ADAMTS-9 
was not pre-incubated with aggrecan and was not available to interact with the cell 
surface or to act intracellularly. ADAMTS-9 may act through proteolytic mechanisms, 
as heat-inactivated ADAMTS-9 with no catalytic activity did not have the same efficacy. 
Aside from being processed by ADAMTS-9, aggrecan is also susceptible to cleavage by 
ADAMTS-1, ADAMTS-4 and ADAMTS-5 (Rauch, 2004). These other members of the 
ADAMTS family may demonstrate efficacy similar to ADAMTS-9 and would require 
further investigation.
ADAMTSs have been studied in adult CNS injury; the expression of ADAMTS-4 was 
altered in CNS white matter degeneration in MS (Haddock et al., 2006). In a rat model 
of stroke, ADAMTS-4 correlated with a decrease in phosphacan accumulation 
(Haddock et al., 2007). ADAMTS-9 is synergistically induced by interleukin-ip and TNF- 
a  in OUMS-27 human chondrocytes (Demircan et al., 2005). ADAMTS-9 mRNA was 
showed to be significantly up-regulated in tMCAo brain tissue compared to sham- 
operated animals at 24h post-ischemia (Reid et al., 2009). ADAMTS-9 is upregulated in
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MS active lesions, where a function would be to remodel the lesion microenvironment 
including potential clearance of CSPGs; however glial scars containing PGs still result 
and persist. The reason for incomplete clearance, include the inadequate production 
of ADAMTS-9, the overabundance of deposition of CSPGs in large lesions, the temporal 
mismatch between ADAMTS-9 and CSPG production, the presence of inhibitors (TIMP 
3) that mitigate ADAMTS-9 activity and the likely requirement of other collaborative 
proteases. Further experiments are needed to address these possibilities. Finally, 
although the focus of this chapter is aggrecan, other ECM components including 
collagen, fibronectin, tenascins, proteoglycans and other classes of CSPGs are also 
deposited in lesions, and the capacity of ADAMTS-9, MMPs and other proteases to 
process these molecules in the context of CNS inflammation in MS remain to be 
investigated.
5.4.2 Effect of pro-inflammatory cytokines on ADAMTS-9 expression in 
CNS cells
In vitro studies with cytokine treatments such as IL-lp and TNF-a, which are implicated 
in MS pathogenesis could induce ADAMTSs (Siebert et al., 2014). A previous study in 
our laboratory indicated that U373, U87-MG, primary astrocytes CHME3 microglia cells 
express ADAMTS-1, -4 and -5 (Cross et al., 2006). The cloning of ADAMTS-9 from CNS 
cell cDNA library previously showed that the peptidase was expressed by such cells in 
the mouse (Clark et al., 2000). These data in this study showed that ADAMTS-9 was 
expressed at the protein level by primary human astrocytes and the human foetal 
microglia cell line (CHME3). ICC, in-cell ELISA and WB also confirmed that ADAMTS-9 
protein was expressed by the neuroblastoma cell line (SHSY-5Y) following 
differentiation. Overall, these data confirm that glial cells and neurons in the human 
CNS have the potential to constitutively express ADAMTS-9 in vivo as shown previously 
in chapter 4. This finding is in contrast to expression in CNS white matter with 
ADAMTS-1 which was not detected in differentiated SFISY-5Y cells, whereas Sasaki et 
al., (2001) showed that neuroblastoma cell line (N1E-115) did express ADAMTS-1.
The effect of pro-inflammatory cytokines on expression of ADAMTS-9 in CNS cells was 
variable. This was highlighted by IFN-Y which had no effect on ADAMTS-9 expression 
level in both CHME3 and SHSY-5Y cell lines but significantly up-regulation expression in
171
primary astrocyte cells. There was no modulation of ADAMTS-9 protein found in the 
differentiated SHSY-5Y cell line with either single treatment of IL-1(3, TNF-a and IFN- T 
or dual treatment with IL-ip plus TNF-a. ADAMTS-9 expression could be regulated at 
different stages including pre-transcriptional (e.g. cytokines modulation expression), 
post-transcriptional (alternative splicing) and post-translational (e.g. pro-domain or c- 
terminal cleavage) (Gibrel et o i, 2012). In contrast to these findings, modulation of 
ADAMTS-9 expression by IL-1|3 and TNF-a has been reported previously by Demircan et 
al., (2005) in chondrocytes and by Bevitt et a l,  (2003) in retinal pigment epithelium 
(RPE)-derived cell line.
Expression of ADAMTS-9 was not modulated by single cytokine treatment with IL-lp or 
TNF-a in primary astrocytes. This finding further adds to previous data published by 
Fladdock et al., (2003), in that neither IL-ip nor TNF-a influenced ADAMTS-1, -4 or -5 
mRNA expression level in U87-MG glioma cell line. In contrast, TGF-01 was 
demonstrated in the same study to significantly down-regulate ADAMTS-1 expression 
level in this cell line, as reported here for dual treatment with IL-1{3 and TNF-a down- 
regulation of ADAMTS-9 expression in primary astrocytes. Data published by our group 
using qRT-PCR in the same cells SFISY-5Y and CHME3 proposed to a certain extent that 
ADAMTS-9 modulation is comparable to that of other ADAMTS aggrecanases in the 
CNS (Reid et a i,  2009). IL-ip had a similar effect on ADAMTS-1, 4 and -5 in CHME3 cells 
as it did on ADAMTS-9 in that no modulation was detected. In contrast to data 
obtained with ADAMTS-9, IL-lp and TNF modulated transcription of ADAMTS-1 and 
ADAMTS-4 in CHME3 and differentiated SFIY-5Y cells (Cross et al., 2006: Reid et a i,
2009).
The concentrations of cytokines used are very important to produce a statistically 
significant modulation of ADAMTS-9 protein in CNS cells, for instance, lng /m l, lOng/ml 
and lOOng/ml (both IL-ip and TNF-a) in SHSY-5Y, Ing/m L (IFN-T) in human primary 
astrocytes and Ing/m L of both TNF-a and IL-ip in CHME3 cells were assessed. These 
concentrations of cytokines are likely to exceed physiological concentrations that are 
found in the normal human brain but exposure to a full combination of cytokines 
during CNS disease e.g. in MS, has a combined effect on the regulation of ADAMTS-9 
(Gouze et a i,  2006). Cells were only tested following cytokine treatm ent for 48 h in 
this project, whereas in vivo, cytokine exposure is an ongoing phenomenon, thus
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regulation of ADAMTS-9 may be potentially more marked. Another reason for not 
detecting modulation of ADAMTS-9 expression protein level following treatment with 
cytokines in certain CNS cells was perhaps because of the time-point studied. 
Furthermore, up-regulation of ADAMTS-9 could occur prior to any alteration in the 
pro-inflammatory cytokines. An alteration of ADAMTS-9 was identified in this study 
and also versican and aggrecan fragments similar to GHAP are produced (Westling et 
al., 2004). The role of these neoepitopes is still not clear. It is suggested that these 
fragments could play an important role in MS pathogenesis, inducing an inflammatory 
response via TLR stimulation (Piccinini & Midwood, 2010).
5.5 Conclusion
The data presented in this chapter provide evidence that, a) ADAMTS-9 is expressed at 
the protein level by CNS cells in vitro under basal conditions, and this study offers 
preliminary evidence that ADAMTS-9 is implicated in normal physiological processes in 
the CNS, b) similar to results obtained from animal models, neurite outgrowth from  
SHSY-5Y cells is inhibited by aggrecan, c) this study suggests a role for ADAMTS-9 in 
overcoming aggrecan in the glial scar matrix to promote axonal regeneration in CNS by 
its up-regulation in the presence of aggrecan. Overcoming aggrecan inhibition may also 
have an impact on other aspects of nerve injury repair, such as remyelination, since 
the maturation of oligodendrocytes and myelin repair is inhibited by CSPGs (Lau et al.,
2013). d) ADAMTS-9 protein expression is up-regulated by IFN-Y in the human primary 
astrocytes e) ADAMTS-9 expression level is downregulated in microglia (CFIME3 cells) 
by IL-ip and TNF-a. f) The cytokines investigated had no effect on expression of 
ADAMTS-9 by SHSY-5Y cells.
Since IFN-Y is the major proinflammatory cytokine produced by T cells, and IL-1(3 and 
TNF-a are predominantly secreted by monocyte/macrophage cell types, including 
microglia, the effects of these cytokines in vivo on resident CNS cell expression of 
ADAMTS-9 would reflect the inflammatory cell component present within lesions in 
the white matter in MS, based on these in vitro findings reported here.
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Chapter 6
G e n e r a l  D i s c u s s i o n
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6.1 Implications of this study
Given that CSPGs are a major barrier for remyelination and axon regeneration, a key 
experimental strategy for improving axonal regeneration and plasticity has been to 
modify the inhibitory extracellular environment (Lau et al., 2013). This inhibitory 
activity of CSPGs could be reduced, but not eliminated by removing GAG-side chains, 
indicating that multiple domains of CSPGs are involved in controlling axon 
regeneration (Cua et al., 2013; Zhao et al., 2013). ADAMTS-9 is a recently discovered 
peptidase which has been studied mainly in embryogenesis because it has highly 
similar structure to C. elegans gonadal morphogenesis proteinase GON-1. However, it 
also generated proteoglycan fragments following spinal cord injury (SCI) in mouse 
(Demircan et al., 2013). Despite ADAMTS-9 protein being expressed in the developing 
and injured adult CNS and having the ability to cleave CSPGs present in brain ECM, it 
has not been studied previously in MS tissue (Reid et al., 2009).
The main overall aim of this thesis was to investigate the role of ADAMTS-9 in the 
pathogenesis of MS, in particular its role in the breakdown of CSPGs. This involved a 
three-pronged approach. The first part of this study involved detailed investigation 
into the expression of aggrecan, versican and their neoepitope fragment proteins using 
antibodies which specially recognise ADAMTS cleavage-derived aggrecan and versican 
neoepitopes or intact protein in post mortem MS and control CNS tissue. The second 
part of the study involved a detailed investigation into the expression of ADAMTS-9 in 
post-mortem MS and control brain tissue in order to determine the cell types 
expressing ADAMTS-9 and any difference in the level of ADAMTS-9 mRNA and protein 
expression between MS and control brain tissue. The third part of this study involved 
an in vitro investigation into the expression of ADAMTS-9 in CNS cells and treatm ent of 
these cells with pro-inflammatory cytokines to determine if cytokines are implicated in 
the modulation of ADAMTS-9. In addition, the effect of CSPGs on ADAMTS-9 
expression and neurite outgrowth using SHSY-5Y cells plated on aggrecan coated wells 
was investigated.
6.2 Postmortem studies
CSPGs are upregulated rapidly in the tissue surrounding a lesion site, due to the 
induction of reactive gliosis (Siebert et ai., 2014) (see figure 6-1). There are many
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members of the CSPG family and individual CSPGs are synthesised by different cell 
types and at different time points following CNS injury (Siebert et al., 2014). The 
results from this thesis confirmed previous findings, that aggrecan and versican are 
increased in MS brain tissue compared to control brain tissue (Westeling et al., 2004). 
In vitro studies demonstrated that CSPGs can interact with adhesion molecules 
expressed on neuronal cells (Afshari et al., 2010; Tan et al., 2011). When axonal 
growth cones come into contact with CSPGs, they collapse and retract. This is expected 
to be reason for the abortive regenerative neuronal sprouting observed in MS. The 
interaction of CSPGs and neurons activates the Rho-ROCK and/or protein kinase C 
(PKC) intracellular signalling cascades, which inhibit process extension (Sharma et al., 
2012; Cua eta!., 2013).
T r a u m a
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Figure 6-1: CSPG Deposition at CNS lesions
Damage of the CNS, either by disease or trauma mechanism initiates an increase in 
pro-inflammatory cytokines, which stimulate the up-regulation of CSPG family 
expression (adapted from Siebert et al., (2014).
Though the inhibitory effects of CSPGs on axons have been known for some time, the 
effects they exert on other cell populations, such as oligodendrocytes have only been 
recently deliberated. In vivo, CSPG expression can modulate the migration and 
differentiation of endogenous OPCs that are attracted to glial scars and accumulation 
o f OPCs at the edges of a lesion can be observed after spinal cord injury (Karimi et al., 
2012; Lau et al., 2013). ADAMTS mediated cleavage of aggrecan, versican and brevican
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in the CNS ECM, via their glutamyl endopeptidase (GEP) activity, could have a potential 
role in MS pathogenesis. Detection of neoepitopes of aggrecan and versican (V0/V2) 
useing antibody specific for the new C-terminal sequence generated by cleavage of 
aggrecan and versican at Glu373-Ala374 and Glu405-Gln406 respectively were 
performed. IHC and western blotting results showed increased aggrecan and versican 
neoepitropes in lesional MS compared to normal control. This result is in agreement 
with Westling et ol., (2004) who observed a similar sized fragment with this antibody 
on versican V0/V2 cleavage by ADAMTS-4, which locally promoted motor function 
after spinal cord injury.
It has been reported that ADAMTS-9 may be involved in the loss of ECM by cleaving 
CSPGs, as demonstrated in other tissues (Demircan et al., 2013). Sobel and Ahmed, 
(2001) showed that in the active lesion core, versican, aggrecan and neurocan were 
decreased in the ECM. The findings in this study are consistent with this report 
suggesting that the breakdown of versican in the lesion core in MS is due to excess 
ADAMTSs cleavage. Furthermore levels of ADAMTS-9 mRNA and protein were 
significantly increased, as observed by qRT-PCR, immunohistochemistry and western 
blotting in MS active lesions compared to normal control tissue from the same blocks 
used for CSPGs investigation in chapter 3. Intense ADAMTS-9 immunoreactivity was 
observed in areas of active lesions, assessed by increased HLA-DR expression and the 
presence of myelin breakdown in the activated lipid-laden macrophages stained with 
ORO. Staining was more intense in the active lesion core and ADAMTS-9 expression 
was highly upregulated associated with aggrecan and versican up-regulation. Strong 
ADAMTS-9 immunoreactivity was found associated with cells that phenotypically were 
identified as GFAP+ astrocytes, HLA-DR+ microglia and vWF+ endothelia, localized in 
active demyelinating MS lesions. The data suggests that the aggrecan and versican 
neoepitopes were generated by ADAMTS-9 mediated cleavage. Since ADAMTS-9 
cleaves the Glu373-Ala374 and Glu405-Glu406 bonds of aggrecan and versican 
respectively, it is likely that this enzyme, as well as other described aggrecanases 
(ADAMTS-1, -4 or -5), play a crucial role in the processing of these molecules and other 
lecticans including brevican, neurocan and phosphacan in the CNS in vivo (Westling et 
al., 2004).
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6.3 In vitro studies
The findings in chapter 3 showed that versican and aggrecan neoepitopes were 
generated by characteristic ADAMTS (aggrecanase) cleavage. Data in chapter 4 also 
showed that ADAMTS-9 protein was expressed by astrocytes, endothelium, neurons 
and activated microglia with up-regulation in active lesions compared to the normal 
control in ex vivo CNS tissue, indicating that ADAMTS-9 secreted from these cells could 
play a part in ECM remodelling, particularly of aggrecan and versican. However, it has 
been demonstrated that expression of a number of ADAMTS enzymes can be 
modulated by a range of mediators (e.g. cytokines) in different CNS cell types (Cross et 
al., 2006; Reid et al., 2009). ADAMTS-1 and -4 expressions in astrocytes and neurons 
has been reported following physical or toxic injury to the CNS and it was modulated 
by pro-inflammatory cytokines, suggesting that this expression at the site of injury may 
support neurite outgrowth (Cross eta l., 2006; Cua eta l., 2013).
The data in chapter 5 demonstrated that ADAMTS-9 is expressed under basal 
conditions by human primary astrocytes, a foetal human microglia cell line and a 
neuroblastoma cell line differentiated with RetA in vitro, which suggests that ADAMTS- 
9 may be constitutively expressed in brain. There is evidence from this current study to 
show that ADAMTS-9 expression is upregulated by external factors including CSPGs 
and pro-inflammatory cytokines as summarised in figure 6-2. Each of the factors 
exerted different effects on ADAMTS-9 protein expression across the cell-types 
suggesting that in vivo modulation of the protein expression is complex. Three of the 
pro-inflammatory cytokines (TNF-a, IL-lp and IFN-y) highly reported to be involved in 
CNS inflammation modulated ADAMTS-9 expression suggesting this is a key event in 
pathogenesis of MS (reviewed by Siebert et al., 2014). Support for this finding was the 
demonstration that ADAMTS-9 expression was significantly increased in MS active 
lesions compared to normal controls as well as its up-regulation following treatm ent 
with INF-y in primary astrocytes.
However, no modulation in the expression of ADAMTS-9 was observed in SHSY-5Y cells
with pro-inflammatory cytokines in this current study (Table 5-1). This result is in
agreement with Gibrel, (2012) who found similar results with ADAMTS-1. A previous in
vitro study demonstrated no modulation of ADAMTS-9 mRNA expression by TNF-a in
an astrocytoma cell line (U87-MG) (Reid et al., 2009). This current study also showed
178
that IL-1(3 and TNF-a did not significantly alter ADAMTS-9 expression in primary 
astrocytes but down-regulated ADAMTS-9 expression in CHME3 cell line. Cross et al., 
(2006) showed that IL-ip treatment did not significantly alter the mRNA expression 
level of ADAMTS-1, -5 and TIMP in astrocytes, although there was increased expression 
of ADAMTS-9 on treatment with IL-1(3 and TNF-a in other systems (Demircan et al., 
2005).
To further understand the role of ADAMTS-9 within the CNS, in particular its role in 
breakdown of CSPGs, it would be important to detect where the protein is localised in 
cells in vitro. ICC of SHSY-5Y cells cultured in wells coated with aggrecan demonstrated 
that ADAMTS-9 was up-regulated and localised within the nucleus and possibly in 
intracellular vesicles but not in the ECM. Unfortunately, ICC and WB detection of the 
aggrecan and versican neoepitope were not performed in this study due to the limit of 
detection of protein expressed. However, this may have been because the experiment 
(ICC) was performed on monolayer cells after 48 h treatment, which was unlikely to 
have synthesised high levels of ECM within the time frame of the experiment. Others 
have indicated that ADAMTS-9 is a secreted protein which remains localised to the cell 
surface, potentially in the pericellular matrix, which is an area of ECM closely 
associated with the plasma membrane (Koo et al., 2007). The results here provide 
support for this since ADAMTS-9 was shown to be significantly raised in SHSY-5Y cells 
grown on plates coated with aggrecan at a concentration 2pg/ml and it was not found 
more widely associated with the ECM by ICC.
6.4 Future Directions
To further understand the functional role of ADAMTS-9 and its substrates in MS, both 
an in vivo and in vitro approach should be considered.
There is evidence from this current study indicating a functional role of ADAMTSs as 
determined by an increase in the levels of aggrecan and versican neoepitopes in MS 
active lesions, compared to normal control brain tissue, which is a result of their 
cleavage by ADAMTS-9 possibly as a result of increased production and/or activity. 
Other studies indicated that ADAMTS-4 as well as other aggrecanases (ADAMTS-1 and - 
5), may play a crucial role in MS pathogenesis by degradation of other lecticans 
including brevican, neurocan and phosphacan (Westling et al., 2004; Haddock et al.,
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2007; Tauchi et al., 2012). Brevican and neurocan are degraded by ADAMTSs; their 
neoepitopes could be detected with specific antibodies in further investigations 
(Matthews et al., 2000, Tauchi et al., 2012). CSPG fragments similar to glial 
hyaluronate binding protein fragments (GHAP) are produced following ADAMTS 
cleavage and the functional role of these fragments is still unknown (Westling et al., 
2004). However, the CSPG degradation products reported here may result in activation 
of TLRs inducing inflammatory responses in the same way as GHAP fragments (Piccinini 
& Midwood, 2010). TLR expression and the effect of synthetic GHAP could be studied 
in CNS cells in vitro on parameters such as cytokine and ADAMTS expression.
To further clarify the role of ADAMTS-9 in MS, it would be important to focus on 
functional studies in vitro. Using ADAMTS-9 knock-out mice would be a useful tool to 
assess the role of ADAMTS-9 in normal physiology not just in MS. It also would be 
informative to assess neurite outgrowth in transfected neuronal cells over expressing 
ADAMTS-9 enzyme. ADAMTS-9 could be stably transfected using an inducible 
expression vector system into the neuronal cell line and could be induced by the 
addition of low level protein. Hamel et al., (2008) described over expression of 
ADAMTS-4 following transfection in primary astrocytes. In addition to over expression, 
these authors also added ADAMTS-4 enzymes to neuronal cells grown in culture as 
well as in co-culture with astrocytes. This approach could also be taken as part of 
future work to investigate ADAMTS-9 function.
Changes in ECM after neuronal injury can inhibit remyelination, an ADAMTS-9 
approach that normalises the level of ECM components such as CSPGs and hyaluronan 
may form part of novel therapies to enhance the repair of myelin. A promising 
approach to promote remyelination is the use of enzymatic clearance of deposited 
ECM components using hyaluronidases to remove excess inhibitory hyaluronan and 
CSPGs from lesion sites. Further studies are necessary to determine the balance of the 
potential beneficial and inhibitory roles of hyaluronidases in the context of re­
myelination (reviewed by Lau eta l., 2013).
Another approach to reduce the deposition of inhibitory ECM components would be to 
prevent the transport of these components into the extracellular environment. CSPG 
biosynthesis is catalysed by a series of intracellular enzymes including
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xylosyltransferase-1 which initiates GAG polymerisation on the core protein to 
complete formation of the PGs for secretion into the ECM (Grimpe et al., 2004). 
Targeting of xylosyltransferase-1 mRNA with locally applied novel DNA deoxyribose 
molecules has been shown to disrupt CSPG synthesis resulting in increased neurite 
outgrowth and axonal regeneration around CNS lesions (reviewed by Gloster et al., 
2012).
6.5 Conclusion
The study documented in this thesis provides evidence that CSPGs, including aggrecan 
and versican are upregulated in MS active lesions. These CSPGs are also upregulated 
after spinal cord injury and they probably contribute to the failure of axon 
regeneration and neurite outgrowth (Jones et al., 2003; Tauchi et al., 2012). It also 
provides evidence that ADAMTS-9 expression was increased in active lesions 
associated with CNS cell injury. ADAMTS-9 could degrade aggrecan and versican and 
reverse the neurite outgrowth inhibition mediated by human brain CSPGs. On the 
contrary they may be detrimental by increasing inflammatory cell access to the site of 
injury. In vitro studies showed that ADAMTS-9 is constitutively expressed in CNS cells 
(human foetal microglia cell line CHME3, primary astrocyteS and neuroblastoma cell 
line SHSY-5Y) suggesting that ADAMTS-9 has the potential to be implicated in both 
normal physiology and pathology in the CNS. It also demonstrated that ADAMTS-9 
expression was up-regulated in differentiated SHSY-5Y cell line grown on plates coated 
with aggrecan. ADAMTS-9 was also modulated by pro-inflammatory cytokines in both 
astrocytes and microglia. Further investigation of the primary neuronal cells is required 
to elucidate further the role of neuronal ADAMTSs in MS pathogenesis.
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Appendix I
MS Society Tissue Bank
Wolfson Neuroscience Laboratories 
Imperial College London 
Hammersmith Hospital Campus 
160 Du Cane Road 
London W12 ONN 
Phone+ 44(0)20 7594 9734 
Fax+ 44(0) 20 7594 9735 
UKmstissuebank@imperial.ac.uk 
WWW.UKmstissuebank.imperial.ac.uk
7 March 2013
Nicola Woodroofe 
Sheffield Hallam University 
Biomedical Research Centre 
Floor 7 Owen building 
Howard Street 
Sheffield SI 1WB
Dear Prof Nicola Woodroofe
Study Title: The role of ADAMTS-1, 4 and 9 and associated changes in the extracellular 
matrix in the pathogenesis of multiple sclerosis
REC Reference number: 08/MRE09/31
Tissue supplied for the project: 84 snap frozen block of human brain tissue from 28 MS 
and 8 control cases.
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Appendix II
Buffers and Solutions 
4% Paraformaldehyde
Phosphate buffer 0.2M  
(Solution A)
Weight out 11.36g Na2HP04 and dissolve in 400ml of distilled H20  
(Solution B)
3.2 g NaH2P04 2H20  in 100ml dH20
0.2M phosphate buffer was made by mixing solution A& B above
in fume hood, 16g of paraformaldehyde was added to lOOmL of distilled H20  and 
heated to 60°C then add 2M N2OH to dissolve. Added distilled H20  to make a total 
volume of 200ml. Add 200ml of 0.2M phosphate buffer and pH to 7.2.
Preparation instruction of Chondroitinase
Reconstitute in a 0.01% bovine serum albumin aqueous solution. Subsequent dilutions 
can be made into a buffer containing 50mM Tris, pH 8.0, 60mM sodium acetate and 
0.02% bovine serum albumin. Solutions should be prepared fresh.
Running Buffer lx
Running Buffer was made by mixing 100ml methanol, 850mL H20  and 50mL running 
buffer 20X (invitrogen, UK)
Reconstitution of cytokine
Recombinant cytokines IL-(3 (50pg), TNF-a (50pg) and IFN-Y (20 pg) were reconstituted 
from lyophilised powder in 500pL, 500 pL, 200 pL PBS respectively, to give final stock 
concentration of lOOug/mL. These stock solutions of cytokines were stored in 20pL 
aliquots at -20°C for further dilution on the day of experiments.
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Appendix ill
ADAMTS-9
co-localisation
Dual label immunofluorescence of ADAMTS-9 and vWF in normal control brain tissue
Dual-label immunofluorescence for (a) vWF (green) and (b) ADAMTS-9 (red) in normal 
control brain tissue white matter with low levels of parenchymal ADAMTS-9 
immunoreactivity. (c) Co-localisation is not represented by pixels in quadrant 3 on the 
graph and is not demonstrated as yellow pixels in the composite image as shown in 
chapter 4.
Co-localisation software of the Zeiss 510 CSLM was utilised to conclude whether or not 
individual pixels were tru ly co-localised for the ADAMTS-9. The software produce as 
spectra dot plots that displays channel 1 pixels in quadrant 2, channel 2 pixels in 
quadrant 1 and pixels that are both channel 1 + 2 in quadrant 3.
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Appendix IV 
Published Abstracts
•  Abuneeza E, Cross AK, Haddock G, Bunning RAD and Woodroofe MN. 
Expression of ADAMTS-9 in the central nervous system in multiple sclerosis and 
its relationship to cleavage of aggrecan and versican. Poster presented at 
International society of neuroimmunology, 9-13th November 2014, Esni Course- 
European School of Neuroimmunology, Mainz, Germany. International Journal 
of Neuroimmunology.
•  Abuneeza E, Cross AK, Haddock G, Bunning RAD and Woodroofe MN. Changes
in extracellular matrix chondroitin sulphate proteoglycan in multiple sclerosis
white matter lesions: a role for ADAMTS-9.Poster presented at British Society 
for immunology Congress 2nd- 5th December 2013, The Arena & Convention 
Centre, Liverpool, UK.
Department Oral Presentation (BMRC)
•  Final year presentation: February 2015
•  Second year presentation: August 2014
•  First year presentation: March 2013
•  Introductory oral presentation: July 2012
Conference attendance
•  Yorkshire Immunology Group Symposium 12th June 2013, Alfred Denny Biology 
LT1, University of Sheffield, Sheffield, UK.
•  BMRC/MERI Winter Poster session 17th December 2013, Sheffield Hallam 
University, Sheffield, UK.
•  British Society for immunology Congress 2nd- 5th December 2013, The Arena & 
Convention Centre, Liverpool, UK.
•  British Society for immunology Summer School 29 July- 1 August 2013, 
University of Newcastle, Newcastle, UK.
•  The first BMRC PhD Summer Research Conference 9th July 2012, Sheffield 
Hallam University, Sheffield, UK.
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Appendix Vl-A
Directory of suppliers for the reagents used in this thesis
Supplier Address
Abeam 330 Cambridge Science Park, Cambridge, M ilton Rd, CB4 
OFL, UK
Applied Bioscience Lingley House, 120 Birchwood Boulevard, Warrington, 
WA3 7QH, UK
Bioline 16 The Edge Business Centre, Humber Rd., London, NW2 
6EW
Dako Denmark House, Angel Drove, Ely, Cambridgshire, CB7 
4ET, UK
Fisher Scientific Inc Bishop Meadow Rd., Loughborough, Leicestershire, LE11 
5RG, UK
Invitrogen 3 Fountain Drive, Inchinnan Business Park, Paisley, PA4 
9RF, UK
Leica Larch House, Woodlands Business Park, Breckland, 
Linford W ood,Milton Keynes, MK14 6FG, UK
Lonza Muenchensteinerstrasser 38, CH -  4002, Basel, 
Switzerland
Millipore Suite 3 & 5, Building 6, Croxley Green Business Park, 
Watford, WD18 8YH, UK
Sigma-Aldrich The Old Brickyard, New Road, Gillingham, Dorset, SP8 
4XT, UK
LI-COR Biosciences Ltd John's Innovation Centre, Cowley Road, Cambridge, CB4 
OWS, UK
Vector Laboratories Ltd 3 Accent Park, Bakewell Road, Orton Southgate, 
Peterborough, PE2 6XS, U.K
Fisher Scientific Inc Bishop Meadow Rd., Loughborough, Leicestershire, LE11 
5RG, UK;
Santa Cruz 2145 Delaware Ave, California, 95060, USA
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Appendix Vl-A: Director 
(continued)
y of suppliers for the reagents used in this thesis
Supplier Address
Peprotech EC Ltd Peprotech House, 29 Margravine Rd., London, W6 8LL, 
UK
R&D systems 19 Barton Lane, Abingdon Science Park, Abingdon, 0X14 
3NB, UK
Mettler-Toledo
Mettler-Toledo Ltd., 64 Boston Road, 
Beaumont Leys, Leicester, LE4 1AW , UK
ScienceCell™ Research 
laboratories
6076 Corte Del Cedro, Carlsbad, CA 92011, California, 
USA
TAAB Labratories 
Equipment
SciQuip LTD Newtown Wem Shropshire SY4 5NU, UK
Cell Path Ltd 80 Mochdre Enterprise Park, Newtown, Powys, SY16 4LE, 
UK
Grant Equipment Ltd Grant Instruments (Cambridge) Ltd, Shepreth,
Cambridgeshire
SG8 6GB, UK
Raymond A lamb Ltd 4-5, Park View Industrial Estate, Alder Cl, Eastbourne, 
East Sussex BN23 6QE, UK
Heraeus Instrument Postfach 1561, Hanau, D-63450, Germany
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